

# Nicotine replacement therapy for smoking cessation (Review)

Stead LF, Perera R, Bullen C, Mant D, Lancaster T



**THE COCHRANE  
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2008, Issue 2

<http://www.thecochranelibrary.com>



## TABLE OF CONTENTS

ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
BACKGROUND . . . . .	2
OBJECTIVES . . . . .	3
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW . . . . .	3
SEARCH METHODS FOR IDENTIFICATION OF STUDIES . . . . .	4
METHODS OF THE REVIEW . . . . .	4
DESCRIPTION OF STUDIES . . . . .	5
METHODOLOGICAL QUALITY . . . . .	6
RESULTS . . . . .	7
DISCUSSION . . . . .	10
AUTHORS' CONCLUSIONS . . . . .	13
NOTES . . . . .	14
FEEDBACK . . . . .	14
POTENTIAL CONFLICT OF INTEREST . . . . .	16
ACKNOWLEDGEMENTS . . . . .	16
SOURCES OF SUPPORT . . . . .	16
REFERENCES . . . . .	16
TABLES . . . . .	32
Characteristics of included studies . . . . .	32
Characteristics of excluded studies . . . . .	77
Characteristics of ongoing studies . . . . .	79
ADDITIONAL TABLES . . . . .	80
Table 01. Nicotine replacement therapies . . . . .	80
Table 02. Glossary of terms . . . . .	80
ANALYSES . . . . .	82
Comparison 01. Any type of NRT versus placebo/ no NRT control . . . . .	82
Comparison 02. Subgroup: Definition of abstinence . . . . .	82
Comparison 03. Subgroup: Level of behavioural support . . . . .	82
Comparison 04. Subgroup: Recruitment /treatment setting . . . . .	83
Comparison 05. Nicotine gum: 4mg versus 2mg dose . . . . .	83
Comparison 06. Nicotine gum: Fixed versus ad lib dose schedule . . . . .	83
Comparison 07. Nicotine patch: High versus standard dose patches . . . . .	83
Comparison 08. Nicotine patch: 16hr or 24hr use, subgroups & direct comparison . . . . .	83
Comparison 09. Nicotine patch: Duration of therapy, subgroups & direct comparison . . . . .	83
Comparison 10. Nicotine patch: Effect of weaning/tapering dose at end of treatment . . . . .	84
Comparison 11. Combinations of different types of NRT . . . . .	84
Comparison 12. Direct comparisons between NRT types . . . . .	84
Comparison 13. Purchased NRT without support versus physician support . . . . .	84
Comparison 14. Precessation treatment with nicotine patch . . . . .	84
Comparison 15. Nicotine patch and bupropion; direct comparisons and combinations . . . . .	84
INDEX TERMS . . . . .	84
COVER SHEET . . . . .	84
GRAPHS AND OTHER TABLES . . . . .	85
Analysis 01.01. Comparison 01 Any type of NRT versus placebo/ no NRT control, Outcome 01 Smoking cessation at 6+ months follow up . . . . .	86
Analysis 02.01. Comparison 02 Subgroup: Definition of abstinence, Outcome 01 Nicotine gum. Smoking cessation . . . . .	91
Analysis 02.02. Comparison 02 Subgroup: Definition of abstinence, Outcome 02 Nicotine patch: Smoking cessation . . . . .	94
Analysis 03.01. Comparison 03 Subgroup: Level of behavioural support, Outcome 01 Nicotine gum. Smoking cessation . . . . .	96
Analysis 03.02. Comparison 03 Subgroup: Level of behavioural support, Outcome 02 Nicotine patch. Smoking cessation . . . . .	99
Analysis 03.03. Comparison 03 Subgroup: Level of behavioural support, Outcome 03 Long versus short support . . . . .	101

Analysis 04.01. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 01 Nicotine gum. Smoking cessation . . . . .	102
Analysis 04.02. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 02 Nicotine patch. Smoking cessation . . . . .	105
Analysis 04.03. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 03 Nicotine Inhaler/inhalator. Smoking cessation . . . . .	107
Analysis 04.04. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 04 Nicotine tablet/lozenge. Smoking cessation . . . . .	108
Analysis 04.05. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 05 Nicotine Intranasal spray. Smoking cessation . . . . .	108
Analysis 04.06. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 06 Combination of NRT. Smoking cessation . . . . .	109
Analysis 04.07. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 07 Choice of NRT. Smoking cessation . . . . .	110
Analysis 05.01. Comparison 05 Nicotine gum: 4mg versus 2mg dose, Outcome 01 Smoking Cessation . . . . .	110
Analysis 06.01. Comparison 06 Nicotine gum: Fixed versus ad lib dose schedule, Outcome 01 Smoking cessation . . . . .	111
Analysis 07.01. Comparison 07 Nicotine patch: High versus standard dose patches, Outcome 01 Smoking cessation at maximum follow up . . . . .	112
Analysis 08.01. Comparison 08 Nicotine patch: 16hr or 24hr use, subgroups & direct comparison, Outcome 01 Smoking Cessation . . . . .	113
Analysis 09.01. Comparison 09 Nicotine patch: Duration of therapy, subgroups & direct comparison, Outcome 01 Smoking Cessation . . . . .	115
Analysis 10.01. Comparison 10 Nicotine patch: Effect of weaning/tapering dose at end of treatment, Outcome 01 Smoking Cessation . . . . .	117
Analysis 11.01. Comparison 11 Combinations of different types of NRT, Outcome 01 Long-term smoking cessation . . . . .	119
Analysis 12.01. Comparison 12 Direct comparisons between NRT types, Outcome 01 Smoking cessation . . . . .	121
Analysis 13.02. Comparison 13 Purchased NRT without support versus physician support, Outcome 02 Smoking cessation using physician prescribed NRT versus NRT without support (all NRT purchased) . . . . .	122
Analysis 14.01. Comparison 14 Precessation treatment with nicotine patch, Outcome 01 Smoking cessation . . . . .	122
Analysis 15.01. Comparison 15 Nicotine patch and bupropion; direct comparisons and combinations, Outcome 01 Smoking cessation at longest follow up . . . . .	123

# Nicotine replacement therapy for smoking cessation (Review)

Stead LF, Perera R, Bullen C, Mant D, Lancaster T

## This record should be cited as:

Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2008, Issue 1. Art. No.: CD000146. DOI: 10.1002/14651858.CD000146.pub3.

**This version first published online:** 23 January 2008 in Issue 1, 2008.

**Date of most recent substantive amendment:** 01 November 2007

## ABSTRACT

### Background

The aim of nicotine replacement therapy (NRT) is temporarily to replace much of the nicotine from cigarettes to reduce motivation to smoke and nicotine withdrawal symptoms, thus easing the transition from cigarette smoking to complete abstinence.

### Objectives

The aims of this review were:

To determine the effect of NRT compared to placebo in aiding smoking cessation, and to consider whether there is a difference in effect for the different forms of NRT (chewing gum, transdermal patches, nasal spray, inhalers and tablets/lozenges) in achieving abstinence from cigarettes.

To determine whether the effect is influenced by the dosage, form and timing of use of NRT; the intensity of additional advice and support offered to the smoker; or the clinical setting in which the smoker is recruited and treated.

To determine whether combinations of NRT are more likely to lead to successful quitting than one type alone.

To determine whether NRT is more or less likely to lead to successful quitting compared to other pharmacotherapies.

### Search strategy

We searched the Cochrane Tobacco Addiction Group trials register for papers with 'nicotine' or 'NRT' in the title, abstract or keywords. Date of most recent search July 2007.

### Selection criteria

Randomized trials in which NRT was compared to placebo or to no treatment, or where different doses of NRT were compared. We excluded trials which did not report cessation rates, and those with follow up of less than six months.

### Data collection and analysis

We extracted data in duplicate on the type of participants, the dose, duration and form of nicotine therapy, the outcome measures, method of randomization, and completeness of follow up.

The main outcome measure was abstinence from smoking after at least six months of follow up. We used the most rigorous definition of abstinence for each trial, and biochemically validated rates if available. We calculated the risk ratio (RR) for each study. Where appropriate, we performed meta-analysis using a Mantel-Haenszel fixed-effect model.

### Main results

We identified 132 trials; 111 with over 40,000 participants contributed to the primary comparison between any type of NRT and a placebo or non-NRT control group. The RR of abstinence for any form of NRT relative to control was 1.58 (95% confidence interval [CI]: 1.50 to 1.66). The pooled RR for each type were 1.43 (95% CI: 1.33 to 1.53, 53 trials) for nicotine gum; 1.66 (95% CI: 1.53 to 1.81, 41 trials) for nicotine patch; 1.90 (95% CI: 1.36 to 2.67, 4 trials) for nicotine inhaler; 2.00 (95% CI: 1.63 to 2.45, 6 trials) for oral tablets/lozenges; and 2.02 (95% CI: 1.49 to 3.73, 4 trials) for nicotine nasal spray. The effects were largely independent of the duration of therapy, the intensity of additional support provided or the setting in which the NRT was offered. The effect was similar in a small group of studies that aimed to assess use of NRT obtained without a prescription. In highly dependent smokers there was a significant benefit of 4 mg gum compared with 2 mg gum, but weaker evidence of a benefit from higher doses of patch. There was

evidence that combining a nicotine patch with a rapid delivery form of NRT was more effective than a single type of NRT. Only one study directly compared NRT to another pharmacotherapy. In this study quit rates with nicotine patch were lower than with the antidepressant bupropion.

### **Authors' conclusions**

All of the commercially available forms of NRT (gum, transdermal patch, nasal spray, inhaler and sublingual tablets/lozenges) can help people who make a quit attempt to increase their chances of successfully stopping smoking. NRTs increase the rate of quitting by 50-70%, regardless of setting.

The effectiveness of NRT appears to be largely independent of the intensity of additional support provided to the individual. Provision of more intense levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of NRT.

## **PLAIN LANGUAGE SUMMARY**

All forms of nicotine replacement therapy (NRT) can help people quit smoking

NRT aims to reduce withdrawal symptoms associated with stopping smoking by replacing the nicotine from cigarettes. NRT is available as skin patches that deliver nicotine slowly, and chewing gum, nasal spray, inhalers, and lozenges/tablets, all of which deliver nicotine to the brain more quickly than from skin patches, but less rapidly than from smoking cigarettes. This review includes 132 trials of NRT, with over 40,000 people in the main analysis. It found evidence that all forms of NRT made it more likely that a person's attempt to quit smoking would succeed. The chances of stopping smoking were increased by 50 to 70%. Most of the studies were performed in people smoking more than 15 cigarettes a day. What limited evidence there is suggests no overall difference in effectiveness of different forms of NRT nor a benefit for using patches beyond 8 weeks. NRT works with or without additional counselling, and does not need to be prescribed by a doctor. Heavier smokers may need higher doses of NRT. People who use NRT during a quit attempt are likely to further increase their chance of success by using a combination of the nicotine patch and a faster acting form. Preliminary data suggests that starting to use NRT shortly before the planned quit date may increase the chance of success. Adverse effects from using NRT are related to the type of product, and include skin irritation from patches and irritation to the inside of the mouth from gum and tablets. There is no evidence that NRT increases the risk of heart attacks.

## **BACKGROUND**

Nicotine replacement therapy (NRT) aims to reduce motivation to smoke and the physiological and psychomotor withdrawal symptoms often experienced during an attempt to stop smoking, and therefore increase the likelihood of remaining abstinent (West 2001). Nicotine undergoes first pass metabolism in the liver, reducing the overall bioavailability of swallowed nicotine pills. A pill that could reliably produce high enough nicotine levels in the central nervous system would risk causing adverse gastrointestinal effects. To avoid this problem, nicotine replacement products are formulated for absorption through the oral mucosa (chewing gum, lozenges, sublingual tablets, inhaler/inhalator) or skin (transdermal patches). Other products are also under development (Bolliger 2007; D'Orlando 2004; Ikinici 2006; Park 2002).

Nicotine patches differ from the other products in that they deliver the nicotine dose slowly and passively. They do not replace any of the behavioural activities of smoking. In contrast the other types are faster acting, but require more effort on the part of the user. Transdermal patches are available in several different doses, and deliver between 5 mg and 22 mg of nicotine over a 24-hour period, resulting in plasma levels similar to the trough levels seen in heavy

smokers (Fiore 1992). Some brands of patch are designed to be worn for 24 hours whilst others are intended to be worn for 16 hours each day. Nicotine lozenges and nicotine chewing gum are available in both 2 mg and 4 mg strengths. None of the available products deliver such high doses of nicotine as quickly as cigarettes. An average cigarette delivers between 1 and 3 mg of nicotine and the typical pack-per-day smoker absorbs 20 to 40 mg of nicotine each day (Henningfield 2005).

The availability of NRT products on prescription or for over-the-counter purchase varies from country to country. Table 01 summarises the products currently licensed in the United Kingdom.

In earlier versions, this review focused on the effect of nicotine replacement therapy in comparison to placebo for helping people stop smoking. The evidence that NRT helps some people to stop smoking is now well accepted, and many clinical guidelines recommend NRT as a first line treatment for people seeking pharmacological help to stop smoking (Fiore 2000; Italy ISS 2004; Le Foll 2005; NZ NACHD 2002; West 2000; Woolacott 2002; Zwar 2004). This review still provides an estimate of the expected effect of using NRT, using meta-analysis. We also address questions about when and how to use NRT most effectively. This in-

cludes consideration of the effect of the type of NRT used, including the use of combinations of different types of NRT, the effect of the setting in which it is used (including purchasing over the counter versus prescription use), the effect of dosing according to characteristics of the individual quitter and whether the effect of NRT is altered by different levels of behavioural support. NRT is now one of several forms of pharmacotherapy available to support quit attempts, including antidepressants such as bupropion and the nicotine receptor partial agonist varenicline. These pharmacotherapies are evaluated in separate Cochrane reviews (Hughes 2007; Cahill 2007). This review includes in its scope evaluations of randomized trials directly comparing NRT to these treatments, or combining NRT with them.

## OBJECTIVES

To determine the effectiveness of nicotine replacement therapy (NRT), including gum, transdermal patch, intranasal spray and inhaled and oral preparations, in achieving long-term smoking cessation.

We addressed the following questions:

- Is NRT more effective than a placebo or 'no NRT' intervention in promoting smoking cessation?
- Is NRT relatively more effective when given with higher levels of behavioural support?
- Is NRT relatively more effective for people who are highly motivated to quit smoking?
- Is 4 mg nicotine gum more effective than 2 mg nicotine gum?
- Are fixed dosing schedules for nicotine gum more effective than ad lib use?
- Is higher dose nicotine patch therapy more effective than standard dose (~1mg/hour) therapy?
- Are nicotine patches worn for 24 hours more effective than 16-hour patches?
- Is a longer duration of nicotine patch use more effective than shorter treatment?
- Is weaning from nicotine patch use more effective than an abrupt end of therapy?
- Are combinations of different forms of NRT more effective than the usual dose of a single type?
- Does NRT assist cessation amongst people who have relapsed after recent use of NRT?
- Is initiating nicotine patch use before making a quit attempt more effective than starting on the quit day?

- Is NRT more or less effective than bupropion for smoking cessation?
- Are there harms associated with using NRT?

## CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW

### Types of studies

Randomized controlled trials. Trials where allocation to treatment was by a quasi-randomized method were also included, but appropriate sensitivity analysis was used to determine whether their inclusion altered the results.

### Types of participants

Men or women who smoked were included irrespective of the setting from which they were recruited and/or their initial level of nicotine dependence. We included studies that randomized therapists, rather than smokers, to offer NRT or a control, provided that the specific aim of the study was to examine the effect of NRT on smoking cessation. Trials that randomized physicians or other therapists to receive an educational intervention, which included encouraging their patients to use NRT, were not included, but have been reviewed separately (Lancaster 2000).

### Types of intervention

Comparisons of NRT (including chewing gum, transdermal patches, nasal spray, inhalers and tablets or lozenges) versus placebo or no nicotine replacement therapy control. The terms 'inhaler' and 'inhalator' (a cigarette-like device which delivers nicotine to the buccal mucosa by sucking) are used interchangeably in the literature. We have used the term 'inhaler' throughout the rest of this review.

We also included trials comparing different doses of NRT and comparing more than one type of NRT to a single type.

In some analyses we categorized the trials into groups depending on the level of additional support provided (low or high). The definition of the low-intensity category was intended to identify a level of support that could be offered as part of the provision of routine medical care. If the duration of time spent with the smoker (including assessment for the trial) exceeded 30 minutes at the initial consultation or the number of further assessment and reinforcement visits exceeded two, the level of additional support was categorized as high. The high intensity category included trials where there were a large number of visits to the clinic/trial centre, but these were often brief, spread over an extended period during treatment and follow up, and did not include a specific counselling component. It also included trials where the support included multi-session group-based counselling, with frequent sessions around the quit date. In the present update of the review we have attempted to provide a more fine-grained analysis and

have distinguished between high intensity group-based support and other trials within the high intensity category.

### Types of outcome measures

The review evaluates the effects of NRT versus control on smoking cessation, rather than on withdrawal symptoms. We excluded trials that followed up participants for less than six months. For each study we chose the strictest available criteria to define abstinence. For example, in studies where biochemical validation of cessation was available, only those participants who met the criteria for biochemically confirmed abstinence were regarded as being abstinent. Wherever possible we chose a measure of sustained cessation rather than point prevalence. People who were lost to follow up were regarded as being continuing smokers.

Trials that evaluated the effect of NRT for individuals who were attempting to reduce the number of cigarettes smoked rather than to quit are no longer included in this review. They are covered by a separate review on harm reduction approaches (Stead 2007)

## SEARCH METHODS FOR IDENTIFICATION OF STUDIES

See: Cochrane Tobacco Addiction Group methods used in reviews.

We searched the specialized register of the Cochrane Tobacco Addiction Group in July 2007 for trials with any reference to the use of nicotine replacement therapy of any type, by searching for 'nicotine' or 'NRT' in the title, abstract or keywords. The most recent issues of the databases included in the register as searched for the current update of this review are: the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library) Issue 4, 2006, MEDLINE (Ovid) update code 20070629, EMBASE (Ovid) week 20 2007, PsycINFO (Ovid) update code 20070709, Science Citation Index (Web of Science) 1/2007. The trials register also includes trials identified by handsearch of abstract books from meetings of the Society for Research on Nicotine & Tobacco. For earlier versions of this review we performed searches of additional databases; Cancerlit, Health Planning and Administration, Social Scisearch, Smoking & Health and Dissertation Abstracts. Since the searches did not produce any additional trials we did not search these databases after December 1996. During preparation of the first version of this review, we also sent letters to manufacturers of NRT preparations. Since this did not result in additional data we did not repeat the exercise for subsequent updates.

## METHODS OF THE REVIEW

Two individuals independently extracted data from the published reports and abstracts. Disagreements were resolved by discussion or referral to a third party. We made no attempt to blind these

individuals either to the results of the primary studies or to which treatment participants received. Reports published only in non-English language journals were examined with the assistance of translators.

We extracted smoking cessation rates in the intervention and control groups from the reports at six or 12 months. Since not all studies reported cessation rates at exactly these intervals, we allowed a window period of six weeks at each follow-up point. For trials without 12-month follow up we used six-month data. For trials which also reported follow up for more than a year we used 12-month outcomes in most cases. (We note exceptions in the included study table.) Following changes to the Cochrane Tobacco Addiction Group's recommended method of data analysis since this review was last updated, we have changed the way in which we summarize the effects of treatment. We now use the risk ratio rather than the odds ratio for summarizing individual trial outcomes and for estimates of pooled effect. Treatment effects will seem smaller when expressed as risk ratios than when expressed as odds ratios, unless the event rates are very low. For example, if 20 out of 100 participants have quit in the intervention group, and 10 out of 100 in the control group, the risk ratio is 2.0  $[(20/100)/(10/100)]$ , whilst the odds ratio is 2.25  $[(20/80)/(10/90)]$ . Whilst there are circumstances in which odds ratios may be preferable, there is a danger that they will be interpreted as if they are risk ratios, making the treatment effect seem larger (Deeks 2005). We estimated a pooled weighted average of risk ratios using a Mantel-Haenszel method, with 95% confidence intervals.

To investigate heterogeneity we use the  $I^2$  statistic, given by the formula  $[(Q - df)/Q] \times 100\%$ , where  $Q$  is the chi-squared statistic and  $df$  is its degrees of freedom (Higgins 2003). This describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). A value greater than 50% may be considered to indicate substantial heterogeneity. When there are large numbers of trials as in this review, the chi-squared test for heterogeneity will be unduly powerful and may identify statistically significant but clinically unimportant heterogeneity

In comparing NRT to placebo, we performed subgroup analysis for each form of NRT. We did additional subgroup analyses within type of NRT (gum, patch etc) to investigate whether the relative treatment effect differed according to the way in which smoking cessation was defined, the intensity of behavioural support and the clinical setting of treatment. We also used subgroup analyses to compare effect sizes across nicotine patch trials using different lengths of treatment, durations of daily use and tapering of dose at the end of treatment. Where the estimates of effect clearly differed across subgroups we used metaregression to test for significance. For descriptive purposes we calculated an average quit rate for the control groups in some subgroup analyses, weighting by the inverse variance. To provide a clinical perspective in the Discussion we estimated the number of people who would need to be treated

(NNT) with NRT in order to produce one successful quitter at 12 months beyond that which would be achieved from a quit attempt without NRT. To do this we specified baseline quit rates and used the risk ratio derived from meta-analysis to calculate the quit rate likely with treatment: we then calculated the NNT as the inverse of the difference between the treated and untreated quit rates (Altman 2002).

We include in this updated review the Cochrane Tobacco Addiction Group's Glossary of smoking-related terms (Table 02).

## DESCRIPTION OF STUDIES

The review includes 132 studies. Trials were conducted in North America (66 studies), Europe (55), Australasia (4 studies), Japan (2 studies), South Africa (2 studies), Taiwan, Thailand, and Venezuela, or in multi-region trials (3 studies). The median sample size was around 200 but ranged from less than 50 to over 1500 participants.

### Participants

Participants were typically adult cigarette smokers with an average age of 40 to 50. One trial recruited adolescents (Moolchan 2005). Most trials had approximately similar numbers of men and women. Kornitzer 1987 recruited only men, in a workplace setting. Cooper 2005 and Pirie 1992 recruited only women and Wisborg 2000 recruited only pregnant women. Two trials recruited African-American smokers (Ahluwalia 1998; Ahluwalia 2006). Trials typically recruited people who smoked at least 15 cigarettes a day. Although some trials included lighter smokers as well, the average number smoked was over 20 per day in most studies. One trial recruited only people who smoked 10 or fewer cigarettes/day (Ahluwalia 2006). Killen 1999 recruited people smoking 25 or more per day and two trials recruited only people smoking 30 or more per day (Hughes 1990; Hughes 2003). Two trials recruited people with a history of alcohol dependence (Hughes 2003; Kalman 2006). One study recruited people with a history of cardiac disease (Joseph 1996).

### Type and dose of nicotine replacement therapy

One hundred and eleven studies contributed to the primary analysis of the efficacy of one or more types of NRT compared to a placebo or other control group not receiving any type of NRT. In this group of studies there were 53 trials of nicotine gum, 41 of transdermal nicotine patch, six of an oral nicotine tablet or lozenge, four of intranasal nicotine spray, four of nicotine inhaler, one providing patch and inhaler (Hand 2002) and two offering a choice of products (Kralikova 2002; Molyneux 2003). Trials that did not contribute to the primary analysis addressed a range of other questions including treatment duration, dose, combinations of different types of NRT compared to a single type, and using NRT for a short period before the target quit day.

Most trials comparing nicotine gum to control provided the 2 mg dose. A few provided 4 mg gum to more highly addicted smokers, and two used only the 4mg dose (Blondal 1989; Puska 1979). Five trials included a comparison of 2 mg and 4 mg doses (Garvey 2000; Herrera 1995; Hughes 1990; Kornitzer 1987; Tonnesen 1988). In three trials the physician offered nicotine gum but participants did not necessarily accept or use it (Ockene 1991; Page 1986; Russell 1983). Two trials compared a fixed dosage regimen with an ad lib regimen (Killen 1990; Goldstein 1989). The treatment period was typically 2-3 months, but ranged from 3 weeks to 12 months. Some trials did not specify how long the gum was available. Many of the trials included a variable period of dose tapering, but most encouraged participants to be gum-free by six to 12 months.

In nicotine patch trials the usual maximum daily dose was 15 mg for a 16-hour patch, or 21 mg for a 24-hour patch. Thirty-one studies used a 24-hour formulation and ten a 16-hour product. If studies tested more than one dose we combined all active arms in the comparison to placebo. For one study we included an arm with a lower maximum dose of 14 mg but excluded a 7 mg dose arm (TNSG 1991). One trial (Daughton 1991) included a direct comparison between groups wearing 16-hour or 24-hour patches in addition to a placebo control. Seven trials directly compared a higher dose patch to a standard dose (CEASE 1999; Dale 1995; Hughes 1999; Jorenby 1995; Kalman 2006; Killen 1999; Paoletti 1996). The minimum duration of therapy ranged from three weeks (Glavas 2003a, half the participants of Glavas 2003b) to three months, with a tapering period, if required, in 31 of the trials. Four trials directly compared two durations of therapy (Bolin 1999; CEASE 1999; Glavas 2003b; Hilleman 1994).

There are five studies of nicotine sublingual tablets or lozenges. Three used 2 mg sublingual tablets (Glover 2002; Tonnesen 2006; Wallstrom 2000). One used a 1 mg nicotine lozenge (Dautzenberg 2001). A fifth trial used 2 mg or 4 mg lozenges according to dependence level based on participants' time to first cigarette of the day (TTFC). Smokers whose TTFC was more than 30 minutes were randomized to 2 mg lozenges or placebo (Shiffman 2002 (2mg)), whilst smokers with a TTFC less than 30 minutes had higher dose 4 mg lozenges or placebo (Shiffman 2002 (4mg)). The two groups are treated in the meta-analysis as separate trials making 6 in total. There are four trials of intranasal nicotine spray (Blondal 1997; Hjalmarson 1994; Schneider 1995; Sutherland 1992), and four trials of nicotine inhaler (Hjalmarson 1997; Leischow 1996; Schneider 1996; Tonnesen 1993). One trial of a nicotine inhaler was excluded as follow up was for only three months (Glover 1992). Leischow refers to another unpublished study by different investigators that did not demonstrate any benefit of a nicotine inhaler. One trial compared four different types of NRT (patch, gum, inhaler and nasal spray) but only followed patients for 12 weeks and was excluded (Hajek 1999).

Six trials compared combinations of two forms of nicotine therapy with only one form; patch with gum to patch alone (Kornitzer



1995); patch with gum to gum alone (Puska 1995); patch with nasal spray to patch alone (Blondal 1999); patch with inhaler to inhaler alone (Bohadana 2000), patch with inhaler to either one alone (Tonnesen 2000) and patch with nasal spray to either one alone (Croghan 2003). In addition to these last two trials allowing a direct comparison between two single types, Lerman 2004 compared patch to nasal spray. A factorial trial compared nicotine and bupropion (Zyban) (Jorenby 1999). Two unpublished trials of combination therapies with only three-month follow up are excluded but contribute to a sensitivity analysis in the results (Sutherland 1999; Finland unpublished).

### Treatment setting

Twelve of the gum trials and six of the patch trials in the main comparison were conducted in a primary care setting where smokers were usually recruited in response to a specific invitation from their doctor during a consultation. A further two gum trials were undertaken in workplace clinics (Fagerstrom 1984; Roto 1987), and one in a university clinic (Harackiewicz 1988). One trial recruited via community physicians (Niaura 1994). Since participants in these trials were recruited in a similar way to primary care, we aggregated them in the subgroup analysis by setting. One patch trial conducted in Veterans Affairs Medical Centers and recruiting patients with cardiac diseases (Joseph 1996) was also included in the primary care category. One trial in an antenatal clinic (Wisborg 2000) is kept in a separate category. Six of the gum trials, one of the nasal spray trials and one of the inhaler trials, were carried out in specialized smoking cessation clinics to which participants had usually been referred. Eight trials (three gum, four patch, one giving a choice of products and one giving a combination of products) were undertaken with hospital in- or out-patients, some of who were recruited because they had a coexisting smoking-related illness. Three patch trials were undertaken in settings intended to resemble 'over-the-counter' (OTC) use of NRT (Davidson 1998; Hays 1999; Sonderskov 1997). One of these also allowed a comparison between purchased and free patches with minimal support (Hays 1999). Two trials compared purchased NRT without behavioural support (simulating an OTC setting) to purchased NRT with brief physician support (using patch, Leischow 1999, using inhaler, Leischow 2004). These two trials did not have a non-NRT control so do not contribute to the primary comparison. One trial in a primary care setting evaluated the effect of cost on the use and efficacy of nicotine gum (Hughes 1991). The remaining gum, patch, inhaler and nasal spray trials were undertaken in participants from the community, most of whom had volunteered in response to media advertisements, but who were treated in clinical settings. One of the patch trials was conducted in relapsed smokers (Gourlay 1995).

### Pre-cessation use of NRT

Four trials (Rose 1994; Rose 1998; Rose 2006; Schuurmans 2004) tested the use of nicotine patch compared to placebo initiated two weeks before the quit date. Following the quit date all study arms received active NRT. Three of the studies included other factorial

arms testing mecamylamine. We combined the arms with the same pre-quit NRT conditions in our analysis.

Excluded studies are listed with reasons in the Table of Excluded Studies. Some studies were excluded due to short follow up. Some of these had as their primary outcome withdrawal symptoms rather than cessation. Studies that provided NRT or placebo to people trying to cut down their smoking but not make an immediate quit attempt are now excluded and are considered in detail in a separate review of interventions for reduction (Stead 2007). We exclude one trial which included a test of mailed patches (Velicer 2006). This trial proactively recruited people by telephone and those in one intervention group were mailed a six-week course of nicotine patches if they were judged to be in the preparation stage or in contemplation and had more pros than cons for quitting. They did not need to be intending to make a quit attempt.

## METHODOLOGICAL QUALITY

Four trials are included based on data available from abstracts or conference presentations (Dautzenberg 2001; Kralikova 2002; Mori 1992; Nakamura 1990) so had limited methodological details.

Thirty-five studies (28%) reported allocation procedures in sufficient detail to be rated A for their attempts to control selection bias by using a system whereby treatment allocation could not be known or predicted until a participant is enrolled and assigned to a study condition. The majority of studies either did not report how randomization was performed and allocation concealed, or reported it in insufficient detail to determine whether a satisfactory attempt to control selection bias had been made (rated B). A small number of nicotine gum trials randomized to treatment according to day or week of clinic attendance (Page 1986; Richmond 1993; Russell 1983), birth date (Fagerstrom 1984), or smokers' clinic group (McGovern 1992) (rated C). One study (Nebot 1992) randomized by physician and there was no information about avoidance of selection bias in enrolment of smokers so this was also rated C. The main findings were not sensitive to the exclusion of C, or B and C grade studies from the meta-analysis.

Fifteen gum trials (Gilbert 1989; Gross 1995; Hall 1985; Harackiewicz 1988; Jensen 1991; McGovern 1992; Nakamura 1990; Nebot 1992; Niaura 1994; Niaura 1999; Richmond 1993; Roto 1987; Segnan 1991; Villa 1999; Zelman 1992) and four patch trials (Cinciripini 1996; Otero 2006; Velicer 2006; Wong 1999) did not have a matched placebo control, and a further two had both a placebo and non-placebo control which were combined for the meta-analysis control group (Buchkremer 1988; Russell 1983). The main findings were not sensitive to the exclusion of studies and arms without a placebo.

Definitions of abstinence varied considerably. Eighty-six (65%) reported some measure of sustained abstinence, which included

continuous abstinence with not even a slip since quit day, repeated point prevalence abstinence (with or without biochemical validation) at multiple follow ups, or self-reported abstinence for a prolonged period. Thirty-two (24%) reported only the point prevalence of abstinence at the longest follow up. In five studies it was unclear exactly how abstinence was defined. In one trial, participants who smoked up to three cigarettes per week were still classified as abstinent (Abelin 1989). Most studies reported follow up at least 12 months from start of treatment. Thirteen gum trials, 12 patch trials and one lozenge trial in the primary analysis had only six months follow up. We report the findings of a subgroup analysis by type of abstinence and length of follow up in the results section.

Biochemical validation of self-reported smoking cessation was used in all but 14 of the trials. Validation of abstinence was carried out by measurement of nicotine metabolites in saliva, urine or blood in 27 trials. The most common form of validation was measurement of carbon monoxide (CO) in expired air. The 'cut-off' level of CO used to define abstinence varied from less than 4 to 11 parts per million. The main findings were not sensitive to the exclusion of studies that did not attempt to validate abstinence.

Some of the studies involve NRT versus usual care and are inevitably not double-blind in design. We did not assess whether trials reported an assessment of the integrity of blinding, in line with the CONSORT guidelines (CONSORT 1996). Where they are done, assessments of blinding integrity should always be carried out before the clinical outcome has been determined, and the findings reported (Altman 2004). Mooney 2004 notes that few published trials report this information. While those that do provide some evidence that participants are likely to assess their treatment assignment correctly, it is insufficient to assess whether this is associated with differences in treatment effects. Further, there may be an apparent breaking of the blinding in trials where the treatment effect is marked, for either an intended outcome or an adverse effect, but participants who successfully decipher assignment may disguise their unblinding actions (Altman 2004). Also it is possible that those who believe that they are receiving a placebo may be more likely to stop trying to quit.

## RESULTS

Each of the five forms of nicotine replacement therapy (NRT) significantly increased the rate of cessation compared to placebo, or no NRT (Comparison 1). This meta-analysis included 111 trials, with over 43,000 participants. For the different types of NRT the risk ratio (RR) was 1.43 (95% confidence interval (CI): 1.33 to 1.53, 53 trials) for nicotine gum, 1.66 (95% CI: 1.53 to 1.81, 41 trials) for nicotine patch, 1.90 (95% CI: 1.36 to 2.67, 4 trials) for nicotine inhaler, 2.00 (95% CI: 1.63 to 2.45, 6 trials) for oral tablets/lozenges, and 2.02 (95% CI: 1.49 to 2.73, 4 trials) for nicotine nasal spray. Although the estimated effect sizes varied

across the different products, confidence intervals were wide for the products with higher estimates which had small numbers of trials. In a metaregression with gum as baseline, only the difference with the tablets/lozenges group was statistically significant ( $P$  value = .014), whilst the difference with nasal spray was marginally significant ( $P$  = .055). The pooled risk ratio for abstinence for any form of NRT relative to control was 1.58 (95% CI: 1.50 to 1.66). The  $I^2$  statistic was 24%, indicating that little of the variability was attributable to between-trial differences. Seven nicotine gum and two patch trials had lower quit rates in the treatment than control groups at the end of follow up, and in a further 56 (50%) of trials the 95% confidence interval for the risk ratio included 1 (i.e. the trials did not detect a significant treatment effect). Many of these trials had small numbers of smokers, and hence insufficient power to detect a modest treatment effect with reasonable certainty. One large trial of nicotine patches for people with cardiovascular disease had lower quit rates in the intervention than control group (Joseph 1996). At six months the quit rates were 14% for active patch and 11% for placebo, but after 48 weeks there had been greater relapse in the active group and rates were 10% and 12% respectively.

### Sensitivity to definition of abstinence

For the nicotine gum and patch trials we assessed whether trials that reported sustained abstinence at 12 months had different treatment effects from those that only reported a point prevalence outcome, or had shorter follow up (Comparison 2). Subgroup categories were sustained abstinence at 12 months or more, sustained abstinence at six months, point prevalence or unclear definition at 12 months, and point prevalence/unclear at six months. For nicotine gum 32/53 studies (60%) reported sustained 12-month abstinence and the estimate was almost identical to that for all 53 studies (sustained 12-month RR 1.43, 95% CI 1.31 to 1.56,  $I^2$  = 34%). For nicotine patch, 21/41 studies (51%) reported sustained 12-month abstinence, and the relative risk estimate was lowest in this subgroup (sustained 12-month RR 1.51, 95% CI 1.35 to 1.70,  $I^2$  = 27%). For neither the gum nor patch trials was there evidence from metaregression that the risk ratios differed significantly between subgroups.

### Sensitivity to intensity of behavioural support

Each trial provided the same behavioural support in terms of advice, counselling, and number of follow-up visits to the active pharmacotherapy and control groups, but different trials provided different amounts of support. We conducted subgroup analyses by intensity of support for gum and patch trials separately (Comparison 3). For nicotine gum the relative risk estimate was similar across all three subgroups. The control group quit rates did vary as expected, averaging 5.9% with low intensity support, 9.8% with high intensity individual support and 11.7% with group-based support. Nicotine patch trials showed the same pattern; the relative risk estimates were similar for each subgroup and the average control group quit rates were 6.3% with low intensity support, 6.7% with high intensity individual support and 14.8% with group-

based support. Using metaregression we confirmed that there was no evidence that the relative effect differed by type of support.

Two small studies in primary care directly compared the effect of providing high versus low intensity follow up to participants receiving nicotine gum (Fagerstrom 1984; Marshall 1985). The pooled results favoured intensive follow up but the result was not statistically significant. In the one patch trial that compared minimal counselling with two forms of more intensive counselling in patients receiving one of two nicotine doses, the intensive intervention did not lead to improved outcomes (Jorenby 1995). Pooling all three studies showed no effect of increased behavioural support (Comparison 3.3, RR 1.14, 95% CI 0.88 to 1.47). It should be emphasised that these three studies do not address the efficacy of NRT and that only a factorial placebo-controlled trial with different intensities of support can adequately investigate whether pharmacotherapy and behavioural interventions have interactive effects.

### **Sensitivity to treatment settings**

We did a further subgroup analysis based on the setting in which smokers were recruited or treated, for each type of NRT (Comparison 4). For nicotine gum there was no evidence that the relative effect differed substantially across the main subgroups. The subgroup of three trials recruiting hospital in- or outpatients had a lower and non-significant estimated effect. As expected the average control group quit rate was highest amongst smokers recruited and treated in specialist smoking clinics (16%), lower in community volunteers (11%) and lowest in people recruited and treated in primary care settings (5%).

For nicotine patch, effects in subgroups were again generally similar. We did not think that any of the patch trials recruited people attending smoking cessation clinics, but it is possible that some trials in community volunteers provided treatment in specialist clinics. For patches used in hospital settings the results, based on four trials, are consistent with those seen in other settings. In the single trial of a nicotine patch for women trying to quit during pregnancy no benefit of the patch was detected (Wisborg 2000). Nasal spray and inhaler trials did not show differences in effect by setting, and all lozenge trials involved community volunteers. Two other trials of other types of NRT involved hospital patients; Molyneux 2003 offered a choice of type of NRT to hospital inpatients, in which 63% chose patch; the use of NRT increased quit rates but the difference was not significant. Hand 2002 provided a combination of patch and inhaler to hospital in- or outpatients for three weeks, compared to individual counselling alone, and quit rates were similar at 12 months. Three patch studies have assessed the effect of patch amongst community volunteers treated in an 'Over the Counter' (OTC) setting offering low levels of support and little or no contact with healthcare professionals. The effect estimate was similar to that in other settings (RR 1.98, 95% CI 1.40 to 2.79, Comparison 04.02.02).

Two trials compared patch (Leischow 1999) or inhaler (Leischow 2004) with minimal physician support and patch/inhaler with no support in a simulated OTC setting. Abstinence rates were low in both conditions and confidence intervals wide, but when pooled there was a significant advantage of the physician support compared to no support (RR 4.58, 95% CI: 1.18 to 17.88) (Comparison 13).

### **Nicotine gum - effects of dose and scheduling**

Most trials used the 2 mg dose so we did not do a subgroup analysis for indirect comparison. Four trials directly compared 4 mg and 2 mg gum for treating highly dependent smokers with a pooled estimate suggesting a significant benefit of the higher dose (RR 1.85, 95% CI: 1.36 to 2.50, Garvey 2000; Herrera 1995; Kornitzer 1987; Tonnesen 1988. Comparison 5.1.1). In low dependence or unselected smokers there was no evidence for an effect (RR 0.77, 95% CI 0.49 to 1.21, Garvey 2000; Hughes 1990; Kornitzer 1987. Comparison 5.1.2).

Two trials compared a fixed dose regimen of 2 mg nicotine gum against use of an ad lib regimen (Goldstein 1989; Killen 1990). The fixed dose regimen had higher quit rates but the difference was non-significant (RR 1.22 95% CI: 0.92 to 1.61, Comparison 6).

### **Nicotine patch - effects of dose and scheduling**

Seven trials have compared a high dose patch to standard dose (Comparison 7). Four used 24-hour patches and compared 42/44 mg doses to standard 21/22 mg doses (Dale 1995; Hughes 1999; Jorenby 1995; Kalman 2006). Three used 16-hour patches and compared a 25 mg high dose to 15 mg standard dose (CEASE 1999; Killen 1999; Paoletti 1996). Three studies (Hughes 1999; Killen 1999; Kalman 2006) specifically recruited heavy smokers, and one selected smokers with baseline cotinine levels of over 250 mg/ml (Paoletti 1996). One study was in heavy smokers with a history of alcohol dependence (Kalman 2006). Pooling all seven studies gives an estimated RR of 1.15 (95% CI: 1.01 to 1.30) providing only marginal evidence of a small benefit from higher doses. Three studies had point estimates favouring the lower dose group but there was no evidence of significant heterogeneity in the results ( $I^2 = 25\%$ ). Only one study showed a significantly higher quit rate with the higher dose (CEASE 1999).

Indirect comparison failed to detect evidence of a difference in effect between 16-hour and 24-hour patch, with similar point estimates and overlapping confidence intervals in the two subgroups. There was some evidence of heterogeneity in the results of the 10 trials that used a 16-hour patch ( $I^2 = 54\%$ ) (Comparison 8). One trial directly compared the effect of 16-hour and 24-hour patch use (Daughton 1991). The study did not detect a significant difference, but with just 106 participants had low power (24-hour patch versus 16-hour patch: RR 0.70, 95% CI: 0.36 to 1.34).

### **Nicotine patch - effect of treatment duration and dose tapering**

Indirect comparisons did not suggest a difference in treatment effect between 15 trials providing up to eight weeks of pharma-

cotherapy and 26 offering a longer period. (Comparison 9). One large trial that compared a 28- to a 12-week course of treatment did not detect evidence of benefit from longer treatment (CEASE 1999). Smaller trials comparing a three-week to a 12-week course (Bolin 1999) and a three-week to a six-week course (Glavas 2003b) also found no evidence for a difference.

Indirect comparison did not detect a difference in effect between 31 trials where participants were weaned from patch use by gradually tapering the dose and eight trials where withdrawal was abrupt (Comparison 10). Similarly, no difference was detected in the two trials that directly compared weaning with abrupt withdrawal, (Hilleman 1994; Stapleton 1995).

### Combinations of different forms of nicotine therapy

Six trials compared the use of two types of NRT with using a single type only, and one compared two types to no NRT (Hand 2002). Pooling all seven trials suggests a statistically significant benefit (Comparison 11, RR 1.35, 95% CI: 1.11 to 1.63), with little statistical heterogeneity ( $I^2=25\%$ ), but the trials are relatively clinically heterogeneous in the combinations and comparison therapies used. The effect was similar when excluding the trial with a no-NRT control. Only one of the trials, comparing nasal spray and patch with patch alone, showed a significantly higher rate of sustained abstinence at one year with the combined therapy (Blondal 1999). We are aware of two unpublished studies that failed to detect significant short-term effects and did not have longer-term follow up (Sutherland 1999; Finland unpublished). Brief details in Table of Excluded Study). In case their exclusion biased the outcome we tested the sensitivity of the meta-analysis to including their results for cessation at three months. The meta-analysis maintained a significant, though slightly smaller, effect. We also tested the sensitivity to including only comparisons between a combination therapy and a nicotine patch only control. The effect remained just significant, with or without the relevant unpublished study.

### Direct comparison between different types of NRT

Three trials have directly compared types (Comparison 12). None detected significant differences. Pooling the two that compared nasal spray with patch also failed to detect a significant difference (Nasal spray versus patch RR 0.90, 95% CI 0.64 to 1.27). Whilst confidence intervals are wide, the direct comparison is consistent with indirect comparisons reported above in the primary analysis, suggesting that the different types have similar effects.

### Pre-cessation use of NRT

The pooled estimate from four trials suggests that using a nicotine patch for a brief period before the target quit day significantly increases the rate of cessation compared with initiating active patch use on the quit day (Comparison 14, RR 1.79, 95% CI 1.17 to 2.72). One other trial included groups who began using nicotine gum or placebo gum before quit day (Herrera 1995). This procedure did not significantly increase quitting at six weeks and long-term outcomes were not reported, but when we tested the inclu-

sion of short-term outcomes in the meta-analysis with the four patch trials a significant effect remained.

### Relapsed smokers

Although many of the trials reported here did not specifically exclude people who had previously tried and failed to quit with NRT, one trial recruited people who had relapsed after patch and behavioural support in an earlier phase of the study but were motivated to make a second attempt (Gourlay 1995). This study did not detect an effect on continuous abstinence (RR 1.25 95% CI 0.34 to 4.60), although it did detect a significant increase in 28-day point prevalence abstinence (RR 2.49, 95% CI 1.11 to 5.57). Quit rates were low in both groups with either definition of abstinence.

### Cost of therapy

One study comparing the effectiveness of free and purchased patch in an OTC model setting found no significant difference in quit rates between the two conditions; 8.7% (28/321) quit with free patch, 11% (34/315) with purchased patch, RR 0.81, 95% CI 0.50 to 1.30 (Hays 1999). Those receiving free NRT were part of a placebo-controlled substudy. One small study of the cost of nicotine gum for patients receiving brief physician advice found non-significantly higher quit rates for participants who could obtain free gum compared to those paying close to full price; 6/32 (22%) versus 3/38 (12%). People who could get free gum were much more likely to obtain it (Hughes 1991).

### Comparison with bupropion

In one study the cessation rate was significantly lower for nicotine patch and placebo tablet than bupropion and placebo patch (Jorenby 1999). The combination of bupropion and nicotine patch significantly increased the rate over placebo alone or patch alone, but not over bupropion alone (Comparison 15). Another trial compared nicotine gum and bupropion to bupropion alone (Piper 2007); pooling this and the patch+bupropion combination trial also failed to detect a significant additional benefit from NRT.

### Adverse Effects

No attempt was made in this overview to synthesize quantitatively the incidence of the various side effects reported with the different NRT preparations. This was because of the extensive variation in reporting the nature, timing and duration of symptoms. The major side effects usually reported with nicotine gum include hiccoughs, gastrointestinal disturbances, jaw pain, and orodental problems (Fiore 1992; Palmer 1992). The only side effect that appears to interfere with use of the patch is skin sensitivity and irritation; this may affect up to 54% of patch users, but it is usually mild and rarely leads to withdrawal of patch use (Fiore 1992). The major side effects reported with the nicotine inhaler and nasal spray are related to local irritation at the site of administration (mouth and nose respectively). For example, symptoms such as throat irritation, coughing, and oral burning were reported significantly more frequently with subjects allocated to the nicotine inhaler than to placebo control (Schneider 1996); none of the experiences, how-

ever, were reported as severe. With the nasal spray, nasal irritation and runny nose are the most commonly reported side effects. Nicotine sublingual tablets have been reported to cause hiccoughs, burning and smarting sensation in the mouth, sore throat, coughing, dry lips and mouth ulcers (Wallstrom 1999).

A review of adverse effects based on 35 trials with over 9,000 participants did not find evidence of excess adverse cardiovascular events amongst those assigned to nicotine patch, and the total number of such events was low (Greenland 1998). There has been concern about the safety of NRT in smokers with cardiac disease (TNWG 1994). A trial of nicotine patch (Joseph 1996) that recruited smokers aged over 45 with at least one diagnosis of cardiovascular disease found no evidence that serious adverse events were more common in smokers in the nicotine patch group. Events related to cardiovascular disease such as an increase in angina severity occurred in approximately 16% of patients, but did not differ according to whether or not patients were receiving NRT. A review of safety in patients with cardiovascular disease found no evidence of an increased risk of cardiac events (Joseph 2003). This included data from two randomized trials with short-term follow up that are excluded from the present review (Tzivoni 1998; Working Group 1994) and a case-control study in a population-based sample. An analysis of 187 smokers admitted to hospital with acute coronary syndromes who received nicotine patches showed no evidence of difference in short- or long-term mortality compared to a propensity-matched sample of smokers in the same database who did not receive NRT (Meine 2005).

## DISCUSSION

This overview provides reliable evidence from trials including over 40,000 participants that offering nicotine replacement therapy (NRT) to dependent smokers who are prepared to try to quit increases their chance of success over that achieved with the same level of support without NRT. This applies to all forms of NRT and is independent of any variations in methodology or design characteristics of trials included in the meta-analysis. In particular we did not find evidence that the relative effect of NRT was smaller in trials with longer follow up beyond our six-month minimum for inclusion. We did not compare end of treatment risk ratios with post-treatment follow up, and relapse rates may be higher in active treatment participants once they stop using NRT products, but later relapse is probably unrelated to NRT use.

The absolute effects of NRT use will depend on the baseline quit rate, which varies in different clinical settings. Studies of people attempting to quit on their own suggest that success rates after six to 12 months are 3-5% (Hughes 2004a). Use of NRT might be expected to increase the rate by 2-3%, giving a number needed to treat (NNT) of 33-50. If however the quit rate without pharmacotherapy was estimated to be 15%, either because the population had other predictors of successful quitting or received intensive

behavioural support, then another 8% might be expected to quit, giving an NNT of 12.

### Type and dose of NRT

The conclusion that the relative effects of the different forms of NRT are similar is largely based on indirect comparisons. Although the estimated risk ratio was highest for the nasal spray the confidence intervals are wide. In a metaregression the estimated difference in effect between gum and the tablet/lozenge subgroup was statistically significant. Most of the trials included in the comparison of nicotine gum versus placebo used 2 mg gum, although the 4 mg dose has been shown to be better for highly dependent smokers. One lozenge study used a 4 mg dose and excluding this would reduce the difference between gum and tablet/lozenge subgroups. There have been no direct comparisons between these different forms. Three studies have directly compared different types, and differences between them were non-significant individually and when pooled. One study that randomized people to use nicotine gum, patch, spray or inhaler did not detect significant differences in abstinence rates after 12 weeks (Hajek 1999), supporting the indirect estimates from the longer term studies. Where a range of products are available, choice of product may be guided by patients' preferences (McClure 2006), although one study showed that allowing people to try different products may alter their perceptions (Schneider 2004). In one study directly comparing nicotine patch and nasal spray there were no overall difference in quit rates but there were three significant subgroup/treatment interactions (Lerman 2004). The patch showed better results for white smokers while the spray showed better results for obese smokers and highly nicotine-dependent smokers. These effects need confirmation in additional studies before they can be relied on for treatment matching.

Direct comparisons support the use of 4 mg gum for more nicotine dependent smokers. There is borderline evidence for a small benefit from use of the nicotine patch at doses higher than the standard dose (21 mg for 24 hours or 15 mg for 16 hours). Use of these may be considered for heavy smokers (i.e. smoking 30 or more cigarettes a day), or for patients relapsing because of persistent craving and withdrawal symptoms on standard dose therapy (Hughes 1995).

### Combinations of NRT products

The evidence suggests that using a combination of NRT products is better than one product alone. The trials showed fairly consistent effects, with a range of different comparators. The combined therapies all included the patch and an acute dosing type. The 2000 US clinical practice guidelines (Fiore 2000) recommended the use of nicotine patch with another form of NRT as a second-line therapy for patients unable to quit on a single type of NRT or bupropion. At that time the strength of evidence was recognized as less than optimal due to the clinical heterogeneity of the studies in the meta-analysis. Two further trials have been published since then, strengthening the evidence. It is not entirely clear whether

the benefit of combination therapy is due to the sensory effects provided by multiple types of delivery systems, to the higher percentage of nicotine substitution achieved, the better relief of craving by ad lib use of acute dosing forms or some combination of these and other factors (Sweeney 2001).

### **Intensity of additional support**

We did not detect important differences in relative effect within patch or gum studies by our classification of level of support. A recent letter (Walsh 2007) identified inconsistencies in the classification of low and high intensity support in this review. In response we have changed the classification of a small number of trials. This has not altered the conclusion that intensity of support does not appear to be an important moderator of NRT effect. Most of the trials in the low intensity category were conducted in medical settings and the cut off for level of support was not intended to distinguish between 'over the counter' use of NRT and use with support from healthcare providers. We did a separate analysis of OTC type trials in the treatment setting subgroup analysis. As judged by the average control group quit rate, people receiving support and placebo had similar quit rates in low intensity and high intensity individual support groups, and one interpretation of this is that although the latter group typically had more frequent contact with study co-ordinators, this was not markedly increasing quitting or preventing relapse. Control group quit rates were however higher when people had intensive group-based support provided by specialists.

### **Treatment setting**

We did not detect differences in relative effect within patch or gum studies according to the setting of recruitment and treatment. These subgroup analyses had considerable overlap with the support subgroup since for example people recruited in primary care settings typically had lower intensity support. Again there was variation between the control group quit rates, attributable to differences in motivation and to the level of behavioural support. People recruited from primary care who received placebo had average quit rates around 5 to 7%. This was similar to the rate amongst community volunteers who were treated in 'OTC' settings. People recruited in smoking clinics had much higher control group quit rates, averaging 15%, but this reflects both their motivation and the high level of behavioural support provided. Although some trials of NRT use in hospital inpatients have reported relatively less successful results, in the subgroup of four studies of nicotine patch amongst people recruited in inpatient and outpatient settings there was evidence of benefit.

There has been continuing debate about the amount of evidence for efficacy of NRT when obtained OTC without advice or support from a healthcare professional (Hughes 2001; Walsh 2000; Walsh 2001). The small number of placebo-controlled trials in settings intended to replicate OTC settings support the conclusion that the relative effect of NRT is similar to settings where more advice and behavioural support is provided, although quit

rates in both control and intervention groups have been low. One other meta-analysis supports the conclusion of efficacy, although it differs in its inclusion criteria (Hughes 2003). In addition to the same three trials comparing nicotine patch to placebo in an OTC setting (Davidson 1998; Hays 1999; Sonderskov 1997), that review includes one study excluded here due to short follow up (Shiffman 2002a). It also pools four trials comparing NRT provided OTC to NRT provided under prescription. We exclude one paper that compared both gum and patch in these settings, but was not randomized (Shiffman 2002b), and another that has not been published and for which we have been unable to obtain reliable data for inclusion (Korberly 1999). The abstract reported that there were no significant differences in quit rates between users of nicotine patch who purchased it via a non-healthcare facility, and those receiving it on prescription. On the basis of one published and one unpublished study we find a marginally significant benefit of NRT with prescription compared to OTC, but the confidence intervals are wide.

It has been suggested that the 'real world' effectiveness of NRT declines or disappears once it becomes available to purchase without a requirement for contact with a health professional who can offer behavioural support and guidance on appropriate use (Pierce 2002). This was based on a comparison of two cross sectional surveys in California. Before OTC availability quit rates for self-selected NRT users were higher than rates for non-users but after the switch to OTC this difference disappeared. We and others have questioned the conclusions from this study (Franzon 2002; Stead 2002). One source of confounding which may have been incompletely controlled is the level of addiction of people who chose to use NRT compared to those who did not (Shiffman 2005). People who have used NRT may also be more likely to recall quit attempts. A second study suggested that both use of NRT and quit rates rose in the immediate aftermath of OTC availability (Hyland 2005). In this longitudinal study of smokers in the COMMIT study cohort there was a small reduction in the average success rates for patch users after the switch but no reduction in success rates for gum users. A more recent multicountry prospective study (West 2007) found that NRT users who did not use formal behavioural support had higher quit rates than non-users, even when controlling for baseline differences in motivation and other possible predictors of success. Although no study in which participants self-select treatment can be free from the possibility of bias due to unmeasured confounders, the results of this study provide additional reassurance. A review on the impact of NRT on population trends in smoking behaviour concluded that at the moment not enough smokers are using NRT during quit attempts for there to have been a measurable effect (Cummings 2005).

### **Trials in special populations**

One trial of nicotine patch in pregnant women is now included in the review. Women still smoking after their first trimester were recruited, and they were followed up until one year post partum. No significant benefit of treatment was detected, although the con-

fidence interval does not exclude the possibility of benefit. Quit rates one year after delivery were 15% in the patch group and 14% in the placebo group. Using quit rates at the final prenatal follow up did not alter the conclusions, with rates of 28% versus 25%. Possible explanations for the lack of relative benefit may have been low compliance with patch use, and the intensive cessation counselling offered to all participants. We excluded two other small trials of nicotine patch in pregnancy: Kapur 2001 had follow up only to end of treatment at 12 weeks. In this trial 0/13 in the placebo group quit compared to 4/17 (24%) in the active treatment group. Enrolment was ended early in this study because of a possible adverse event in the placebo arm. A second small study without placebo control had high rates of withdrawal and non-compliance (Hotham 2006), although 3/20 in the patch group were abstinent at delivery compared to 0/20 in the counselling only control. Another trial was published too late to be included in this update (Pollak 2007). A recent study measuring nicotine metabolism in smokers during their pregnancy and postpartum has suggested that nicotine is metabolised more quickly by pregnant women and that this may affect the dose of NRT required (Dempsey 2002). More studies are needed to establish whether or not NRT does aid quitting in pregnancy and what effects there are on birth outcomes (Benowitz 2000). A large trial is now underway in the UK (Coleman 2007)

Trials generally restricted recruitment to adults over the age of 18; in a small number of trials the age range was not specified. One trial in adolescents is now included (Moolchan 2005). This compared nicotine patch, gum, and double placebo. Two trials with less than six months follow up were excluded. One trial examining the effects of the nicotine patch on craving and withdrawal symptoms, safety, and compliance among 100 adolescents had 10 weeks follow up. No significant difference was detected at this point (Hanson 2003). In a second trial of the patch with 13 weeks follow up there were no quitters in either group at that point (Roddy 2006). Compliance with therapy and participant retention were both reported to be problems.

#### **Evidence for differential treatment effects in different subgroups**

We made no attempt to conduct separate analyses for any subgroups of trial participants, because subgroup results are uncommon in trial reports, and where data cannot be obtained from all studies there is a risk of bias from using incomplete data. Munafa and colleagues have reported the results of a meta-analysis of nicotine patch by sex (Munafa 2004a). They were able to include data from 11 out of 31 (35%) of eligible trials and 36% of study participants. They found no evidence that the nicotine patch was more effective for men than women as has been hypothesised, although there was a non-significant trend in that direction for outcomes at 12 months. There was also no difference in average placebo quit rates between men and women, which has been reported in some studies. In a commentary (Perkins 2004) some additional data were identified, but this did not alter the

conclusions (Munafa 2004b). A second meta-analysis of any type of NRT (Cepeda-Benito 2004) reported that in women the odds ratio for cessation declined with increasing length of follow up with a non-significant difference at 12 months. Amongst males the odds ratio declined less over time and remained significant. Based on a further subgroup analysis they also reported that the decline in long-term efficacy in women was greater in trials with low intensity support than high intensity support, suggesting that the more intensive support helped prevent late relapse in women who had initially received NRT. Although there was no evidence of bias, the review could only include a subset of published studies so the finding should be regarded as hypothesis generating. All review authors agreed that trials are underpowered to identify any interaction between treatment and any type of individual characteristics, and recommended public archiving of data from studies, as well as new research specifically designed to test group by treatment interactions. At the moment there does not appear to be sufficient evidence of clinically important differences between men and women to guide treatment matching.

#### **Pre-cessation use of NRT**

When nicotine replacement therapies were first introduced there was concern that any smoking whilst using a product would increase the potential for adverse effects such as nausea and vomiting, due to nicotine overdose. However studies with higher dose products and combinations of products have found no evidence of harm from moderate increases in nicotine intake. There is some evidence that smokers who use NRT whilst not trying to alter their smoking behaviour either smoke less or reduce their nicotine from cigarettes, especially when using acute dosing types of NRT (Fagerstrom 2002). Trials have now investigated two situations in which it has been proposed that use of an NRT product can help long-term abstinence if initially used while continuing to smoke. The first of these is to begin using the nicotine patch for a short period before an abrupt quit attempt on the theoretical basis that it might diminish the reinforcing effects of cigarette smoking or reduce the dependence on inhaled nicotine (Rose 2006). Based on meta-analysis of four trials included in this review there appears to be evidence that this increases quit rates over that achieved by post-quitting NRT alone. A large trial of pre-cessation NRT use is now underway in New Zealand.

The second proposed use of NRT pre-cessation is for a period of weeks to months while people not willing or able to quit abruptly gradually reduce the number of cigarettes, before quitting completely. The use of two forms of NRT, gum and inhaler, has now been approved by licensing authorities in some European countries for this cessation approach, described variously as 'Reduce to Stop' or 'Cut Down to Quit'. Trials of this approach are included in a Cochrane review of interventions for reducing harm from continued smoking (Stead 2007). The long-term use of NRT whilst continuing to smoke smaller numbers of cigarettes cannot be supported by the evidence because it is not clear what reduction in consumption is needed for a useful health benefit.

### Retreating relapsed smokers

Whilst end of treatment success rates may be quite high, many people relapse after the end of therapy. There is suggestive evidence (Gourlay 1995) that repeated use of NRT in patients who have relapsed after an initial course may produce further quitters, though the absolute effect is small. A subgroup analysis in another trial (Jorenby 1999, reported in Durcan 2002) indicated that the relative effect of treatment with nicotine patch compared to placebo was at least as high for people who had used NRT before. The authors noted that there was no way to distinguish between people who had completely failed to quit using NRT and those who had been initially successful but relapsed.

### Direct comparison and combination with non-nicotine pharmacotherapies

There is evidence from one large study (Jorenby 1999) that bupropion is more effective than nicotine patch. A combination of NRT and bupropion has not been found to be significantly more effective than bupropion alone. No trial of a direct comparison between NRT and varenicline has yet been published.

### Addictive Potential of NRT

Some successful quitters continue to use NRT products beyond the recommended treatment period (Shiffman 2003), but few develop true dependence (Hughes 2004b; Hughes 2005). Although nicotine has the potential to cause harm, it is very much less harmful than tobacco smoke, so whilst complete abstinence from nicotine is preferred, the risk to health from NRT use is small compared to the risk from continued smoking.

### Methodological Limitations

There are two possible methodological limitations of this overview, which need to be borne in mind: use of tabulated data predominantly derived from published reports (Stewart 1993) and publication bias (Simes 1986). We tried to partly address any shortcomings from having limited our analysis to tabulated data by approaching investigators, where necessary, to obtain additional unpublished data or to clarify areas of uncertainty. Although steps were taken to minimize publication bias by writing to the manufacturers of NRT products when this review was first prepared, the response was poor and we have not repeated this exercise. It is therefore possible that there are some unpublished trials, with less favourable results, that we have not identified despite our efforts to do so. A statistical analysis (Egger 1997, Egger personal communication) suggests that this is the case. A regression method to assess the symmetry of funnel plots showed evidence of asymmetry, and hence possible publication bias, for both nicotine gum and transdermal patches in an earlier version of this review. For the nicotine inhaler we are aware of one unpublished trial with a non-significant result. A recent meta-analysis has also demonstrated that nicotine gum and patch studies that received pharmaceutical industry funding have on average slightly higher effect sizes than other studies after controlling for some trial characteristics (Etter 2007). The practical effect of these considerations is that the mag-

nitude of the effectiveness of nicotine replacement may be smaller than our estimates suggest.

This review excludes studies with less than six months follow up from the start of treatment; the outcome used reflects the effect of NRT after the end of active treatment. A comparison of abstinence rates during treatment and abstinence at one year (Fagerstrom 2003) suggests that the relative effect of NRT declines once active therapy stops, that is, people who quit with the help of NRT are a little more likely to relapse after they discontinue treatment than those on placebo. The relative effect of NRT could continue to decline even after a year of follow up. A meta-analysis comparing one-year and long-term outcomes in twelve NRT trials with follow up beyond one year suggested that the relative efficacy did not change, with similar relapse rates in the active and placebo groups, but further relapse does reduce the absolute difference in quit rates (Etter 2006).

## AUTHORS' CONCLUSIONS

### Implications for practice

1. All of the commercially available forms of nicotine replacement therapy (NRT), i.e. gum, transdermal patch, nasal spray, inhaler, lozenge and sublingual tablet, are effective as part of a strategy to promote smoking cessation. They increase the rate of long-term quitting by approximately 50% to 70% regardless of setting. These conclusions apply to smokers who are motivated to quit and who have high levels of nicotine dependence. There is little evidence about the role of NRT for individuals smoking less than 10 to 15 cigarettes a day.
2. The choice of which form to use should reflect patient needs, tolerability, and cost considerations. Patches are likely to be easier to use than gum or nasal spray or inhaler but patches cannot be used for relief of acute cravings.
3. Eight weeks of patch therapy is as effective as longer courses and there is no evidence that tapered therapy is better than abrupt withdrawal. Wearing the patch only during waking hours (16 hours a day) is as effective as wearing it for 24 hours a day.
4. If gum is used, it may be offered on a fixed dose or ad lib basis. For highly dependent smokers, or those who have failed with 2 mg gum, 4 mg gum should be offered.
5. There is borderline evidence for a small benefit from use of the nicotine patch at doses higher than the standard dose (21 mg for 24 hours or 15 mg for 16 hours).
6. There is evidence of benefit from combining the nicotine patch with an acute dosing type (e.g. gum) to allow ad lib dosing compared to use of a single form.
7. The effectiveness of NRT in terms of the risk ratio appears to be largely independent of the intensity of additional support



provided. Provision of more intensive levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of NRT. It should be noted though that the absolute increase in success rates attributable to the use of NRT will be larger when the baseline chance of success is already raised by the provision of intensive behavioural support.

8. There is minimal evidence that a repeated course of NRT in patients who have relapsed after recent use of nicotine patches will result in a small additional probability of quitting.

9. NRT does not lead to an increased risk of adverse cardiovascular events in smokers with a history of cardiovascular disease.

10. Nicotine patch was less effective than bupropion in one trial, but further trials are needed to confirm this. Any decision about which pharmacotherapies to use should take into account potential adverse effects as well as benefits.

### Implications for research

Further research is required in several areas:

1. Direct comparisons between the various forms of NRT and between different doses and durations of treatment.
2. Use of combinations of different forms of NRT.
3. Direct comparisons between NRT and newer pharmacotherapies including varenicline
4. The effect of starting NRT use before the quit date.

## NOTES

Prof Chris Silagy died in December 2001. In recognition of his major contribution he remained as first author until 2007. The authorship changed from 2008 issue 1.

## FEEDBACK

### How should efficacy be measured?

#### Summary

The comment (December 2002) states that NRT is not more effective than abrupt cessation. We summarise the supporting arguments and our response to each below:

#### Author's reply

1. Pierce & Gilpin (Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *JAMA* 2002;288:1260-4) found no difference in long-term cessation rates between those who did and who did not use NRT.

This point is addressed in a letter commenting on the study (Stead LF et al. Effectiveness of over-the-counter nicotine replacement

therapy. *JAMA* 2002;288:3109-10). The main limitation of their study is that the comparison between groups of people who chose or did not chose to use NRT. These two groups probably differ in many respects related to their chance of successful quitting, and it is impossible to adjust for these possible confounders. Therefore the conclusions of the study are stronger than the evidence justifies.

The criticism authors also cite the Minnesota insurance review (Boyle RG et al. Does insurance coverage for drug therapy affect smoking cessation? *Health Affairs* 2002 Nov-Dec;21:162-8) but it does not seem to give further support to the point made. The main finding of Boyle et al was that introducing an insurance benefit did not increase use of NRT.

2. In the real-world those relying exclusively upon NRT are relapsing and dying at pre-NRT rates.

This is an assertion which is not supported by evidence.

3. NRT study instruction is designed and sequenced in order to foster device transfer. In fact the placebo group must be deprived of critical abrupt cessation instructional tips because if given and followed many could have a negative impact upon the active group.

The review does not make the assertion or implication attributed to it. In the studies involving behavioural support as well as active versus placebo NRT, both active and placebo groups are typically given instructions designed to maximise their chances of success. In these circumstances NRT if anything shows a larger advantage over placebo than it does in minimal support settings. If it is being asserted that placebo groups are being deprived of progressive cigarette weaning or some form of lapse management strategy, there is no evidence to suggest that this approach is effective.

4. The duration of abstinence for NRT groups should begin from the time they stop using NRT.

In response to this it should be noted that it is cigarettes which are causing the harm to health and the aim is to help people stop smoking. Secondly, studies that have followed up smokers long-term show that the medication genuinely improves long-term cessation rates and does not simply set the relapse clock back by the time period when nicotine replacement is being used.

5. There are clinic programmes achieving success rates at least as good as those using NRT.

It is necessary to make direct comparisons ensuring that the same criteria are applied to both groups to be able to draw conclusions.

Finally it must be noted that the Cochrane review shows that NRT is estimated to help some 7% smokers to stop long-term who would not have stopped had they used a similar approach but without NRT. This effect is small but given the health benefits from stopping smoking it is a highly cost-effective life-preserving medication. That is not to say that other interventions, including a different kind of behavioural intervention that was incompatible with NRT could not get better results. However, it is not enough

just to assert the possibility; with so many lives at stake it would be imperative to demonstrate the effectiveness of such approaches.

Contributors

Comment by John R. Polito. Response by Tim Lancaster & Lindsay Stead on behalf of review authors. Criticism editor Robert West.

### How should effectiveness be measured

Summary

The comment (October 2003) suggests that randomised controlled trials (RCTs) alone cannot establish the effectiveness of an intervention in a population.

Author's reply

RCTs establish the size of effect of an intervention in a particular context in a sample who are eligible and willing to receive the intervention. It always remains possible that the effect size would be different in a different population under different conditions which is why it is important to assess in RCTs how representative the samples are, and how far the context of the trial represents the likely clinical scenarios in which the intervention will be applied. In other words an RCT seeks to achieve internal validity (corresponding to efficacy) and aspires to maximise external validity (corresponding to effectiveness). A 'real-world' comparison of two groups that are not comparable, and where the differences are not adequately controlled for by design or analysis, does not permit attribution of differences or similarities in outcome to the intervention under investigation.

Contributors

Comment by John Pierce. Reply by Lindsay Stead & Tim Lancaster on behalf of review authors.  
Criticism Editors: Robert West (internal), Lisa Bero (external).

### Impact of failure to assess blinding on validity

Summary

The comment (May 2004) drew attention to a recent paper (Mooney M, White T, Hatsukami D. The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials. *Addictive Behaviors* 2004; 29(4):673-684) that notes that most NRT trials do not report whether blinding was maintained, and of those that did, blinding failure was common. The comment also suggests that smokers failing to quit with an NRT-assisted attempt will not benefit from NRT use in subsequent attempts, and questions whether people who quit smoking but continue to use NRT should be regarded as having quit or not.

Author's reply

The issue of possible failure of blinding, and hence of possible bias in estimates of treatment effect, is a potential problem in many

areas of medicine. Failure to report whether the success of blinding has been tested is widespread (1). There are problems with how best to test the effectiveness of blinding. If participants' guesses are influenced by their success in quitting, then apparent breaking of the blind might be more common where treatment was effective (2).

Where there is evidence that blinding has failed, there still needs to be an assessment of whether this has led to bias in effect estimates. Mooney's paper makes it clear that there are insufficient data to try to assess whether there was evidence of a bias in treatment estimates in the existing trials. There are many potential sources of bias in trials, and we don't have any evidence to suggest that failure of blinding is more of a problem in trials of NRT. We focus on outcomes at least six months after the quit attempt, so that any differential effect of guessing the treatment assignment on the likelihood of successful quitting would need to be long lasting.

Small amounts of nicotine have been used in placebo products in attempts to improve maintenance of the blind by giving a characteristic taste or smell. In most cases the amounts are small. If there were sufficient nicotine to be pharmacologically active it would seem more likely to decrease the effect of active NRT than inflate the treatment effect.

We do not think there is evidence to state that an initial failure with NRT means that subsequent attempts will also fail. People who have a failed quit attempt in a trial seem to have a low chance of success if they immediately try again, as noted in the studies by Gourlay, and Tonnesen (which was uncontrolled). A recent study found a similar poor outcome when people who had failed to quit using nicotine patch were randomized to second line therapy with bupropion or placebo (5). In contrast, two recent studies have found that people who reported failed quit attempts using NRT do at least as well when enrolled in trials and treated with NRT as do NRT-naïve participants. (6,7).

It is important that smokers realise that their chance of a successful long-term quit from each attempt is low and that NRT, although increasing the likelihood of success, is not a 'magic bullet', and this point is made in the review.

We do not agree that people who give up smoking cannot regard themselves as quitters whilst they are using NRT. In the context of a history of chronic smoking over a period of years we do not think that it is a major concern that 6.7% of new gum users may be still using it after six months. The rate of persistent use appears to fall rapidly, with the same study noting a rate of 2.8% for use after a year or more. Rates of persistent patch use are lower.

References

(1) Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. *BMJ*. 2004 Feb 21;328(7437):432 2004

- (2) Altman DG, Schulz KF, Moher D. Turning a blind eye: testing the success of blinding and the CONSORT statement. *BMJ*. 2004 May 8;328(7448):1135
- (3) Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. *BMJ* 1995;311:363-366
- (4) Tonnesen P, Norregaard J, Sawe U, Simonsen K. Recycling with nicotine patches in smoking cessation. *Addiction*. 1993 Apr;88(4):533-9
- (5) Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. *J Clin Oncology* 2003; 21(5):914-920.
- (6) Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ et al. Impact of prior nicotine replacement therapy on smoking cessation efficacy. *Am J Health Behav* 2002; 26(3):213-220.
- (7) Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. *Addiction* 2004; 99(1):83-92.

#### Contributors

Comment by John R. Polito. Reply by Lindsay Stead, Tim Lancaster

Criticism editor Robert West

## POTENTIAL CONFLICT OF INTEREST

Chris Bullen is undertaking a trial on precessation use of NRT.

David Mant was involved in a trial of transdermal nicotine (ICRF 1994). Chris Silagy, an original author, received funds for consultancy work undertaken (at various times) on behalf of Pharmacia and Upjohn, Marion Merrell Dow, Glaxo Wellcome and SmithKline Beecham.

## ACKNOWLEDGEMENTS

Chris Silagy was original first author, contributed to updates until his death in 2001 and was listed as an author until 2008. Godfrey Fowler was also an author until 2008. Mark Lodge assisted in the preparation of the initial version of this review. Ruth Ashenden provided technical support. Drs. Tjeder-Burton, Campbell, Hjalmarson, Fagerstrom, Mori, Glover, Hughes, Fortmann, Killen and Varady co-operated with our requests for clarification of previously reported data. Z. Ilic and L. Silagy assisted with translation of foreign language reports. P. Yudkin provided statistical advice on early updates. Marc Mooney provided copies of two papers we had not been able to obtain. John Hughes and Paul Aveyard provided helpful comments for the most recent update.

## SOURCES OF SUPPORT

### External sources of support

- NHS Research and Development Programme UK

### Internal sources of support

- Department of Primary Health Care, Oxford University UK

## REFERENCES

### References to studies included in this review

#### Abelin 1989 *{published data only}*

\*Abelin T, Buehler A, Muller P, Vesanen K, Imhof PR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. *Lancet* 1989;1(8628):7-10.

Abelin T, Ehrsam R, Buhler-Reichert A, Imhof PR, Muller P, Thommen A. Effectiveness of a transdermal nicotine system in smoking cessation studies. *Methods and Findings in Experimental and Clinical Pharmacology* 1989;11:205-14.

Muller P, Abelin T, Ehrsam R, Imhof P, Howald H, Mauli D. The use of transdermal nicotine in smoking cessation. *Lung* 1990;168:445-53.

#### Ahluwalia 1998 *{published data only}*

Ahluwalia JS, McNagny SE, Clark WS. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. *Journal of General Internal Medicine* 1998;13:1-8.

#### Ahluwalia 2006 *{published data only}*

\*Ahluwalia JS, Okuyemi K, Nollen N, Choi WS, Kaur H, Pulvers K, et al. The effects of nicotine gum and counseling among African American light smokers: A 2 x 2 factorial design. *Addiction* 2006; 101:883-91.

Nollen NL, Mayo MS, Sanderson CL, Okuyemi KS, Choi WS, Kaur H, et al. Predictors of quitting among African American light smokers enrolled in a randomized, placebo-controlled trial. *Journal of General Internal Medicine* 2006;21:590-5.

Okuyemi KS, Cox LS, Nollen NL, Snow TM, Kaur H, Choi W, et al. Baseline characteristics and recruitment strategies in a randomized clinical trial of African-American light smokers. *American Journal of Health Promotion* 2007;21:183-91.

#### Areechon 1988 *{published data only}*

Areechon W, Punnotok J. Smoking cessation through the use of nicotine chewing gum: a double-blind trial in Thailand. *Clinical Therapeutics* 1988;10:183-6.

- Blondal 1989** *{published data only}*  
Blondal T. Controlled trial of nicotine polacrilex gum with supportive measures. *Archives of Internal Medicine* 1989;**149**:1818–21.
- Blondal 1997** *{published data only}*  
\*Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. *European Respiratory Journal* 1997;**10**:1585–90.  
Blondal T, Olafsdottir I, Gunnarsdottir R, Franzon M, Westin A. Controlled trial of nicotine nasal spray as an aid to stopping smoking [abstract]. *European Respiratory Journal* 1993;**6**(Suppl 17):631S.
- Blondal 1999** *{published data only}*  
\*Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. *BMJ* 1999;**318**:285–9.  
Blondal T, Ludviksdottir D, Gudmundsson L, Olafsdottir I, Gustavsson G, Westin A. Efficacy of nicotine nasal spray added to transdermal nicotine patches in smoking cessation [Abstract]. Proceedings of the 10th World Conference on Tobacco or Health; Aug 24-28; Beijing, China. 1997:48.
- Bohadana 2000** *{published data only}*  
Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Gender differences in quit rates following smoking cessation with combination nicotine therapy: influence of baseline smoking behavior. *Nicotine & Tobacco Research* 2003;**5**(1):111–6.  
\*Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation - A randomized, double-blind, placebo-controlled trial. *Archives of Internal Medicine* 2000;**160**:3128–34.  
Bohadana AB, Nilsson F, Martinet Y. Nicotine inhaler and nicotine patch: a combination therapy for smoking cessation [abstract]. *Nicotine & Tobacco Research* 1999;**1**(2):189.
- Bolin 1999** *{published data only}*  
Bolin LJ, Antonuccio DO, Follette WC, Krumpal P. Transdermal nicotine: the long and the short of it. *Psychology of Addictive Behaviors* 1999;**13**:152–6.
- Br Thor Society 1983** *{published data only}*  
Research Committee of the British Thoracic Society. Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society. *British Medical Journal* 1983;**286**(6365):595–7.
- Buchkremer 1988** *{published data only}*  
\*Buchkremer G, Bents H, Horstmann M, Opitz K, Tolle R. Combination of behavioral smoking cessation with transdermal nicotine substitution. *Addictive Behaviors* 1989;**14**:229–38.  
Buchkremer G, Bents H, Minneker E, Opitz K. Long-term effects of a combination of transdermal nicotine administration with behavior therapy for smoking cessation [Langfristige Effekte einer Kombination von transdermalen Nikotinzufuhr mit Verhaltenstherapie zur Raucherentwöhnung]. *Nervenarzt* 1988;**59**:488–90.
- Campbell 1987** *{published data only}*  
Campbell IA, Lyons E, Prescott R. Do nicotine chewing-gum and postal encouragement add to doctors' advice. *Practitioner* 1987;**231**:114–7.
- Campbell 1991** *{published data only}*  
Campbell IA, Prescott RJ, Tjeder-Burton SM. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. *Respiratory Medicine* 1991;**85**:155–7.
- Campbell 1996** *{published data only}*  
Burton S, Campbell IA, Prescott RJ. Nicotine patches versus placebo in 235 hospital patients [abstract 191]. Abstracts from the 8th World Conference on Tobacco or Health, Mar 30-Apr 3; Buenos Aires, Argentina. 1992.  
\*Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. *Respiratory Medicine* 1996;**90**:47–51.
- CEASE 1999** *{published data only}*  
Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial. *European Respiratory Journal* 1999;**13**:238–46.
- Cinciripini 1996** *{published data only}*  
\*Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W. Behavior therapy and the transdermal nicotine patch: Effects on cessation outcome, affect, and coping. *Journal of Consulting and Clinical Psychology* 1996;**64**:314–23.  
Cinciripini PM, Wetter DW, Fouladi RT, Blalock JA, Carter BL, Cinciripini LG, et al. The effects of depressed mood on smoking cessation: mediation by postcessation self-efficacy. *Journal of Consulting and Clinical Psychology* 2003;**71**:292–301.
- Clavel 1985** *{published data only}*  
Clavel F, Benhamou S. Tobacco withdrawal. Comparison of the efficacy of various methods. Intermediate results of a comparative study [French] [Désintoxication tabagique. Comparaison de l'efficacité de différentes méthodes. Résultats intermédiaires d'une étude comparative]. *Presse Médicale* 1984;**13**:975–7.  
\*Clavel F, Benhamou S, Company Huertas A, Flamant R. Helping people to stop smoking: randomised comparison of groups being treated with acupuncture and nicotine gum with control group. *British Medical Journal* 1985;**291**:1538–9.
- Clavel-Chapelon 1992** *{published data only}*  
\*Clavel-Chapelon F, Paoletti C, Benhamou S. A randomised 2 x 2 factorial design to evaluate different smoking cessation methods. *Revue d'Epidemiologie et de Sante Publique* 1992;**40**:187–90.
- Cooper 2005** *{published data only}*  
\*Cooper TV, Klesges RC, Debon MW, Zbikowski SM, Johnson KC, Clemens LH. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. *Addictive Behaviors* 2005;**30**:61–75.  
Cooper TV, Montgomery GV, Debon MW, Zbikowski SM, Klesges RC, Johnson KC. The effects of PPA and nicotine gum on cessation rates and post cessation weight gain in women [POS3-46]. Abstract Book. Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA. 2003.

- Croghan 2003** {published data only}  
 Croghan GA, Hurt RD, Croghan IT, Sloan J, Novotny P, Loprinzi C. Comparison of a 15 mg transdermal nicotine patch alone versus nicotine nasal spray alone versus both for smoking cessation. *Journal of Addictive Diseases* 1998;**17**:121.
- \*Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: A minimal intervention, randomized multicenter trial in a nonspecialized setting. *Nicotine & Tobacco Research* 2003;**5**(2):181–7.
- Dale 1995** {published data only}  
 \*Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy - percentage of replacement and smoking cessation. *JAMA* 1995;**274**:1353–8.
- Dale LC, Schroeder DR, Wolter TD, Croghan IT, Hurt RD, Offord KP. Weight change after smoking cessation using variable doses of transdermal nicotine replacement. *Journal of General Internal Medicine* 1998;**13**:9–15.
- Daughton 1991** {published data only}  
 \*Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. *Archives of Internal Medicine* 1991;**151**:749–52.
- Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, et al. Effects of transdermal nicotine as an adjunct in smoking cessation therapy. A double-blind randomized study controlled with placebo [Italian] [Effetti del rilascio transdermico di nicotina come terapia di supporto per lo svezzamento dal fumo di sigaretta. Uno studio randomizzato in doppio cieco con controlli trattati con placebo]. *Archivio Monaldi* 1992;**47**:17–29.
- Daughton 1998** {published data only}  
 Daughton D, Susman J, Sitorius M, Belenky S, Millatmal T, Nowak R, et al. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. *Archives of Family Medicine* 1998;**7**:425–30.
- Dautzenberg 2001** {published and unpublished data}  
 Dautzenberg B, Peiffer G, Toulouse F, Yvinec MJ, Jacob N, Kienzler JL. Randomized trial assessment of nicotinell lozenge 1mg, a new oral nicotine replacement therapy. Abstract Book. Society for Research on Nicotine and Tobacco 3rd European Conference, Paris. 2001:55.
- \*Dautzenberg B, Ruff F, Vaucher M, Maillon P, Jacob N, Kienzler JL, et al. First demonstration of the good efficacy/safety ratio of Nicotinell (r) 1mg Lozenge (NL 1mg), a new form of nicotine substitution, by randomised clinical trial. *European Respiratory Journal* 2001;**18** Suppl 33:12s.
- Davidson 1998** {published data only}  
 Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. *Archives of Family Medicine* 1998;**7**:569–74.
- Ehram 1991** {published data only}  
 Abelin T, Ehram R, Imhof P, Muller P, Howald H. Clinical experience with a transdermal nicotine system in healthy nicotine-dependent smokers. In: Wilhemsen L editor(s). *Smoking as a cardiovascular risk factor - new strategies for smoking cessation*. Hogrefe & Huber, 1991:35–46.
- Abelin T, Ehram R, Buhler-Reichert A, Imhof PR, Muller P, Thommen A, et al. Effectiveness of a transdermal nicotine system in smoking cessation studies. *Methods and Findings in Experimental and Clinical Pharmacology* 1989;**11**:205–14.
- \*Ehram RE, Buhler A, Muller P, Mauli D, Schumacher PM, Howald H, et al. Weaning of young smokers using a transdermal nicotine patch [German] [Entwöhnung junger Raucher mit Hilfe eines transdermalen Nikotinpflasters]. *Schweizerische Rundschau für Medizin Praxis* 1991;**80**:145–50.
- Muller P, Abelin T, Ehram R, Imhof P, Howald H, Mauli D. The use of transdermal nicotine in smoking cessation. *Lung* 1990;**168**:445–53.
- Fagerstrom 1982** {published data only}  
 \*Fagerstrom KO. A comparison of psychological and pharmacological treatment in smoking cessation. *Journal of Behavioral Medicine* 1982;**5**:343–51.
- Fagerstrom KO. Tolerance, withdrawal and dependence on tobacco and smoking termination. *International Review of Applied Psychology* 1983;**32**:29–52.
- Fagerstrom 1984** {published data only}  
 Fagerstrom KO. Effects of nicotine chewing gum and follow-up appointments in physician-based smoking cessation. *Preventive Medicine* 1984;**13**:517–27.
- Fee 1982** {published data only}  
 Fee WM, Stewart MJ. A controlled trial of nicotine chewing gum in a smoking withdrawal clinic. *Practitioner* 1982;**226**:148–51.
- Fiore 1994A** {published data only}  
 Elan Pharmaceutical Research Corp. NDA 19-983 for Approval of PROSTEP. Study 90-03 1992.
- \*Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. *Chest* 1994;**105**:524–33.
- Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation. Who will quit with and without the nicotine patch. *JAMA* 1994;**271**:589–94.
- Fiore 1994B** {published data only}  
 Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. *Chest* 1994;**105**:524–33.
- Fortmann 1995** {published data only}  
 Fortmann SP, Killen JD. Nicotine gum and self-help behavioral treatment for smoking relapse prevention - results from a trial using population-based recruitment. *Journal of Consulting and Clinical Psychology* 1995;**63**:460–8.
- García 1989** {published data only}  
 Quilez García C, Hernando Arizaleta L, Rubio Diaz A, Estruch Riba J, Fornes Ramis MV. Treatment for smoking with nicotine gum in primary care. A double blind trial [Spanish] [Tratamiento del tabaquismo, con chicle de nicotina, en atención primaria. Estudio a doble ciego]. *Revista Clinica Espanol* 1993;**192**(4):157–61.

- \*Quilez Garcia C, Hernando Arizaleta L, Rubio Diaz A, Granero Fernandez EJ, Vila Coll MA, Estruch Riba JSO. Double-blind study of the efficacy of nicotine chewing gum for smoking cessation in the primary care setting [Spanish] [Estudio doble ciego de la eficacia del chicle de nicotina en la deshabitacion tabaquica dentro del ambito de la atencion primaria]. *Atencion Primaria* 1989;**6**:719–26.
- Garvey 2000** {published data only}  
Doherty K, Militello FS, Kinnunen T, Garvey AJ. Nicotine gum dose and weight gain after smoking cessation. *Journal of Consulting and Clinical Psychology* 1996;**64**:799–807.
- \*Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner B, et al. Effects of nicotine gum dose by level of nicotine dependence. *Nicotine & Tobacco Research* 2000;**2**:53–63.
- Nordstrom BL, Kinnunen T, Utman CH, Garvey AJ. Long-term effects of nicotine gum on weight gain after smoking cessation. *Nicotine & Tobacco Research* 1999;**1**:259–68.
- Gilbert 1989** {published data only}  
Gilbert JR, Wilson DM, Best JA, Taylor DW, Lindsay EA, Singer J, et al. Smoking cessation in primary care. A randomized controlled trial of nicotine-bearing chewing gum. *Journal of Family Practice* 1989;**28**:49–55.
- Glavas 2003a** {published data only}  
Glavas D, Rumboldt M, Rumboldt Z. Smoking cessation with nicotine replacement therapy among health care workers: randomized double-blind study. *Croatian Medical Journal* 2003;**44**:219–24.
- Glavas 2003b** {published data only}  
Glavas D, Rumboldt Z. Smoking cessation using the transdermal nicotine system [Croatian] [Odvikavanje od pusenja transdermalnim nikotinskim sustavom]. *Lijecnicki Vjesnik* 2003;**125**(1-2):8–12.
- Glover 2002** {published data only}  
Glover E, Glover P, Franzon M, Sullivan R, Cerullo C. Safety and efficacy of a nicotine sublingual tablet for smoking cessation [abstract]. Smoke Free 21st Century, 2nd European Conference on Tobacco or Health; Las Palmas de Gran Canaria. 1999.
- Glover ED, Franzon M, Sullivan CR, Cerullo CL. A nicotine sublingual tablet for treating tobacco dependence [Abstract]. Society for Research on Nicotine and Tobacco 3rd Europe Conference, Paris September 2001 Abstract Book. 2001:48.
- \*Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell RM, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. *Nicotine & Tobacco Research* 2002;**4**:441–50.
- Glover ED, Glover PN, Franzon M, Sullivan R, Sullivan P, Howell R, et al. A nicotine sublingual tablet for smoking cessation: 6-month data [Abstract]. Proceedings of the 10th World Conference on Tobacco or Health; Aug 24–28 Beijing, China. 1997.
- Goldstein 1989** {published data only}  
Goldstein MG, Niaura R, Follick MJ, Abrams DB. Effects of behavioral skills training and schedule of nicotine gum administration on smoking cessation. *American Journal of Psychiatry* 1989;**146**:56–60.
- Gourlay 1995** {published data only}  
Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. *BMJ* 1995;**311**(7001):363–6.
- Gross 1995** {published data only}  
Gross J, Johnson J, Sigler L, Stitzer ML. Dose effects of nicotine gum. *Addictive Behaviors* 1995;**20**:371–81.
- Hall 1985** {published data only}  
Hall SM, Tunstall C, Rugg D, Jones R, Benowitz N. Nicotine gum and behavioral treatment in smoking cessation. *Journal of Consulting and Clinical Psychology* 1985;**53**:256–8.
- Hall 1987** {published data only}  
Hall SM, Tunstall CD, Ginsberg D, Benowitz NL, Jones RT. Nicotine gum and behavioral treatment: a placebo controlled trial. *Journal of Consulting and Clinical Psychology* 1987;**55**:603–5.
- Hall 1996** {published data only}  
Hall SM, Munoz RF, Reus VI, Sees KL, Duncan C, Humfleet GL, et al. Mood management and nicotine gum in smoking treatment - a therapeutic contact and placebo-controlled study. *Journal of Consulting and Clinical Psychology* 1996;**64**:1003–9.
- Hand 2002** {published data only}  
Hand S, Edwards S, Campbell IA, Cannings R. Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. *Thorax* 2002;**57**:715–8.
- Harackiewicz 1988** {published data only}  
Harackiewicz JM, Blair LW, Sansone C, Epstein JA, Stuchell RN. Nicotine gum and self-help manuals in smoking cessation: an evaluation in a medical context. *Addictive Behaviors* 1988;**13**:319–30.
- Hays 1999** {published data only}  
\*Hays JT, Croghan GA, Offord KP, Hurt RD, Schroeder DR, Wolter TD, et al. Over-the-counter nicotine patch therapy for smoking cessation: Results from randomized, double-blind, placebo-controlled and open label trials. *American Journal of Public Health* 1999;**89**:1701–7.
- Hays JT, Croghan GA, Offord KP, Wolter TD, Nides MA, Davidson M. Over-the-Counter (OTC) transdermal nicotine patch therapy [abstract]. *Journal of Addictive Diseases* 1997;**16**:136.
- Hays JT, Croghan IT, Offord KP, Hurt RD, Schroeder DR, Wolter TD, et al. Over the counter 22mg nicotine patch therapy for smoking cessation: results from randomized double-blind placebo-controlled and open label trials. Abstract Book. Society for Research on Nicotine and Tobacco 5th Annual Meeting, San Diego (CA) 1999.
- Herrera 1995** {published data only}  
Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerstrom KO. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. *Chest* 1995;**108**:447–51.
- Hilleman 1994** {published data only}  
Hilleman DE, Mohiuddin SM, Delcore MG. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and bupropion in smoking cessation. *Journal of Clinical Pharmacology* 1994;**34**(3):222–4.
- Hjalmarsen 1984** {published data only}  
Hjalmarsen AI. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study. *JAMA* 1984;**252**:2835–8.
- Hjalmarsen 1994** {published data only}  
Hjalmarsen AI, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled,

- double-blind study. *Archives of Internal Medicine* 1994;**154**:2567–72.
- Hjalmarson 1997** {published data only}  
Hjalmarson A, Nilsson F, Sjoström L, Wiklund O. The nicotine inhaler in smoking cessation. *Archives of Internal Medicine* 1997;**157**:1721–8.
- Huber 1988** {published data only}  
Huber D. Combined and separate treatment effects of nicotine chewing gum and self-control method. *Pharmacopsychiatry* 1988;**21**:461–2.
- Hughes 1989** {published data only}  
Hughes JR, Gust SW, Keenan R, Fenwick JW, Skoog K, Higgins ST. Long-term use of nicotine vs placebo gum. *Archives of Internal Medicine* 1991;**151**:1993–8.  
\*Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML. Nicotine vs placebo gum in general medical practice. *JAMA* 1989;**261**:1300–5.
- Hughes 1990** {published data only}  
Hughes JR, Gust SW, Keenan RM, Fenwick JW. Effect of dose on nicotine's reinforcing, withdrawal-suppression and self-reported effects. *Journal of Pharmacology and Experimental Therapeutics* 1990;**252**:1175–83.
- Hughes 1991** {published data only}  
Hughes JR, Wadland WC, Fenwick JW, Lewis J, Bickel WK. Effect of cost on the self-administration and efficacy of nicotine gum: a preliminary study. *Preventive Medicine* 1991;**20**:486–96.
- Hughes 1999** {published data only}  
Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation?. *Nicotine & Tobacco Research* 1999;**1**:169–74.
- Hughes 2003** {published data only}  
Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. Efficacy of nicotine patch in smokers with a history of alcoholism. *Alcoholism-Clinical and Experimental Research* 2003;**27**:946–54.
- Hurt 1990** {published data only}  
Elan Pharmaceutical Research Corp. NDA 19-983 for Approval of PROSTEP. Study 88-02 1992.  
\*Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC. Nicotine-replacement therapy with use of a transdermal nicotine patch—a randomized double-blind placebo-controlled trial. *Mayo Clinic Proceedings* 1990;**65**:1529–37.
- Hurt 1994** {published data only}  
Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: One-year outcome and percentage of nicotine replacement. *JAMA* 1994;**271**:595–600.
- ICRF 1994** {published data only}  
David SP, Munafo MR, Murphy MF, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. *Nicotine & Tobacco Research* 2007;**9**(2):225–231.  
\*Imperial Cancer Research Fund General Practice research Group. Randomised trial of nicotine patches in general practice: results at one year. *BMJ* 1994;**308**:1476–7.
- Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. *BMJ* 1993;**306**:1304–8.
- Johnstone EC, Yudkin PI, Hey K, Roberts SJ, Welch SJ, Murphy MF, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. *Pharmacogenetics* 2004;**14**(2):83–90.
- Yudkin P, Hey K, Roberts S, Welch S, Murphy M, Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. *BMJ* 2003;**327**(7405):28–29.
- Yudkin P, Munafo M, Hey K, Roberts S, Welch S, Johnstone E, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. *BMJ* 2004;**328**(7446):989–90.
- Jamrozik 1984** {published data only}  
Jamrozik K, Fowler G, Vessey M, Wald N. Placebo controlled trial of nicotine chewing gum in general practice. *British Medical Journal* 1984;**289**:794–7.
- Jarvis 1982** {published data only}  
Jarvis MJ, Raw M, Russell MAH, Feyerabend C. Randomised controlled trial of nicotine chewing-gum. *British Medical Journal* 1982;**285**:537–40.
- Jensen 1991** {published data only}  
Jensen EJ, Schmidt E, Pedersen B, Dahl R. Effect of nicotine, silver acetate, and ordinary chewing gum in combination with group counselling on smoking cessation. *Thorax* 1990;**45**:831–4.  
Jensen EJ, Schmidt E, Pedersen B, Dahl R. Effect on smoking cessation of silver acetate, nicotine and ordinary chewing gum. Influence of smoking history. *Psychopharmacology (Berl)* 1991;**104**:470–4.  
\*Jensen EJ, Schmidt E, Pedersen B, Dahl R. The effect of nicotine, silver acetate, and placebo chewing gum on the cessation of smoking. The influence of smoking type and nicotine dependence. *International Journal of the Addictions* 1991;**26**:1223–31.
- Jorenby 1995** {published data only}  
Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, et al. Varying nicotine patch dose and type of smoking cessation counseling. *JAMA* 1995;**274**:1347–52.
- Jorenby 1999** {published data only}  
Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, et al. Impact of prior nicotine replacement therapy on smoking cessation efficacy. *American Journal of Health Behaviors* 2002;**26**:213–20.  
Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, et al. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. *Clinical Therapeutics* 2001;**23**:744–52.  
\*Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *New England Journal of Medicine* 1999;**340**:685–91.

**Joseph 1996** {published data only}

Joseph AM, Antonnucio DO. Lack of efficacy of transdermal nicotine in smoking cessation. *New England Journal of Medicine* 1999;**341**:1157–8.

\*Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. *New England Journal of Medicine* 1996;**335**:1792–8.

**Kalman 2006** {published data only}

Kalman D, Denison H, Penk W, Peer J, Kresman D, Monti P. Early findings from a treatment study of heavy smokers in alcohol recovery (PO2 34). Abstract Book. Society for Research on Nicotine and Tobacco 7th Annual Meeting March 23–23 Seattle, Washington. 2001: 61.

\*Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. *Journal of Substance Abuse Treatment* 2006;**30**:213–7.

Kalman D, Kahler CW, Tirch D, Kaschub C, Penk W, Monti PM. Twelve-week outcomes from an investigation of high-dose nicotine patch therapy for heavy smokers with a past history of alcohol dependence. *Psychology of Addictive Behaviors* 2004;**18**:78–82.

Kalman D, Tirch D, Penk W, Denison H. An investigation of predictors of nicotine abstinence in a smoking cessation treatment study of smokers with a past history of alcohol dependence. *Psychology of Addictive Behaviors* 2002;**16**:346–9.

Kalman D, Tirch D, Penk W, Kaschub C. Preliminary findings from a treatment study of heavy smokers in alcohol recovery: end of treatment outcomes (PO2 38). Abstract Book. Society for Research on Nicotine and Tobacco 8th Annual Meeting February 20–23 Savannah, Georgia. 2002:58.

**Killen 1984** {published data only}

Killen JD, Maccoby N, Taylor CB. Nicotine gum and self-regulation training in smoking relapse prevention. *Behavior Therapy* 1984;**15**:234–48.

**Killen 1990** {published data only}

Fortmann SP, Killen JD, Telch MJ, Newman B. Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford Stop Smoking Project. *JAMA* 1988;**260**:1575–80.

\*Killen JD, Fortmann SP, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. *Journal of Consulting and Clinical Psychology* 1990;**58**:85–92.

**Killen 1997** {published data only}

Killen JD, Fortmann SP, Davis L, Varady A. Nicotine patch and self-help video for cigarette smoking cessation. *Journal of Consulting and Clinical Psychology* 1997;**65**:663–72.

**Killen 1999** {published data only}

\*Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy?. *Experimental and Clinical Psychopharmacology* 1999;**7**:226–33.

**Kornitzer 1987** {published data only}

Kornitzer M, Kittel F, Dramaix M, Bourdoux P. A double blind study of 2 mg versus 4 mg nicotine-gum in an industrial setting. *Journal of Psychosomatic Research* 1987;**31**:171–6.

**Kornitzer 1995** {published data only}

\*Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. *Preventive Medicine* 1995;**24**:41–7.

Kornitzer M, Boutsen M, Thijs J, Gustavsson G. Efficiency and safety of combined use of nicotine patches and nicotine gum in smoking cessation: a placebo controlled double-blind trial [abstract]. *European Respiratory Journal* 1993;**6**(Suppl 17):630S.

**Kralikova 2002** {published and unpublished data}

Kralikova E, Kozak J, Rasmussen T, Cort N. The clinical benefits of NRT-supported smoking reduction. *Nicotine & Tobacco Research* 2002;**4**:243.

**Leischow 1996** {published data only}

Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. *American Journal of Health Behavior* 1996;**20**:364–71.

**Leischow 1999** {published data only}

\*Leischow SJ, Muramoto ML, Cook GN, Merikle EP, Castellini SM, Otte PS. OTC nicotine patch: effectiveness alone and with brief physician intervention. *American Journal of Health Behavior* 1999;**23**:61–9.

**Leischow 2004** {published data only}

\*Leischow SJ, Ranger-Moore J, Muramoto ML, Matthews E. Effectiveness of the nicotine inhaler for smoking cessation in an OTC setting. *American Journal of Health Behavior* 2004;**28**:291–301.

Leischow SJ, Ranger-Moore J, Muramoto ML, Matthews E. The safety and effectiveness of the nicotine inhaler for smoking cessation in an over-the-counter setting (POS4-78). Abstract Book. Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA. 2003:100.

**Lerman 2004** {published data only}

Lerman C, Jepsen C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. *Neuropsychopharmacology* 2006;**31**(1):231–42.

\*Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. *Annals of Internal Medicine* 2004;**140**:426–33.

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. *Clinical Pharmacology & Therapeutics* 2006;**79**:600–8.

Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. *Pharmacogenomics Journal* 2004;**4**(3):184–92.



- Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tynedale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. *Molecular Psychiatry* 2006;**11**(4):400–409.
- Patterson F, Jepson C, Kaufmann V, Rukstalis M, Audrain-McGovern J, Kucharski S, et al. Predictors of attendance in a randomized clinical trial of nicotine replacement therapy with behavioral counseling. *Drug and Alcohol Dependence* 2003;**72**:123–31.
- Lewis 1998** {published data only}  
Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB. Transdermal nicotine replacement for hospitalized patients: A randomized clinical trial. *Preventive Medicine* 1998;**27**(2):296–303.
- Llivina 1988** {published data only}  
Salvador Llivina T, Marin Tuya D, Gonzalez Quintana J, Iniesta Torres C, Castellvi Barrera E, Muriana Saez C, et al. Treatment of smoking: efficacy of the use of nicotine chewing gum. Double-blind study [Spanish] [Tratamiento del tabaquismo: eficacia de la utilizacion del chicle de nicotina. Estudio a doble ciego]. *Medicina Clinica Barcelona* 1988;**90**:646–50.
- Malcolm 1980** {published data only}  
Malcolm RE, Sillett RW, Turner JA, Ball KP. The use of nicotine chewing gum as an aid to stopping smoking. *Psychopharmacology Series* 1980;**70**:295–6.
- Marshall 1985** {published data only}  
Marshall A, Raw M. Nicotine chewing gum in general practice: effect of follow up appointments. *British Medical Journal* 1985;**290**:1397–8.
- McGovern 1992** {published data only}  
McGovern PG, Lando HA. An assessment of nicotine gum as an adjunct to Freedom from Smoking cessation clinics. *Addictive Behaviors* 1992;**17**:137–47.
- Molyneux 2003** {published data only}  
Molyneux A, Lewis S, Leivers U, Anderton A, Antoniak M, Brackenridge A, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. *Thorax* 2003;**58**(6):484–8.
- Moolchan 2005** {published data only}  
Franken FH, Pickworth WB, Epstein DH, Moolchan ET. Smoking rates and topography predict adolescent smoking cessation following treatment with nicotine replacement therapy. *Cancer Epidemiology, Biomarkers & Prevention* 2006;**15**:154–7.
- \*Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. *Pediatrics* 2005;**115**(4):e407–e414.
- Robinson ML, Schroeder JR, Moolchan ET. Adolescent smokers screened for a nicotine replacement treatment trial: Correlates of eligibility and enrollment. *Nicotine & Tobacco Research* 2006;**8**:447–54.
- Mori 1992** {unpublished data only}  
Mori T, Shimao T, Yulchiro G, Namiki M, Hyachi T. A clinical trial of nicotine chewing gum for smoking cessation [abstract 428]. 8th World Conference on Tobacco or Health; Buenos Aires, Argentina 1992.
- Nakamura 1990** {unpublished data only}  
Nakamura M, Saito J, Oshima A, Miyamoto M, Matsushita A, Endo S. Effect of nicotine chewing gum in smoking cessation classes. The Global War. Proceedings of the 7th World Conference on Tobacco and Health; Perth, Western Australia. Perth: Health Department of Western Australia, 1990:665–7.
- Nebot 1992** {published data only}  
Nebot M, Cabezas C. Does nurse counseling or offer of nicotine gum improve the effectiveness of physician smoking-cessation advice?. *Family Practice Research Journal* 1992;**12**:263–70.
- Niaura 1994** {published data only}  
Niaura R, Goldstein MG, Abrams DB. Matching high and low-dependence smokers to self-help treatment with or without nicotine replacement. *Preventive Medicine* 1994;**23**:70–7.
- Niaura 1999** {published data only}  
Niaura R, Abrams DB, Shadel WG, Rohsenow DJ, Monti PM, Sirota AD. Cue exposure treatment for smoking relapse prevention: A controlled clinical trial. *Addiction* 1999;**94**(5):685–96.
- Ockene 1991** {published data only}  
\*Ockene JK, Kristeller J, Goldberg R, Amick TL, Pekow PS, Hosmer D, et al. Increasing the efficacy of physician-delivered smoking interventions: a randomized clinical trial. *Journal of General Internal Medicine* 1991;**6**:1–8.
- Ockene JK, Kristeller J, Pbert L, Hebert JR, Luippold R, Goldberg RJ, et al. The physician-delivered smoking intervention project: can short-term interventions produce long-term effects for a general outpatient population?. *Health Psychology* 1994;**13**:278–81.
- Oncken 2007** {published data only}  
\*Oncken C, Cooney J, Feinn R, Lando H, Kranzler HR. Transdermal nicotine for smoking cessation in postmenopausal women. *Addictive Behaviors* 2007;**32**:296–309.
- Oncken C, Cooney J, Lando H, Feinn R, Kranzler H. Transdermal nicotine for smoking cessation in postmenopausal women (POS1-045). Abstract Book. Society for Research on Nicotine and Tobacco 11th Annual Meeting, Prague. 2005.
- Otero 2006** {published data only}  
\*Otero UB, Perez CA, Szklo M, Esteves GA, dePinho MM, Szklo AS, et al. Randomized clinical trial: effectiveness of the cognitive-behavioral approach and the use of nicotine replacement transdermal patches for smoking cessation among adults in Rio de Janeiro, Brazil [Portuguese] [Ensaio clinico randomizado: efetividade da abordagem cognitivo-comportamental e uso de adesivos transdermicos de reposicao de nicotina, na cessacao de fumar, em adultos residentes no Municipio do Rio de Janeiro, Brasil]. *Cadernos de Saude Publica* 2006;**22**:439–49.
- Page 1986** {published data only}  
Page AR, Walters DJ, Schlegel RP, Best JA. Smoking cessation in family practice: the effects of advice and nicotine chewing gum prescription. *Addictive Behaviors* 1986;**11**:443–6.
- Paoletti 1996** {published data only}  
Paoletti P, Fornai E, Maggiorelli F, Puntoni R, Viegi G, Carrozzi L, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double blind study with nicotine patch. *European Respiratory Journal* 1996;**9**:643–51.

- Perng 1998** *{published data only}*  
 Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. *American Journal of Respiratory and Critical Care Medicine* 1999;**159**(3SS):A735.
- \*Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. *Journal of the Formosan Medical Association* 1998;**97**:547–51.
- Piper 2007** *{published data only}*  
 Piper ME, Federman EB, Bolt DM, Smith SS, Fiore MC, Baker TB. Mediators of bupropion treatment effects (PA5-6). Abstract Book. Society for Research on Nicotine and Tobacco 12th Annual Meeting, Orlando, FL. 2006:27.
- \*Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. Efficacy of bupropion alone and in combination with nicotine gum. *Nicotine & Tobacco Research* 2007;**9**:947–54.
- Piper ME, Federman EB, Smith SS, Fiore MC, Baker TB. Efficacy of bupropion SR alone and combined with 4-mg gum (PA2-2). Abstract Book. Society for Research on Nicotine and Tobacco 10th Annual Meeting, Phoenix, AZ. 2004:18.
- Pirie 1992** *{published data only}*  
 Pirie PL, McBride CM, Hellerstedt WL, Jeffery RW, Hatsukami DK, Allen S, et al. Smoking cessation in women concerned about weight. *American Journal of Public Health* 1992;**82**:1238–43.
- Prapavessis 2007** *{published data only}*  
 Prapavessis H, Cameron L, Baldi JC, Robinson S, Borrie K, Harper T, et al. The effects of exercise and nicotine replacement therapy on smoking rates in women. *Addictive Behaviors* 2007;**32**:1416–32.
- Puska 1979** *{published data only}*  
 Puska P, Bjorkqvist S, Koskela K. Nicotine-containing chewing gum in smoking cessation: a double blind trial with half year follow-up. *Addictive Behaviors* 1979;**4**:141–6.
- Puska 1995** *{published data only}*  
 Puska P, Korhonen HJ, Vartiainen E, Urjanheimo EL, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. *Tobacco Control* 1995;**4**:231–5.
- Richmond 1993** *{published data only}*  
 Richmond R, Heather N. General Practitioner interventions for smoking cessation: past results and future prospects. *Behaviour Change* 1990;**7**:110–9.
- Richmond RL, Makinson RJ, Giugni AA, Webster IW. General Practitioner smoking interventions in Australia: results of studies over the past ten years. The Global War, Proceedings of the 7th World Conference on Tobacco and Health. Perth, Western Australia. Perth: Health Department of Western Australia, 1990:657–60.
- \*Richmond RL, Makinson RJ, Kehoe LA, Giugni AA, Webster IW. One-year evaluation of three smoking cessation interventions administered by general practitioners. *Addictive Behaviors* 1993;**18**:187–99.
- Richmond 1994** *{published data only}*  
 \*Richmond RL, Harris K, de Almeida Neto A. The transdermal nicotine patch: results of a randomised placebo-controlled trial. *Medical Journal of Australia* 1994;**161**:130–5.
- Richmond RL, Kehoe L, Neto ACdA. Effectiveness of a 24-hour transdermal nicotine patch in conjunction with a cognitive behavioural programme: One year outcome. *Addiction* 1997;**92**:27–31.
- Rose 1994** *{published data only}*  
 \*Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. *Clinical Pharmacology and Therapeutics* 1994;**56**:86–99.
- Rose JE, Westman EC, Behm FM. Nicotine/mecamylamine combination treatment for smoking cessation [published erratum appears in *Drug Development Research* 1997;**40**:215]. *Drug Development Research* 1996;**38**:243–256.
- Rose 1998** *{published data only}*  
 \*Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. *Experimental and Clinical Psychopharmacology* 1998;**6**:331–43.
- Rose JE, Westman EC, Behm FM. Nicotine/mecamylamine combination treatment for smoking cessation [published erratum appears in *Drug Development Research* 1997;**40**:215]. *Drug Development Research* 1996;**38**:243–56.
- Rose 2006** *{published data only}*  
 Rose JE, Behm FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. *Nicotine & Tobacco Research* 2006;**8**:89–101.
- Roto 1987** *{published data only}*  
 Roto P, Ojala A, Sundman K, Jokinen K, Peltomaki R. Nicotine gum and withdrawal from smoking. *Suomen Laakarilehti* 1987;**36**:3445–8.
- Russell 1983** *{published data only}*  
 Russell MA, Merriman R, Stapleton J, Taylor W. Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking. *British Medical Journal (Clinical Research Ed.)* 1983;**287**:1782–5.
- Sachs 1993** *{published data only}*  
 Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. *Archives of Internal Medicine* 1993;**153**:1881–90.
- Schneider 1985A** *{published data only}*  
 Jarvik ME, Schneider NG. Degree of addiction and effectiveness of nicotine gum therapy for smoking. *American Journal of Psychiatry* 1984;**141**:790–1.
- Schneider NG, Jarvik ME. Nicotine gum vs. placebo gum: comparisons of withdrawal symptoms and success rates. *NIDA Research Monograph* 1985;**53**:83–101.
- \*Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. *Addictive Behaviors* 1983;**8**:253–61.
- Schneider 1985B** *{published data only}*  
 Schneider NG, Jarvik ME. Nicotine gum vs. placebo gum: comparisons of withdrawal symptoms and success rates. *NIDA Research Monograph* 1985;**53**:83–101.

- \*Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. *Addictive Behaviors* 1983;**8**:253–61.
- Schneider 1995** *{published data only}*  
Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. *Addiction* 1995;**90**:1671–82.
- Schneider 1996** *{published data only}*  
\*Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo controlled trial. *Addiction* 1996;**91**:1293–306.
- Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebo-controlled trial [abstract]. *Addiction* 1997;**92**:630.
- Schuurmans 2004** *{published data only}*  
\*Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. *Addiction* 2004;**99**:634–40.
- Schuurmans MM, Diacon AH, van Biljon X, Westin A, Landfeldt B, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms in smokers subsequently quitting with the nicotine patch: a double-blind randomised controlled trial [https://www.ersnetsecure.org/public/prg\_congres.abstract?ww\_i\_presentation=6711]. European Respiratory Society Annual Congress, Stockholm. 2002.
- Segnan 1991** *{published data only}*  
\*Segnan N, Ponti A, Battista RN, Senore C, Rosso S, Shapiro SH, et al. A randomized trial of smoking cessation interventions in general practice in Italy. *Cancer Causes and Control* 1991;**2**:239–46.
- Senore C, Battista RN, Ponti A, Segnan N, Shapiro SH, Rosso S, et al. Comparing participants and nonparticipants in a smoking cessation trial: Selection factors associated with general practitioner recruitment activity. *Journal of Clinical Epidemiology* 1999;**52**:83–9.
- Senore C, Battista RN, Shapiro SH, Segnan N, Ponti A, Rosso S, et al. Predictors of smoking cessation following physicians' counseling. *Preventive Medicine* 1998;**27**:412–21.
- Shiffman 2002 (2mg)** *{published data only}*  
Dresler CM, Shiffman S, Strahs KR. Safety profile of the new nicotine polacrilex lozenge (PO1 36). Society for Research on Nicotine and Tobacco 8th Annual Meeting; Savannah, Georgia. 2002.
- Shiffman S. Nicotine lozenge efficacy in light smokers. *Drug & Alcohol Dependence* 2005;**77**:311–4.
- Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. *Addiction* 2007;**102**:809–14.
- \*Shiffman S, Dresler CM, Hajek P, Gilbert SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. *Archives of Internal Medicine* 2002;**162**:1267–76.
- Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. *Addiction* 2004;**99**:83–92.
- Shiffman 2002 (4mg)** *{published data only}*  
\*Shiffman S, Dresler CM, Hajek P, Gilbert SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. *Archives of Internal Medicine* 2002;**162**:1267–76.
- Sonderskov 1997** *{published data only}*  
Sonderskov J, Olsen J, Meillier L, Overvad OK, Sabroe S. [The effect of transdermal nicotine patches in smoking cessation. A randomized trial in pharmacy customers in Denmark] [Danish]. *Ugeskrift for Laeger* 1999;**161**:593–7.
- \*Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation: A randomized trial among over-the-counter customers in Denmark. *American Journal of Epidemiology* 1997;**145**:309–18.
- Stapleton 1995** *{published data only}*  
Russell MAH, Stapleton JA, Feyerabend C, Wiseman SM, Gustavsson G, Sawa U et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. *BMJ* 1993;**306**(6888):1308–12.
- \*Stapleton JA, Russell MAH, Feyerabend C, Wiseman SM, Gustavsson G, Sawa U, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. *Addiction* 1995;**90**:31–42.
- Sutherland 1992** *{published data only}*  
Stapleton JA, Sutherland G, Russell MAH. How much does relapse after one year erode effectiveness of smoking cessation treatments? Long term follow up of randomised trial of nicotine nasal spray. *BMJ* 1998;**316**(7134):830–1.
- \*Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. *Lancet* 1992;**340**:324–9.
- TNSG 1991** *{published data only}*  
Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, et al. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. *Preventive Medicine* 1999;**28**:113–8.
- Swan GE, Jack LM, Ward MM. Subgroups of smokers with different success rates after use of transdermal nicotine. *Addiction* 1997;**92**:207–17.
- \*Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. Transdermal Nicotine Study Group. *JAMA* 1991;**266**:3133–8.
- Tonnesen 1988** *{published data only}*  
\*Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnarsen AB, Forchammer H, et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. *New England Journal of Medicine* 1988;**318**:15–8.
- Tonnesen 1991** *{published data only}*  
Mikkelsen KL, Tonnesen P, Norregaard J. Three-year outcome of two- and three-year sustained abstainers from a smoking cessation study with nicotine patches. *Journal of Smoking-Related Disorders* 1994;**5**:95–100.

- Norregaard J, Tonnesen P, Petersen L. Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. *Preventive Medicine* 1993;**22**:261–71.
- Tonnesen P, Norregaard J, Sæve U. Two-year outcome in a smoking cessation trial with a nicotine patch. *Journal of Smoking-Related Disorders* 1992;**3**:241–5.
- \*Tonnesen P, Norregaard J, Simonsen K, Sæve U. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. *New England Journal of Medicine* 1991;**325**:311–5.
- Tonnesen P, Norregaard J, Simonsen K, Sæve U. A double-blind trial of nicotine patches in smoking cessation [Danish] [En dobbelt-blind undersøgelse af nikotinplaster ved rygeafvænning]. *Ugeskrift for Læger* 1992;**154**:251–4.
- Tonnesen 1993** {published data only}  
Tonnesen P, Norregaard J, Mikkelsen K, Jørgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. *JAMA* 1993;**269**:1268–71.
- Tonnesen 2000** {published data only}  
Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. *European Respiratory Journal* 2000;**16**:717–22.
- Tonnesen 2006** {published data only}  
Pbert L. Nurse-conducted smoking cessation in patients with COPD, using nicotine sublingual tablets and behavioral support. *Chest* 2006;**130**:314–6.
- \*Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. *Chest* 2006;**130**:334–42.
- Villa 1999** {published data only}  
Villa RS, Alvarez ABD, Hermida JRF. Effectiveness of a multicomponent program to quit smoking with and without nicotine chewing gum [Spanish] [Eficacia de un programa multicomponente para dejar de fumar con y sin chicle de nicotina]. *Psicologia Conductual* 1999;**7**:107–18.
- Wallstrom 2000** {published data only}  
Pharmacia, Upjohn. *Nicorette Nicotine Microtab Monograph*. Chester: Adis International, 1998:Adis International, 1998.
- Wallstrom M, Nilsson F, Hirsch JM. A double-blind placebo controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation [abstract]. *European Respiratory Journal* 1997; Vol. 10, issue Suppl 25:440S.
- \*Wallstrom M, Nilsson F, Hirsch JM. A randomized double-blind placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. *Addiction* 2000;**95**(8):1161–71.
- Westman 1993** {published data only}  
Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. *Archives of Internal Medicine* 1993;**153**:1917–23.
- Wisborg 2000** {published data only}  
\*Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine patches for pregnant smokers: A randomized controlled study. *Obstetrics & Gynecology* 2000;**96**(6):967–71.
- Wong 1999** {published data only}  
\*Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. *Addiction* 1999;**94**:1227–37.
- Zelman 1992** {published data only}  
Zelman DC, Brandon TH, Jorenby DE, Baker TB. Measures of affect and nicotine dependence predict differential response to smoking cessation treatments. *Journal of Consulting and Clinical Psychology* 1992;**60**:943–52.

## References to studies excluded from this review

### Allen 2005

\*Allen SS, Hatsukami D, Brintnell DM, Bade T. Effect of nicotine replacement therapy on post-cessation weight gain and nutrient intake: A randomized controlled trial of postmenopausal female smokers. *Addictive Behaviors* 2005;**30**:1273–80.

Allen SS, Hatsukami DK, Bade T, Center B. Transdermal nicotine use in postmenopausal women: does the treatment efficacy differ in women using and not using hormone replacement therapy?. *Nicotine & Tobacco Research* 2004;**6**(5):777–88.

### Aubin 2006

Aubin HJ, Luthringer R, Demazieres A, Dupont C, Lagrue G. Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep. *Nicotine & Tobacco Research* 2006;**8**:193–201.

### Batra 2005

\*Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: A double-blind, randomized, placebo-controlled study. *Clinical Pharmacology & Therapeutics* 2005;**78**:689–96.

Landfeldt B, Batra A, Friederich HM, Klingler K, Westin A. Smoking reduction with a 4 mg nicotine gum - final results from a placebo-controlled trial over 13 months. Society for Research on Nicotine and Tobacco 5th European Meeting November 20-22 2003 Padua: Abstract book. 2003.

### Bolliger 2000

Bolliger CT. Practical experiences in smoking reduction and cessation. *Addiction* 2000;**95**(1 S1):S19–S24.

Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Influence of long-term smoking reduction on health risk markers and quality of life. *Nicotine & Tobacco Research* 2002;**4**:433–9.

\*Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. *BMJ* 2000;**321**(7257):329–333.

### Bolliger 2007

Bolliger CT, van B, X, Axelsson A. A Nicotine Mouth Spray for Smoking Cessation: A Pilot Study of Preference, Safety and Efficacy. *Respiration* 2007;**74**:196–201.

### Brantmark 1973

Brantmark B, Ohlin P, Westling H. Nicotine-containing chewing gum as an anti-smoking aid. *Psychopharmacologia* 1973;**31**:191–200.

**Carpenter 2003**

Carpenter MJ, Hughes JR, Keely JP. Effect of smoking reduction on later cessation: a pilot experimental study. *Nicotine & Tobacco Research* 2003;**5**(2):155–62.

**Chou 2004**

Chou KR, Chen R, Lee JF, Ku CH, Lu RB. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. *International Journal of Nursing Studies* 2004;**41**:321–30.

**Christen 1984**

Christen AG, Drook C, McDonald JL, Stookey G, Olson B. Efficacy of nicotine chewing gum in facilitating smoking cessation. *Journal of the American Dental Association* 1984;**108**:594–7.

**Cohen 1989a**

Cohen SJ, Stookey GK, Katz BP, Drook CA, Christen AG. Helping smokers quit: a randomized controlled trial with private practice dentists. *Journal of the American Dental Association* 1989;**118**:41–5.

**Cohen 1989b**

Cohen SJ, Stookey GK, Katz BP, Drook CA, Smith DM. Encouraging primary care physicians to help smokers quit. A randomised, controlled trial. *Annals of Internal Medicine* 1989;**110**:648–52.

**Croghan 2007**

Clark MM, Hurt RD, Croghan I, Patten CA, Novotny P, Sloan JA, et al. The prevalence of weight concerns in a smoking abstinence clinical trial (POS2-84). Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida. 2006.

Croghan IT, Hurt RD, Croghan GA, Sloan JA. Comparing nicotine inhaler, bupropion and nicotine inhaler plus bupropion in treating tobacco dependence [abstract]. *Nicotine & Tobacco Research* 2005;**7**(4):680–1.

\*Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. *Mayo Clinic Proceedings* 2007;**82**:186–95.

**Dey 1999**

Dey P, Foy R, Woodman M, Fullard B, Gibbs A. Should smoking cessation cost a packet? A pilot randomized controlled trial of the cost-effectiveness of distributing nicotine therapy free of charge. *British Journal of General Practice* 1999;**49**:127–8.

**Elan Pharm 88-02**

Elan Pharmaceutical Research Corp. NDA 19-983 for Approval of PROSTEP. Study 88-02 1992.

**Elan Pharm 90-03**

Elan Pharmaceutical Research Corp. NDA 19-983 for Approval of PROSTEP. Study 90-03 1992.

**Etter 2004**

Dar R, Stronguin F, Etter JF. Assigned versus perceived placebo effects in nicotine replacement therapy for smoking reduction in Swiss smokers. *Journal of Consulting & Clinical Psychology* 2005;**73**:350–3.

\*Etter JF, Laszlo E, Perneger TV. Postintervention effect of nicotine replacement therapy on smoking reduction in smokers who are unwilling to quit: Randomized trial. *Journal of Clinical Psychopharmacology* 2004;**24**(2):174–9.

Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. *Journal of Clinical Psychopharmacology* 2002;**22**:487–95.

**Fagerstrom 1993**

Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. *Psychopharmacology (Berl)* 1993;**111**:271–7.

**Fagerstrom 1997**

\*Fagerstrom KO, Tejding R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?. *Tobacco Control* 1997;**6**:311–6.

**Fagerstrom 2000**

Fagerstrom KO, Hughes JR, Rasmussen T, Callas PW. Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. *Tobacco Control* 2000;**9**:327–33.

**Finland unpublished**

Anon. Combination NRT; Improving efficacy in smoking cessation. McNeil Consumer Healthcare booklet, 2007. Short term outcomes reported on p17.

**Foulds 1993**

Foulds J, Stapleton J, Hayward M, Russell MA, Feyerabend C, Fleming T, et al. Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial. *Archives of Family Medicine* 1993;**2**:417–23.

**Glover 1992**

\*Glover ED, Glover PN, Sullivan CR, Sullivan P, Nilsson F, Sawe U. Nicotine inhaler versus placebo in smoking cessation [abstract 237]. Abstracts from the 8th World Conference on Tobacco or Health, Buenos Aires, Argentina. 1992.

**Hajek 1999**

\*Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrifex, a transdermal patch, nasal spray, and an inhaler. *Archives of Internal Medicine* 1999;**159**:2033–8.

West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. *Psychopharmacology (Berl)* 2000;**149**:198–202.

**Hanson 2003**

Hanson K, Allen S, Jensen S, Hatsukami D. Treatment of adolescent smokers with the nicotine patch. *Nicotine & Tobacco Research* 2003;**5**(4):515–26.

**Haustein 2003**

\*Haustein KO, Batra A, Landfeldt B, Westin A. The effect of short-term or long-term reduction on smoking cessation; results from a placebo controlled smoking reduction study with the nicotine gum. *Nicotine & Tobacco Research* 2003;**5**:278.

Pfizer. Summary of Clinical Efficacy. Application for licensing of Nicorette Inhalator/Gum for smoking reduction leading to cessation. Company data NICORE-1013-273-SU.

**Hotham 2006**

\*Hotham ED, Gilbert AL, Atkinson ER. A randomised-controlled pilot study using nicotine patches with pregnant women. *Addictive Behaviors* 2006;**31**:641–48.

**Hughes 1989b**

Hughes JR, Gulliver SB, Amori G, Mireault GC, Fenwick JF. Effect of instructions and nicotine on smoking cessation, withdrawal symptoms and self-administration of nicotine gum. *Psychopharmacology (Berl)* 1989;**99**:486–91.

**Hurt 1995**

Hurt RD, Dale LC, Offord KP, Croghan IT, Hays JT, Gomez Dahl L. Nicotine patch therapy for smoking cessation in recovering alcoholics. *Addiction* 1995;**90**(11):1541–6.

**Hurt 2003**

Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. *Journal of Clinical Oncology* 2003;**21**(5):914–20.

**Jarvik 1984**

Jarvik ME, Schneider NG. Degree of addiction and effectiveness of nicotine gum therapy for smoking. *American Journal of Psychiatry* 1984;**141**:790–1.

**Kapur 2001**

Kapur B, Hackman R, Selby P, Klein J, Koren G. Randomized, double-blind, placebo-controlled trial of nicotine replacement therapy in pregnancy. *Current Therapeutic Research Clinical and Experimental* 2001;**62**:274–8.

**Korberly 1999**

Korberly B, Gustavsson G, Kruse E. Over-the-counter efficacy of a 15 mg daytime nicotine patch for smoking cessation: a randomized multicenter trial. Abstract book. Society for Research on Nicotine and Tobacco 4th European Conference October 3-5 Santander, Spain. 2002:23.

\*Korberly BH, Maguire MK. An open label multicenter trial to evaluate and compare the efficacy of nicotrol 15mg as part of an OTC intervention package or as a prescription as an aid in smoking cessation. Abstract Book. Society for Research on Nicotine and Tobacco Fifth Annual Meeting, San Diego CA. 1999.

**Kozak 1995**

Kozak J, Fagerstrom KO, Sawe U. High-dose treatment with the nicotine patch. *International Journal of Smoking Cessation* 1995;**4**(2): 26–8.

**Krumpe 1989**

Krumpe P, Malani N, Adler J. Efficacy of transdermal nicotine administration as an adjunct for smoking cessation in heavily nicotine addicted smokers. *Annual Review of Respiratory Disease* 1989;**139**: A337.

**Kupez 1996**

\*Kupez D, Prochazka A. A comparison of nicotine delivery systems in a multimodality smoking cessation program. *Nurse Practitioner* 1996;**21**(2):73,77–8,81.

**Landfeldt 1998**

Landfeldt B, Kruse E, Westin A, Mattson K, Lojander J. Nicotine replacement treatment in heavy smokers: nicotine nasal spray

combined with nicotine patch in a double-blind controlled study (abstract). *European Respiratory Journal* 1998;**12**(Suppl 28):154S.

**Leischow 1996b**

Leischow SJ, Hill A, Cook G. The effects of transdermal nicotine for the treatment of hispanic smokers. *American Journal of Health Behavior* 1996;**20**:304–11.

**Levin 1994**

Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman S, et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. *Journal of Clinical Psychopharmacology* 1994;**14**:41–9.

**Lin 1996**

Lin HN. The effectiveness of nicotine patch for smoking cessation. *Chinese Psychiatry* 1996;**10**:29–38.

**Marsh 2005**

Marsh HS, Dresler CM, Choi JH, Targett DA, Gamble ML, Strahs KR. Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: A 12-week, randomized, open-label study. *Clinical Therapeutics* 2005;**27**(10):1571–87.

**McCarthy 2006**

McCarthy DE, Piasecki TM, Fiore MC, Baker TB. Life before and after quitting smoking: an electronic diary study. *Journal of Abnormal Psychology* 2006;**115**(3):454–66.

**Meier 1990**

Meier Lammermann E, Mayer M, Boleski PL. Combination of transdermal nicotine substitution and behavioural group therapy in smoking cessation. *European Respiratory Journal* 1990;**3**(Suppl 10):168S.

**Merz 1993**

\*Merz PG, Keller Stanislawski B, Huber T, Woodcock BG, Rietbrock N. Transdermal nicotine in smoking cessation and involvement of non-specific influences. *International Journal of Clinical Pharmacology Therapy and Toxicology* 1993;**31**:476–82.

**Millie 1989**

Millie A, Berriau T, Paget D, Philardeau V, Postal MJ, Dautzenberg B, et al. Can weight gain during weaning from smoking be limited using nicotine gum? [French] [Peut-on limiter la prise de poids chez les fumeurs lors du sevrage tabagique en utilisant la gomme a la nicotine?]. *Revue de Pneumonologie Clinique* 1989;**45**:243–9.

**Minneker 1989**

Minneker E, Buchkremer G, Block M. The effect of different dosages of a transdermal nicotine substitution system on the success rate of smoking cessation therapy. *Methods and Findings in Experimental and Clinical Pharmacology* 1989;**11**:219–22.

**Molander 2000**

Molander L, Lunell E, Fagerstrom KO. Reduction of tobacco withdrawal symptoms with a sublingual nicotine tablet: a placebo controlled study. *Nicotine & Tobacco Research* 2000;**2**:187–91.

**Mooney 2005**

Mooney M, Babb D, Jensen J, Hatsukami D. Interventions to increase use of nicotine gum: A randomized, controlled, single-blind trial. *Nicotine & Tobacco Research* 2005;**7**(4):565–79.

**Mulligan 1990**

Mulligan SC, Masterson JG, Devane JG, Kelly JG. Clinical and pharmacokinetic properties of a transdermal nicotine patch. *Clinical Pharmacology and Therapeutics* 1990;47:331-7.

**Okuyemi 2007**

Okuyemi KS, James AS, Mayo MS, Nollen N, Catley D, Choi WS, et al. Pathways to health: a cluster randomized trial of nicotine gum and motivational interviewing for smoking cessation in low-income housing. *Health Education & Behavior* 2007;34:43-54.

**Pomerleau 2003**

Lerman C, Audrain J, Patterson F, Kaufmann V, Rukstalis M, Wileyto EP, et al. Differential response to nicotine replacement therapies in obese and non-obese women (PA2-6). Abstract Book. Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA. 2003.

\*Pomerleau OF, Pomerleau CS, Marks JL, Snedecor SM, Mehringer AM, Namemek-Brouwer RJ, et al. Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood. *Journal of Substance Abuse Treatment* 2003;24(1):13-18.

**Rennard 2006**

Rennard SI, Glover E, Leischow S, Daughton DM, Glover P, Muramoto M. Efficacy of nicotine inhaler in smoking reduction. *Nicotine & Tobacco Research* 2002;4:380.

\*Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, et al. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. *Nicotine & Tobacco Research* 2006;8:555-64.

**Roddy 2006**

Roddy E, Romilly N, Challenger A, Lewis S, Britton J. Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial. *Tobacco Control* 2006;15:373-6.

**Rose 1990**

Rose JE, Levin ED, Behm FM, Adivi C, Schur C. Transdermal nicotine facilitates smoking cessation. *Clinical Pharmacology and Therapeutics* 1990;47:323-30.

**Sachs 1995**

Sachs DPL. Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. *Archives of Internal Medicine* 1995;155:1973-80.

**Shiffman 2000a**

Shiffman S, Khayrallah M, Nowak R. Efficacy of the nicotine patch for relief of craving and withdrawal 7-10 weeks after cessation. *Nicotine & Tobacco Research* 2000;2:371-8.

**Shiffman 2000b**

Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB, et al. Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. *Addiction* 2000;95(8):1185-95.

**Shiffman 2002a**

Shiffman S, Dresler CM, Gorsline J, Dimarino ME. The efficacy of nicotine patch in an over-the-counter environment: results from a randomized, double-blind, placebo-controlled trial (PO130). Abstract book, 11th World Conference on Tobacco or Health, 6-11 August, Chicago, Illinois. 2000; Vol. 1.

\*Shiffman S, Gorsline J, Gorodetzky CW. Efficacy of over-the-counter nicotine patch. *Nicotine & Tobacco Research* 2002;4:477-83.

**Shiffman 2002b**

Shiffman S, Rolf CN, Hellebusch SJ, Gorsline J, Gorodetzky CW, Chiang YK, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. *Addiction* 2002;97:505-16.

**Shiffman 2006**

Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. *Journal of Consulting and Clinical Psychology* 2006;74:1153-61.

Shiffman S, Ferguson SG, Gwaltney CJ. Immediate hedonic response to smoking lapses: Relationship to smoking relapse, and effects of nicotine replacement therapy. *Psychopharmacology* 2006;184(3-4):608-18.

Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. *Psychopharmacology* 2006;184(3-4):637-44.

\*Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. *Journal of Consulting & Clinical Psychology* 2006;74:276-85.

Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Attentional bias predicts outcome in smoking cessation. *Health Psychology* 2003;22:378-87.

Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Cue-provoked craving and nicotine replacement therapy in smoking cessation. *Journal of Consulting and Clinical Psychology* 2004;72(6):1136-43.

**Sutherland 1999**

Anon. Combination NRT; Improving efficacy in smoking cessation. McNeil Consumer Healthcare booklet. Short term outcomes reported on p18.

\*Sutherland G. A placebo-controlled double-blind combination trial of nicotine spray and patch [abstract]. *Nicotine & Tobacco Research* 1999;1:186.

**Sutherland 2005**

Sutherland G, Stapleton JA, Russell MA. Randomized placebo-controlled trial of nicotine nasal spray in general practice. *Nicotine & Tobacco Research* 2005;7(4):686.

**Sutton 1987**

Sutton S, Hallett R. Randomized trial of brief individual treatment for smoking using nicotine chewing gum in a workplace setting. *American Journal of Public Health* 1987;77:1210-1. [MEDLINE: 87296451].

**Sutton 1988**

Sutton S, Hallett R. Smoking intervention in the workplace using videotapes and nicotine chewing gum. *Preventive Medicine* 1988;17:48-59.

**Thorsteinsson 2001**

Thorsteinsson HS, Gillin JC, Patten CA, Golshan S, Sutton LD, Drummond S, et al. The effects of transdermal nicotine therapy for

smoking cessation on depressive symptoms in patients with major depression. *Neuropsychopharmacology* 2001;**24**(4):350–8.

#### **Tzivoni 1998**

Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. *Cardiovascular Drugs and Therapy* 1998;**12**:239–44.

#### **Uyar 2005**

Uyar M, Bayram N, Filiz A, Elbek O, Topçu A, Dikensoy O, et al. Comparison of nicotine patch and bupropion in treating tobacco dependence. *European Respiratory Journal* 2005;**26**(Suppl 49):388s.

#### **Velicer 2006**

\*Velicer WF, Friedman RH, Fava JL, Gulliver SB, Keller S, Sun X, et al. Evaluating nicotine replacement therapy and stage-based therapies in a population-based effectiveness trial. *Journal of Consulting & Clinical Psychology* 2006;**74**:1162–72.

Velicer WF, Keller S, Friedman RH, Fava JL, Gulliver SB, Ward RM, et al. Comparing participants and nonparticipants recruited for an effectiveness study of nicotine replacement therapy. *Annals of Behavioral Medicine* 2005;**29**:181–91.

#### **Vial 2002**

Vial RJ, Jones TE, Ruffin RE, Gilbert AL. Smoking cessation program using nicotine patches linking hospital to the community. *Journal of Pharmacy Practice and Research* 2002;**32**(1):57–62.

#### **Warner 2005**

Warner DO, Patten CA, Ames SC, Offord KP, Schroeder DR. Effect of nicotine replacement therapy on stress and smoking behavior in surgical patients. *Anesthesiology* 2005;**102**(6):1138–46.

#### **Wennike 2003**

Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. *Addiction* 2003;**98**(10):1395–402.

#### **Wiseman 2005**

Wiseman EJ, Williams DK, McMillan DE. Effectiveness of payment for reduced carbon monoxide levels and noncontingent payments on smoking behaviors in cocaine-abusing outpatients wearing nicotine or placebo patches. *Experimental and Clinical Psychopharmacology* 2005;**13**(2):102–10.

#### **Working Group 1994**

Working Group for the Study of Transdermal Nicotine. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. *Archives of Internal Medicine* 1994;**154**:989–95.

### **References to studies awaiting assessment**

#### **Garvey 2006**

\*Garvey AJ, Hoskinson RA, Wadler BM, Kinnunen T, Sachs DPL. Individualising nicotine patch dose to match smokers' usual nicotine intake levels (PA9-4). Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida. 2006:32.

Mustonen TK, Spencer SM, Hoskinson RA, Sachs DPL, Garvey AJ. The influence of gender, race, and menthol content on tobacco exposure measures. *Nicotine & Tobacco Research* 2005;**7**:581–90.

#### **Hoch 2006**

\*Hoch E, Wittchen HU. Population health perspective on smoking cessation: A randomized controlled trial of different methods in primary health care (RPOS 3-71). Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida. 2006.

Sonntag H, Hoch E, Jahn B, Spiegel B, Pfister H, Wittchen HU. Smoking cessation in primary care: implementation effectiveness and optimized allocation. *Suchtmedizin in Forschung und Praxis* 2003;**5**(2):137–41.

#### **Pollak 2007**

Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, Pletsch PK, et al. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. *American Journal of Preventive Medicine* 2007;**33**:297–305.

#### **Vikhireva 2003**

\*Vikhireva O, Shalnova S, Deev A. Nicotine replacement therapy in Russia: old wine in new skins? Randomized parallel study of nicotine gum/inhaler in smoking cessation/reduction. Abstract book. Society for Research on Nicotine and Tobacco. Fifth European Conference. November 20-22nd, Padua, Italy. 2003.

Vikhireva O, Shalnova S, Deev A, Levshin V, Radkevich N, Kalinina A. NRT-assisted cessation in Russia: individual and population level benefits. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic. 2005.

### **References to ongoing studies**

#### **Coleman 2007**

Coleman T, Thornton J, Britton J, Lewis S, Watts K, Coughtrie MWH, et al. Protocol for the Smoking, Nicotine and Pregnancy (SNAP) trial: Double-blind, placebo-randomised, controlled trial of nicotine replacement therapy in pregnancy. *Bmc Health Services Research* 2007;**7**:2.

### **Additional references**

#### **Altman 2002**

Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. *BMC Medical Research Methodology* 2002;**2**:3.

#### **Altman 2004**

Altman DG, Schulz KF, Moher D. Turning a blind eye: testing the success of blinding and the CONSORT statement. *BMJ* 2004;**328**(7448):1135.

#### **Benowitz 2000**

Benowitz NL, Dempsey DA, Goldenberg RL, Hughes JR, Dolan-Mullen P, Ogburn PL, et al. The use of pharmacotherapies for smoking cessation during pregnancy. *Tobacco Control* 2000;**9**:91–4.

#### **Cahill 2007**

Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database of Systematic Reviews* 2007, Issue 1. Art. No.: CD006103. DOI: [10.1002/14651858.CD006103.pub2](https://doi.org/10.1002/14651858.CD006103.pub2).

#### **Cepeda-Benito 2004**

Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences



- between men and women. *Journal of Consulting and Clinical Psychology* 2004;**72**:712–22.
- CONSORT 1996**  
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. *Journal of the American Medical Association* 1996;**276**:637–9.
- Cummings 2005**  
Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. *Annual Review of Public Health* 2005;**26**:583–99.
- D’Orlando 2004**  
D’Orlando K, Fox B. Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product. *Nicotine & Tobacco Research* 2004;**6**:63–70.
- Deeks 2005**  
Deeks J, Higgins JPT, Altman DG. In: Higgins JPT, Green S, editors. Analysing and presenting results: Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8. <http://www.cochrane.org/resources/handbook/hbook.htm> (accessed 30th October 2007).
- Dempsey 2002**  
Dempsey D, Jacob P, Benowitz L. Accelerated metabolism of nicotine and cotinine in pregnant smokers. *Journal of Pharmacology and Experimental Therapeutics* 2002;**301**:594–8.
- Durcan 2002**  
Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, et al. Impact of prior nicotine replacement therapy on smoking cessation efficacy. *American Journal of Health Behaviors* 2002;**26**:213–20.
- Egger 1997**  
Egger M, Davey Smith G, Schneider M, Minder CE. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629–34.
- Etter 2006**  
Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. *Tobacco Control* 2006;**15**:280–5.
- Etter 2007**  
Etter JF, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis (PA9-6). *Addiction* 2007;**102**:815–22.
- Fagerstrom 2002**  
Fagerstrom KO, Hughes JR. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. *Nicotine & Tobacco Research* 2002;**4**(Suppl 2):S73–S79.
- Fagerstrom 2003**  
Fagerstrom KO. Clinical treatment of tobacco dependence: The endurance of pharmacologic efficacy. *Journal of Clinical Psychiatry Monograph* 2003;**18**:35–40.
- Fiore 1992**  
Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. *JAMA* 1992;**268**:2687–94.
- Fiore 2000**  
Fiore MC, Bailey WC, Cohen SJ, et al. *Treating Tobacco Use and Dependence. A Clinical Practice Guideline*. Rockville, MD: US Dept of Health and Human Services: AHRQ publication No. 00-0032, 2000.
- Franzon 2002**  
Franzon M, Gustavsson G, Korberly BH. Effectiveness of over-the-counter nicotine replacement therapy. *JAMA* 2002;**288**:3109–10.
- Greenland 1998**  
Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. *Drug Safety* 1998;**18**:297–308.
- Henningfield 2005**  
Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. *CA Cancer Journal for Clinicians* 2005;**55**:281–99.
- Higgins 2003**  
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. *BMJ* 2003;**327**:557–60.
- Hughes 1995**  
Hughes JR. Treatment of nicotine dependence. Is more better?. *JAMA* 1995;**274**:1390–1.
- Hughes 2001**  
Hughes JR. The effectiveness of over-the-counter nicotine replacement: a rebuttal. *Drug and Alcohol Review* 2001;**20**:319–22.
- Hughes 2004a**  
Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 2004;**99**:29–38.
- Hughes 2004b**  
Hughes JR, Pillitteri JL, Callas PW, Callahan R, Kenny M. Misuse of and dependence on over-the-counter nicotine gum in a volunteer sample. *Nicotine & Tobacco Research* 2004;**6**:79–84.
- Hughes 2005**  
Hughes JR, Adams EH, Franzon MA, Maguire MK, Guary J. A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler. *Tobacco Control* 2005;**14**:49–54.
- Hughes 2007**  
Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database of Systematic Reviews* 2007, Issue 1. Art. No.: CD000031. DOI:[10.1002/14651858.CD000031.pub3](https://doi.org/10.1002/14651858.CD000031.pub3).
- Hyland 2005**  
Hyland A, Rezaishiraz H, Giovino G, Bauer JE, Cummings KM. Over-the-counter availability of nicotine replacement therapy and smoking cessation. *Nicotine & Tobacco Research* 2005;**7**:547–55.
- Ikinci 2006**  
Ikinci G, Senel S, Tokgozoglul L, Wilson CG, Sumnu M. Development and in vitro/in vivo evaluations of bioadhesive buccal tablets for nicotine replacement therapy. *Pharmazie* 2006;**61**:203–7.
- Italy ISS 2004**  
Osservatorio Fumo, Alcol e Droga. *Linee guida cliniche per promuovere la cessazione dell’abitudine al fumo*. Rome: Istituto Superiore di Sanita, 2004.

**Joseph 2003**

Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. *Progress in Cardiovascular Diseases* 2003;**45**:429–41.

**Lancaster 2000**

Lancaster T, Silagy C, Fowler G. Training health professionals in smoking cessation. *Cochrane Database of Systematic Reviews* 2000, Issue 3.Art. No.: CD000214. DOI:[10.1002/14651858.CD000214](https://doi.org/10.1002/14651858.CD000214).

**Le Foll 2005**

Le Foll B, Melihan-Cheinin P, Rostoker G, Lagrue G. Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency. *European Psychiatry* 2005;**20**:431–41.

**McClure 2006**

McClure JB, Swan GE. Tailoring nicotine replacement therapy: rationale and potential approaches. *Central Nervous System Drugs* 2006;**20**:281–91.

**Meine 2005**

Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. *American Journal of Cardiology* 2005;**95**:976–8.

**Mooney 2004**

Mooney M, White T, Hatsukami D. The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials. *Addictive Behaviors* 2004;**29**(4):673–84.

**Munafò 2004a**

Munafò M, Bradburn M, Bowes L, David S. Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. *Nicotine & Tobacco Research* 2004;**6**:769–76.

**Munafò 2004b**

Munafò M, Bradburn M, Bowes L, David S. Investigating subgroups in smoking cessation treatment response: Response to Perkins. *Nicotine & Tobacco Research* 2004;**6**:865–7.

**NZ NACHD 2002**

National Advisory Committee on Health and Disability. *Guidelines for smoking cessation: revised 2002*. Wellington, New Zealand: National Health Committee, 2002.

**Palmer 1992**

Palmer KJ, Buckley MM, Faulds D. Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. *Drugs* 1992;**44**:498–529.

**Park 2002**

Park CR, Munday DL. Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. *International Journal of Pharmaceutics* 2002;**237**(1-2):215–26.

**Perkins 2004**

Perkins KA. Obstacles to determining individual differences in the efficacy of smoking cessation medications. *Nicotine & Tobacco Research* 2004;**6**:765–7.

**Pierce 2002**

Pierce JB, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *JAMA* 2002;**288**:1260–4.

**Schneider 2004**

Schneider NG, Olmstead RE, Nides M, Mody FV, Otte Colquette P, Doan K, et al. Comparative testing of 5 nicotine systems: initial use and preferences. *American Journal of Health Behavior* 2004;**28**:72–86.

**Shiffman 2003**

Shiffman S, Hughes JR, Pillitteri JL, Burton SL. Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. *Tobacco Control* 2003;**12**:310–6.

**Shiffman 2005**

Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy. *Tobacco Control* 2005;**14**:346–55.

**Simes 1986**

Simes RJ. Publication bias: the case for an international registry of clinical trials. *Journal of Clinical Oncology* 1986;**4**(10):1529–41.

**Stead 2002**

Stead LF, Davis RM, Fiore MC, Hatsukami DK, Raw M, West R. Effectiveness of over-the-counter nicotine replacement therapy. *JAMA* 2002;**288**:3109–10.

**Stead 2007**

Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. *Cochrane Database of Systematic Reviews* 2007, Issue 3.Art. No.: CD005231. DOI:[10.1002/14651858.CD005231.pub2](https://doi.org/10.1002/14651858.CD005231.pub2).

**Stewart 1993**

Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference?. *Lancet* 1993;**341**(8842):418–22.

**Sweeney 2001**

Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. *CNS Drugs* 2001;**15**:453–67.

**TNWG 1994**

Transdermal Nicotine Working Group. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. *Archives of Internal Medicine* 1994;**154**:989–95.

**Wallstrom 1999**

Wallstrom M, Sand L, Nilsson F, Hirsch JM. The long-term effect of nicotine on the oral mucosa. *Addiction* 1999;**94**:417–23.

**Walsh 2000**

Walsh RA, Penman AG. The effectiveness of nicotine replacement therapy over-the-counter. *Drug and Alcohol Review* 2000;**19**:243–7.

**Walsh 2001**

Walsh RA, Penman AG. The effectiveness of over-the-counter nicotine replacement: reply to Hughes. *Drug and Alcohol Review* 2001;**20**:322–4.

**Walsh 2007**

Walsh RA, Stead L, Lancaster T. The Cochrane review on nicotine replacement therapy: incorrect or uncertain classifications of additional support levels & Authors' response. *Tobacco Control* 2007;**16**:215–6.

**West 2000**

West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. *Thorax* 2000;**55**:987–99.

**West 2001**

West R, Shiffman S. Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. *Psychopharmacology Berl* 2001;**155**:115–22.

**West 2007**

West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the “real world”? Findings from a prospective multinational cohort study. *Thorax* 2007;**62**:998–1002.

**Woolacott 2002**

Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. *Health Technology Assessment* 2002; **6**:1–245.

**Zwar 2004**

Zwar N, Richmond R, Borland R, Stillman S, Cunningham N, Litt J. *Smoking cessation guidelines for Australian General Practice*. Guideline Development Group, 2004.

**References to other published versions of this review****Silagy 1994a**

Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. *Lancet* 1994; **343**:139–42.

**Silagy 1994b**

Silagy C, Mant D, Fowler G, Lancaster T. The effectiveness of nicotine replacement therapies in smoking cessation. *Online Journal of Current Clinical Trials* 1994;**Doc No**:113.

**Silagy 1996**

Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 1996, Issue 2.Art. No.: CD000146. DOI: [10.1002/14651858.CD000146.pub3](https://doi.org/10.1002/14651858.CD000146.pub3).

**Silagy 2001**

Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 20001, Issue 3.Art. No.: CD000146. DOI: [10.1002/14651858.CD000146.pub3](https://doi.org/10.1002/14651858.CD000146.pub3).

**Silagy 2002**

Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2002, Issue 4.Art. No.: CD000146. DOI: [10.1002/14651858.CD000146.pub3](https://doi.org/10.1002/14651858.CD000146.pub3).

**Silagy 2004**

Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2004, Issue 3.Art. No.: CD000146. DOI: [10.1002/14651858.CD000146.pub3](https://doi.org/10.1002/14651858.CD000146.pub3).

\* Indicates the major publication for the study

**T A B L E S****Characteristics of included studies**

Study	Abelin 1989
Methods	Country: Switzerland Recruitment: 21 Primary care clinics Randomization: method not stated
Participants	199 primary care patients 40% F, av.age 41, av.cpd 27
Interventions	1. Nicotine patch, 24hr, 12 wk with weaning; 21mg smokers of >20 cpd, 14 mg for <20 cpd 2. Placebo patch Level of support: low (number of visits unclear)
Outcomes	Sustained abstinence at 12m (0-3 cigs/wk) Validation: expired CO
Notes	Methods in Lancet paper, Final follow up in Muller 1990
Allocation concealment	B – Unclear

**Study Ahluwalia 1998**

Methods Country: USA  
Recruitment: hospital in- and outpatients

**Characteristics of included studies (Continued)**

	Randomization: computer-generated random number table
Participants	410 African American smokers Av.age 47, FTND 6
Interventions	1. Nicotine patch (21mg with weaning, 10 wks) 2. Placebo patch Level of support: high (1 hr initial visit and brief follow-up visits)
Outcomes	Prolonged abstinence at 6m (self report of no smoking since end of treatment) Validation: none
Notes	
Allocation concealment	A – Adequate

**Study Ahluwalia 2006**

Methods	Country: USA Recruitment: community volunteers Randomization: central blocked scheme, sequential envelopes
Participants	755 African American light smokers (<= 10 cpd) 67% F, av.age 45, av.cpd 8
Interventions	Factorial trial, behavioural interventions collapsed for this review 1. Nicotine gum (2mg), recommended use tailored to cpd. Highest 10/day for 4wks, tapering for 4wks 2. Placebo gum, 8wks Level of support: high (3 in-person visits at randomization, wk1, wk8, and phone contact at wk3, wk6, wk16, content based on either motivational interviewing or health education principles)
Outcomes	PP abstinence at 6m (7 day PP) Validation: cotinine <=20 ng/ml
Notes	New for 2008 update
Allocation concealment	A – Adequate

**Study Areechon 1988**

Methods	Country: Thailand Recruitment: community volunteers Randomization: method not stated
Participants	200 smokers (>=15 cpd) 6% F, av.age 39, av.cpd 24
Interventions	1. Gum (2 mg) x 8 boxes 2. Placebo gum x 8 boxes Level of support: high (weekly visits with physician, unspecified frequency & duration)
Outcomes	PP abstinence at 6m Validation: CO
Notes	Support level reclassified as high, 2008
Allocation concealment	B – Unclear

**Study Blondal 1989**

Methods	Country: Iceland Recruitment: community volunteers invited to attend a smoking cessation clinic Randomization: method not stated
Participants	182 smokers (included pipe & cigar users, smoked at least once a day)

**Characteristics of included studies (Continued)**

	57% F, av.age 42, av. tobacco use 21g/day
Interventions	1. Gum (4mg) for at least 1m 2. Placebo gum (containing pepper) for 1m or more Level of support: high (group therapy, 5 1hr sessions, TQD at session 1)
Outcomes	Lapse-free abstinence at 12m (24m also reported, no validation) Validation: CO<10ppm
Notes	Lapse-free abstinence used since 2008
Allocation concealment	B – Unclear

<b>Study</b>	<b>Blondal 1997</b>
Methods	Country: Iceland Recruitment: community volunteers Randomization: computer-generated code, dispensed by pharmacy. Double blind.
Participants	159 smokers (>=1 cpd) 44% F, av.age 42, av. tobacco use 25g/day
Interventions	1. Nicotine nasal spray (NNS) ad lib use. Each dose (2 squirts) delivered 1mg nicotine. Maximum dose 5 mg/hr and 40 mg/day. Recommended duration of use 3m. 2. Placebo nasal spray containing piperine to mimic sensory effect of nicotine. Level of support: high (Group therapy x 6 1hr sessions)
Outcomes	Sustained abstinence at 1 yr (continuous abstinence from quit day, follow up also at 2 yrs) Validation: CO<10ppm at each of 5 follow ups
Notes	Abstinence at 24m 15/79 vs 11/78. OR 1.4
Allocation concealment	A – Adequate

<b>Study</b>	<b>Blondal 1999</b>
Methods	Country: Iceland Recruitment: community volunteers Randomization: computer-generated code at pharmacy
Participants	237 smokers (>=1 cpd) 67% F, av.age 41-43, av. tobacco use 25g/day
Interventions	1. Nicotine nasal spray (NNS) (0.5mg/dose) + 15mg nicotine patches for 3m, weaning over further 2m. NNS could be continued for 1 yr 2. Placebo nasal spray + 15 mg nicotine patches on same schedule Level of support: high (4 supportive group meetings)
Outcomes	Sustained abstinence at 12m (6 yr data also reported) Validation: CO<10ppm
Notes	Does not contribute to main comparisons, only combination. 6yr abstinence 19/118 vs 10/119, OR 2.1
Allocation concealment	A – Adequate

<b>Study</b>	<b>Bohadana 2000</b>
Methods	Country: France Recruitment: community volunteers Randomization: computer-generated code
Participants	400 smokers, 18-70 yrs, >10 cpd, >1 previous quit attempt, motivated.

**Characteristics of included studies (Continued)**

	51% F, Av cpd: Group 1 26.1, Group 2 23.5; FTND>6
Interventions	1: Nicotine inhaler, 26wks, combined with nicotine patch (15 mg/16hr) for first 6wks, placebo patch for next 6wks 2: Nicotine inhaler, 26wks, placebo patch for first 12wks All received brief counselling and support from investigator at each visit
Outcomes	Sustained abstinence at 12m, (prolonged from wk 2, no slips allowed) Validation: CO<10ppm at each visit (2wks, 6wks, 6m, 12m) (Study also reports respiratory symptoms and pulmonary function tests for completely abstinent subjects)
Notes	Does not contribute to main comparisons, only combination. Gender subgroup results reported 2003
Allocation concealment	A – Adequate

**Study Bolin 1999**

Methods	Country: USA Recruitment: smoking cessation clinic Randomization: method not stated. Assignment on first day of patch use.
Participants	98 smokers 16% F, av.age 54, av.cpd 20
Interventions	1. Nicotine patch for 12wks (21 mg/3wks, 14 mg/3wks, 7 mg/3wks) 2. Nicotine patch for 3wks (21 mg/1wk, 14 mg/1wk, 7 mg/1wk) All received intensive group programme, 5 sessions prior to quit day.
Outcomes	Continuous abstinence at 5m (PP also recorded) Validation: CO
Notes	Contributes only to length of treatment comparison Borderline follow-up length - 20wks from beginning of programme, 16wks since start of NRT
Allocation concealment	B – Unclear

**Study Br Thor Society 1983**

Methods	Country: UK (95 centres) Recruitment: hospital chest clinics (80%) and inpatient wards Randomization: by numbered envelope
Participants	1618 clinic patients age 18-65 with a smoking-related illness (pulmonary or vascular) 39% F, av.age 49, av.cpd 24
Interventions	1. Brief advice from physician 2. Brief advice + booklet 3. Brief advice + placebo chewing gum 4. Brief advice + booklet + nicotine chewing gum (2mg for up to 3m, up to 6m on request) Level of support: low (1m & 3m follow-up visits)
Outcomes	Sustained validated abstinence at 6m and 12m Validation: Venous carboxyhaemoglobin
Notes	Includes both placebo and no-placebo groups. 4 vs 1+2+3 used in main comparison. 4 vs 3 has lower OR (0.8) but does not alter MA notably
Allocation concealment	B – Unclear

**Study Buchkremer 1988**

Methods	Country: Germany
---------	------------------

**Characteristics of included studies (Continued)**

	Recruitment: community volunteers Randomization: method not stated
Participants	131 smokers 50% F, av.age 35, av.cpd 29
Interventions	1. Nicotine Patch (24hr/day, 8wks, 15cm <sup>2</sup> with weaning) + behavioural therapy 2. Placebo patch + behavioural therapy 3. Behavioural therapy alone Level of support: high (9 weekly group sessions)
Outcomes	Abstinence (not stated how assessed) at 12m Validation: none
Notes	Placebo & no-placebo groups. 1 vs 2+3 used in main comparison
Allocation concealment	B – Unclear

<b>Study</b>	<b>CEASE 1999</b>
Methods	Country: Multicentre - 36 clinic centres in 17 European countries Recruitment: community volunteers Randomization: central computer-generated allocation list, stratified by centre
Participants	3575 smokers (>14 cpd) 48% F, av.age 41, av.cpd 27 (34% had previously used NRT)
Interventions	Factorial design compared 2 patch doses and 2 treatment durations. Dose 15mg or 25mg (16hr), duration of active treatment 28 wks (incl 4 wk fading) or 12 wks (incl 4 wk fading). 1. 25mg patch for 28 wks (L-25) 2. 25mg patch for 12 wks (S-25) 3. 15mg patch for 28 wks (L-15) 4. 15mg patch for 12 wks (S-15) 5. Placebo Level of support: high (brief advice & self help brochure, visits at enrolment, TQD, wk 1, 2, 4, 8, 12, 22, 26)
Outcomes	Prolonged abstinence at 12m, sustained from wk 2 Validation: expired CO<10ppm at each clinic visit
Notes	Doses and durations collapsed in main analyses. Durations compared in comparison 4, dosages in comparison 8. Level of support reclassified to high for 2007 because of repeated visits. Limited support at these visits
Allocation concealment	A – Adequate

<b>Study</b>	<b>Campbell 1987</b>
Methods	Country: UK Recruitment: primary care (45 GPs in 11 centres) Randomization: method not stated
Participants	836 primary care patients agreeing to try to stop smoking after brief advice from their doctor 61% F, av.age 39
Interventions	1. Nicotine gum (2mg) x 6 boxes 2. Placebo gum x 6 boxes Level of support: low (no further face-to-face contact, 2/3rds received a letter after 1m)
Outcomes	Sustained abstinence at 12m Validation: CO

## Characteristics of included studies (Continued)

Notes

Allocation concealment B – Unclear

### Study **Campbell 1991**

Methods Country: UK  
Recruitment: hospital inpatients  
Randomization: not stated

Participants 212 patients with smoking-related diseases  
44% F, 53% 50+, 61% smoked >15 cpd

Interventions 1. Nicotine gum 2-4mg (3m)  
2. Placebo gum  
Level of support: high (support at 2, 3, 5wks, 3m, 6m)

Outcomes Sustained abstinence at 12m  
Validation: CO

Notes

Allocation concealment B – Unclear

### Study **Campbell 1996**

Methods Country: UK  
Recruitment: hospital inpatients and outpatients  
Randomization: method not stated

Participants 234 adult smokers (>1 cpd in previous wk) (172 outpatients, 62 inpatients) Stratified on FTND  
54% F, av.age 49

Interventions 1. Nicotine patch (21mg, 24hr, 12wks with dose tapering)  
2. Placebo patch  
Level of support: high (counselling at 2, 4, 8, 12 wks)

Outcomes Continuous abstinence at 12m  
Validation: CO

Notes Originally included as Burton 1992 which was an abstract of the same trial.

Allocation concealment B – Unclear

### Study **Cinciripini 1996**

Methods Country: USA  
Recruitment: community volunteers  
Randomization: method not stated

Participants 64 smokers (>15 cpd)  
70% F, av.cpd 29/22

Interventions 1. Nicotine patch (21mg, 12 wks incl weaning)  
2. Behaviour therapy only (no placebo)  
Level of support: High (group therapy weekly for 9 wks)

Outcomes Sustained abstinence, 12m post-treatment and all previous points (EOT, 1, 3, 6m)  
Validation: CO<6ppm at each point

Notes 121 smokers recruited but only 64 followed up for 1 yr. 6m quit rates were approx 53% vs 30% (personal communication 2004)

Allocation concealment B – Unclear



**Characteristics of included studies (Continued)**

<b>Study</b>	<b>Clavel 1985</b>
Methods	Country: France Recruitment: community volunteers Randomization: method not stated
Participants	427 smokers ( $\geq 5$ cpd) 51% F, av.age 34, av.cpd 22 for intermediate group (Clavel 1984)
Interventions	1. Nicotine gum (2mg) x 1 box 2. Control group (time lock controlled cigarette case) (Acupuncture arm not included in this review) Level of support: High (3 1hr group therapy sessions in first month)
Outcomes	Sustained abstinence at 13m Validation: 'Smoking cessation adjusted using exhaled CO figures from published trials'
Notes	Classification of support corrected to high in 2008 update
Allocation concealment	B – Unclear

<b>Study</b>	<b>Clavel-Chapelon 1992</b>
Methods	Country: France Recruitment: community volunteers Randomization: method not stated
Participants	996 smokers ( $\geq 10$ cpd) 45% F, av.age 34
Interventions	Factorial trial with active/placebo acupuncture arms, collapsed for this review 1. Nicotine gum (2mg) for up to 6m, max 30/day 2. Placebo gum (contained 1mg unbuffered nicotine) Level of support: high (3 acupuncture session at 0, 7, 28 days)
Outcomes	Abstinence at 13m (1m quitters followed up). 4-yr follow up reported in 1997 with different 1 yr results Validation: none at 1 yr
Notes	First included in 2008 update. Question over inclusion because placebo contained small amount of nicotine Abstinence at 4y 30/481 vs 32/515
Allocation concealment	B – Unclear

<b>Study</b>	<b>Cooper 2005</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	439 female smokers ( $\geq 10$ cpd) Av.age 38, av.cpd 23
Interventions	1. Nicotine gum (2mg), 10-12 pieces/day recommended, for 9 wks, weaning last 3 wks. 2. Placebo gum Level of support: high. x13 1hr weekly cognitive behavioural group sessions. Reduction prior to TQD wk 5 (3rd arm tested phenylpropanolamine gum, not included in review)
Outcomes	PP abstinence at 12m Validation: CO $<$ 10ppm (Weight change in quitters was also a primary outcome in the trial)
Notes	First included as Cooper 2003. Published report from 2007.
Allocation concealment	B – Unclear

**Characteristics of included studies (Continued)**

<b>Study</b>	<b>Croghan 2003</b>
Methods	Country: USA, multicentre Recruitment: community volunteers Randomization: central, controlling for cpd, yrs smoked, gender, site
Participants	1384 smokers (>=15 cpd) 58% F, av.age 42, av.cpd 26
Interventions	1. 15mg/16hr nicotine patch plus 0.5 mg/dose nasal spray, max 5/hr, 40/day, for 6 wks 2. Nicotine nasal spray only 3. Nicotine patch only Level of support: low (advice at each visit, 30-45 mins total)
Outcomes	PP abstinence at 6m Validation: CO
Notes	Does not contribute to main comparison, combination only
Allocation concealment	A – Adequate

<b>Study</b>	<b>Dale 1995</b>
Methods	Country: USA Recruitment: community volunteers and smoking clinic attenders. Randomization: method not stated
Participants	71 smokers stratified according to light, moderate and heavy smoking rates. 56% F, av.age 48, av.cpd 26
Interventions	1. 11mg/24hr nicotine patch 2. 22mg/24hr nicotine patch 3. 44mg/24hr nicotine patch 4. Placebo patch for 1 wk followed by 11 or 22mg patch for 7 wks. Duration of patch use 8 wks. Level of support: high (including 6 day inpatient stay)
Outcomes	PP abstinence at 12m Validation: Blood cotinine
Notes	Does not contribute to main comparison. Contributes to comparison 8 of high and standard dose patch.
Allocation concealment	B – Unclear

<b>Study</b>	<b>Daughton 1991</b>
Methods	Country: USA Recruitment: community volunteers at 2 sites Randomization: method not stated
Participants	158 smokers (at least 1 pack of cpd) 53% F, av.age 42, av.cpd 33
Interventions	1. Nicotine patch (15cm <sup>2</sup> , 4 wks) worn for 16hr/day 2. Nicotine patch (15cm <sup>2</sup> , 4 wks) worn for 24hr/day 3. Placebo patch, 4 wks Level of support: unclear & differed between sites
Outcomes	Sustained abstinence at 6m Validation: None
Notes	1 +2 vs 3 in comparison 1. 16 vs 24 hr in comparison 6. Not used in support intensity subgroup analysis
Allocation concealment	B – Unclear

**Characteristics of included studies (Continued)**

<b>Study</b>	<b>Daughton 1998</b>
Methods	Country: USA (21 sites) Recruitment: patients at family practices - self-referred to study or recruited by physician. Randomization: centrally generated
Participants	369 smokers (> 20 cpd) Av.age 37, av.cpd 27-30
Interventions	1. Nicotine patch (21mg, 16hr, 10 wks with weaning) 2. Placebo patch Level of support: low (Nicoderm Committed Quitters Programme support booklet + follow-up visit 1 wk after quit day)
Outcomes	Sustained abstinence (continuous self-reported from quit day) at 12m Validation: CO ≤ 8ppm and saliva cotinine < 20mg/mL
Notes	There were differences in quit rates between self-referred and physician-selected recruits and between smokers recruited during an illness and at another visit.
Allocation concealment	A – Adequate

<b>Study</b>	<b>Dautzenberg 2001</b>
Methods	Country: France Recruitment: community volunteers Randomization: method not stated
Participants	433 smokers (excludes 25 from ITT population) 52% F, av.age 39, av.cpd 21
Interventions	1. Nicotine lozenge (1mg, 8-24/day, 6 wks + 6 wks weaning for quitters) 2. Placebo lozenge Level of support: not stated
Outcomes	PP abstinence at 26 wks Validation: CO < 10ppm
Notes	Based on published abstract
Allocation concealment	B – Unclear

<b>Study</b>	<b>Davidson 1998</b>
Methods	Country: USA (4 centres) Recruitment: community volunteers in shopping malls (OTC setting) Randomization: central computer-generated schedule
Participants	802 smokers (>20 cpd) who scored 5+ on a questionnaire assessing motivation 54% F, av.age 39, av.cpd 29
Interventions	1. Nicotine patch (22mg, 24 hr, for up to 6 wks) 2. Placebo patch Level of support: low (self-help book provided. Participants visited mall weekly to obtain patches. CO levels were monitored)
Outcomes	Sustained abstinence at 24 wks (from wk 2) Validation: Expired CO ≤ 8ppm at each weekly visit, but 24 wk quit based on self report
Notes	541/802 did not complete the 6 weekly visits
Allocation concealment	A – Adequate

**Characteristics of included studies (Continued)**

<b>Study</b>	<b>Ehrsam 1991</b>
Methods	Country: Switzerland Recruitment: university (primary care) Randomization: method not stated
Participants	112 smokers at 2 universities Av.age 26, av.cpd 23
Interventions	1. Nicotine patch (21 or 14mg/24hr, 9 wks, tapered) 2. Placebo patch Level of support: high (no counselling)
Outcomes	Sustained abstinence at 12m Validation: urinary cotinine
Notes	
Allocation concealment	B – Unclear

<b>Study</b>	<b>Fagerstrom 1982</b>
Methods	Country: Sweden Recruitment: smoking cessation clinic Randomization: method not stated
Participants	100 smokers 59% F
Interventions	1. Nicotine gum (2mg) for at least 4 wks 2. Placebo gum for at least 4 wks Level of support: high (individual counselling, average 7.7 sessions)
Outcomes	PP abstinence at 6m Validation: CO
Notes	
Allocation concealment	B – Unclear

<b>Study</b>	<b>Fagerstrom 1984</b>
Methods	Country: Sweden Recruitment: general practices and industrial clinics (primary care) Randomization: by birthdate
Participants	145 motivated smokers 56% F, av.age 40 years, av. cpd 19 Therapists: 10 Swedish GPs, 3 Swedish industrial physicians
Interventions	1. Short follow up (advice plus 1 appointment) 2. Long follow up (advice plus 2 appointments, phone call + letter) 3. Short follow up plus nicotine gum (2 or 4mg) 4. Long follow up plus nicotine gum Level of support: low
Outcomes	Sustained abstinence at 12m (and at 1,6m) Validation: 15% deception rate detected by expired CO>4ppm in a random subset of claimed non-smokers at 6m. Self-reported 12m rates used in MA
Notes	3 & 4 vs 1 & 2 in Comparison 1. 1 vs 2 in Comparison 3.3
Allocation concealment	C – Inadequate

<b>Study</b>	<b>Fee 1982</b>
Methods	Country: UK

**Characteristics of included studies (Continued)**

	Recruitment: smoking cessation clinic Randomization: method not stated
Participants	352 smokers, no other demographic data
Interventions	1. Gum (2mg) given for 5 wks 2. Placebo gum given for 5 wks Level of support: high (10 group therapy sessions)
Outcomes	PP abstinence at 12m Validation: Blood carboxyhaemoglobin
Notes	
Allocation concealment	B – Unclear

<b>Study</b>	<b>Fiore 1994A</b>
Methods	Country: USA Recruitment: community volunteers Randomization: pregenerated computer sequence
Participants	88 smokers (>15 cpd)
Interventions	1. Nicotine patch (22mg/24hr, 8 wks, no weaning) 2. Placebo patch Level of support: high (intensive group counselling)
Outcomes	PP abstinence at 6m (7 days PP) Validation: CO
Notes	Reported in same paper as Fiore 1994B
Allocation concealment	A – Adequate

<b>Study</b>	<b>Fiore 1994B</b>
Methods	Country: USA Recruitment: community volunteers Randomization: pregenerated computer sequence
Participants	112 smokers (>15 cpd)
Interventions	1. Nicotine patch (22mg/24hr, 6 wks incl weaning) 2. Placebo patch Level of support: high (x8 weekly 10-20 min individual counselling)
Outcomes	PP abstinence at 6m (7 days PP) Validation: CO
Notes	Reported in same paper as Fiore 1994A
Allocation concealment	B – Unclear

<b>Study</b>	<b>Fortmann 1995</b>
Methods	Country: USA Setting: community volunteers (telephone recruitment) Randomization: method not stated
Participants	1044 smokers aged 18-65, able to quit for 24 hr, and without serious illness 42% F, av.age 40, av.cpd 20
Interventions	1. Nicotine gum (2mg, 1 per hr, at least 10/day and not more than 30/day) 2. Self-help materials 3. Nicotine gum plus materials

**Characteristics of included studies (Continued)**

	4. Incentive alone. All groups offered incentive of US\$100 for quitting at 6m. Level of support: low
Outcomes	PP abstinence at 12m Validation: CO<9 ppm/salivary cotinine<20 ng/ml
Notes	Until 2008 only groups 1 and 4 compared. Since the trial was factorial and shows no evidence of interaction, both gum groups now used; 1&3 vs 2&4. The OR is unaltered but CIs narrow.
Allocation concealment	B – Unclear

**Study Garcia 1989**

Methods	Country: Spain Recruitment: primary care Randomization: method not stated
Participants	106 adult smokers (excludes 81 not beginning treatment) 65% F, av.age 36, av.cpd 25
Interventions	1. Gum (2mg) for 3-4m 2. Placebo gum for 3-4m Level of support: high (group therapy, 7 sessions over 3m)
Outcomes	Sustained abstinence at 6m Validation: CO<=7ppm
Notes	
Allocation concealment	B – Unclear

**Study Garvey 2000**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated, stratified by high- and low-dependence
Participants	608 smokers, aged>20, smoking>5 cpd. 51% F, av.cpd 23
Interventions	1. 4mg nicotine gum (recommended 9-15 pieces), weaning from 2m 2. 2mg nicotine gum, use as 1. 3. Placebo gum All received brief counselling (5-10 mins) at each study visit (1, 7, 14, 30 days, 2, 3, 6, 9, 12m) Level of support: high
Outcomes	Sustained abstinence at 12m (relapse defined as 7+ consecutive days or episodes of smoking) Validation: CO<= 8ppm
Notes	4 + 2mg doses combined in main comparison. 4mg compared to 2mg in comparison of doses
Allocation concealment	B – Unclear

**Study Gilbert 1989**

Methods	Country: Canada Recruitment: primary care Randomization: sealed envelopes
Participants	223 patients presenting to primary care doctors and smoking at least 1 cpd (not selected by motivation)
Interventions	1. Support from physician plus offer of nicotine gum prescription (2mg) 2. Support from physician (no placebo)

**Characteristics of included studies (Continued)**

	Level of support: low (enrolment, quit day, offer of 4 support visits, 2 in wk 1, 1m, 2m)
Outcomes	Sustained abstinence at 12m (for 3m) Validation: salivary cotinine
Notes	~30% of gum group did not use any, 14% of support only group did use gum. ~70% attended quit day visit, ~43% attendance for follow-up visits
Allocation concealment	B – Unclear

**Study Glavas 2003a**

Methods	Country: Croatia Recruitment: hospital health professionals Randomization: random numbers and sealed envelopes.
Participants	112 healthcare professionals smoking at least 1 cpd. 26% had FTND score 6+. 66% F, av.age 34, av.cpd: 24
Interventions	1. Nicotine patch, 24hr, 25 mg/15 mg/8 mg starting dose depending on baseline cpd. 3 wks 2. Placebo patch Level of support: low (visits to pick up patch at 7, 14, 21 days, no details about advice given)
Outcomes	Sustained abstinence (3 or fewer cigs/wk) at 1 yr (5-yr abstinence also reported, not used in MA) Validation: CO<11ppm
Notes	
Allocation concealment	A – Adequate

**Study Glavas 2003b**

Methods	Country: Croatia Recruitment: community volunteers Randomization: sealed numbered envelopes independently prepared
Participants	160 smokers
Interventions	1. Nicotine patch, 24hr, 25mg/15mg/8mg starting dose depending on baseline cpd. 6 wks 2. Nicotine patch, 24hr, 25mg/15mg starting dose depending on baseline cpd. 3 wks 3. Placebo patch. 6 wks 4. Placebo patch 3 wks Level of support: low
Outcomes	Abstinence at 6m after EOT Validation: CO<11ppm
Notes	Both durations pooled for main comparison.
Allocation concealment	A – Adequate

**Study Glover 2002**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	241 smokers (>=10 cpd) 54%F, av.age 42, av.cpd 29
Interventions	1. Nicotine sublingual tablet (2mg). Recommended dosage 1 tab/hr for smokers with FTND<7, 2 tabs/hr for scores >= 7. After 3m treatment, tapering period of 3m if necessary 2. Placebo tablet Level of support: high (brief counselling at all visits 1, 2, 3, 6 wks, 3, 6,12m)

**Characteristics of included studies (Continued)**

Outcomes Sustained abstinence at 12m  
Validation: CO<10ppm

Notes

Allocation concealment B – Unclear

**Study Goldstein 1989**

Methods Country: USA  
Recruitment: community volunteers  
Randomization: method not stated

Participants 89 smokers (excluding 18 early treatment drop-outs not included in results)

Interventions Factorial design of 2 types of group treatment, and 2 schedules for use of nicotine gum. Behaviour therapy arms collapsed  
1. Fixed schedule nicotine gum (2mg); 1 piece/hr for 1st week with tapering over 10 wks  
2. Ad lib nicotine gum; to be used when urge to smoke, max 30/day  
Level of support: high (10x 1hr sessions of either intensive cognitive and behavioural skills training or non-specific education and support)

Outcomes PP abstinence at 6m  
Validation: Saliva cotinine<10ng/ml or CO<8ppm for people still using gum

Notes Does not contribute to main comparison. Used in comparison of fixed to ad lib schedule gum.

Allocation concealment B – Unclear

**Study Gourlay 1995**

Methods Country: Australia  
Recruitment: community volunteers  
Randomization: method not stated

Participants 629 smokers (>15 cpd) who had relapsed after transdermal nicotine and behavioural counselling in an earlier phase of the study.  
Minimal additional support

Interventions 1. Nicotine patch 30cm<sup>2</sup> (21mg/24 hr) for 4 wks, 20cm<sup>2</sup> (14mg/24 hr) for 4 wks, 10cm<sup>2</sup> (7mg/24 hrs) for 4 wks.  
2. Placebo patch

Outcomes Sustained abstinence at 6m  
Validation: expired CO<10ppm

Notes Does not contribute to main comparison. Test of patches vs placebo in recently relapsed smokers. Results given in text.

Allocation concealment B – Unclear

**Study Gross 1995**

Methods Country: USA  
Recruitment: community volunteers  
Randomization: method not stated, stratified on measures of addiction, no blinding

Participants 177 smokers  
51% F, av. age 42, av.cpd 33, av. FTND score 7.8

Interventions 1. Nicotine gum (2mg), tapered from wk 12. Active gum groups further randomized to chew 7, 15 or 30 pieces of gum.  
2. No gum  
Level of support: high (1 pre-quit group counselling session, 14 clinic visits in 10 wks)



**Characteristics of included studies (Continued)**

Outcomes	Continuous abstinence at 6m (up to 3 cigs allowed) Validation: CO $\leq$ 10ppm. Saliva thiocyanate in wk 2.
Notes	No placebo. Long-term abstinence rates not affected by amount of gum, so these groups collapsed for comparison with no gum condition.
Allocation concealment	B – Unclear

**Study Hall 1985**

Methods	Country: USA Recruitment: community volunteers and physician referrals Randomization: 'randomly assigned within time constraints' method not stated
Participants	120 smokers (77 in arms contributing to MA) 47% F, av. age 38, av.cpd 31
Interventions	1. Intensive behavioural treatment (14 group sessions over an 8 wk period) 2. Combined - 2mg nicotine gum (period of use not specified) and intensive behavioural treatment 3. Low contact behavioural treatment (4 meetings over 3 wks) and 2mg gum Level of support: high
Outcomes	Abstinence at 12m Validation: CO $<$ 10ppm and blood thiocyanate $<$ 85 mg/mL.
Notes	No placebo. 2 vs 1 in main comparison. 3 not used in MA. Quit rate higher than arm 1
Allocation concealment	B – Unclear

**Study Hall 1987**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	139 adult smokers 47% F, av.age 39, av. cpd 30
Interventions	2x2 factorial trial of gum and behavioural support 1. Nicotine gum (2mg) up to 12m 2. Placebo gum up to 12m Both levels of behavioural support classified as high intensity & collapsed in analysis (both group-based, x14 75 min sessions, or x5 60min sessions)
Outcomes	PP abstinence at 12m Validation: CO $<$ 8ppm & serum thiocyanate $<$ 95 mm/l
Notes	
Allocation concealment	B – Unclear

**Study Hall 1996**

Methods	Country: USA Recruitment: community volunteers Randomization: stratified by history of depression and no. of cpd. Method not stated
Participants	207 smokers of which 6 excluded from analyses because of protocol breaches 52% F, av.age 40, av.cpd 24
Interventions	2x2 factorial trial of gum and psychological treatment 1. Nicotine gum (2mg) for 8 wks, 1 piece/hr for 12 hrs/day recommended 2. Placebo gum, same schedule

### Characteristics of included studies (Continued)

	Both levels of behavioural support classified as high intensity & collapsed in analysis (both group-based, 10 sessions over 8 wks, TQD session 3)
Outcomes	Sustained abstinence at 12m (abstinent at all assessments) Validation: CO $\leq$ 10ppm at 8, 12, 26 wks and urinary cotinine $\leq$ 60ng/ml at 52 wks
Notes	Psychological treatment arms collapsed, no evidence of a significant interaction
Allocation concealment	B – Unclear

#### Study **Hand 2002**

Methods	Country: UK Recruitment: hospital in- or outpatients referred by hospital doctor Randomization: alternation by month of recruitment
Participants	245 patients with smoking-related disease. 46% M, typically aged 50+, smoking 15+ cpd
Interventions	1. Nicotine patch (initially 30 or 20mg based on smoking rate) and inhaler for 3 wks including patch tapering. Same counselling as control 2. Individual counselling, 4 sessions in 4 wks. No placebo Level of support: high
Outcomes	Sustained abstinence at 12m (abstinent at all assessments) Validation: CO $<$ 10ppm
Notes	No placebo. Compliance with NRT was low, 28% did not use, 30% used full supply. Used in main comparisons and comparison 9, combination
Allocation concealment	C – Inadequate

#### Study **Harackiewicz 1988**

Methods	Country: USA Recruitment: primary care (University Health Centre) Randomization: method not stated
Participants	197 smokers (151 used in MA) 63% F, av.age 36, av.cpd 26
Interventions	1. Nicotine gum (2mg, 6 wks initial supply, suggested tapering after 3m, available for 6m) plus self-help manual 2. Self-help manual 3. Control (booklet) Level of support: low (single appointment with doctor or nurse, length not specified)
Outcomes	Sustained abstinence at 12m Validation: CO in all subjects, cotinine and carboxyhemoglobin in a sub-sample of subjects
Notes	No placebo. Arm 3 not included in MA control group - it had a lower quit rate so inclusion would increase the gum treatment effect
Allocation concealment	B – Unclear

#### Study **Hays 1999**

Methods	Country: USA (3 sites) Recruitment: community volunteers Randomization: in 2 stages - first to open label or double-blind study, then to active or placebo patch. At stage 1 participants told about their assigned arm and could decline enrolment but could not cross over. No information given on numbers not enrolling but baseline characteristics similar across groups. For stage 2 of randomization both participants and investigators blinded.
---------	---

### Characteristics of included studies (Continued)

Participants	958 smokers, >15 cpd 50% F, av.age 44, typically smoked 21-40/day
Interventions	1. Nicotine patches (22mg, 24 hr for 6 wks) purchased by participants, open label 2. Nicotine patches (22mg, 24 hr for 6 wks) provided, double blind 3. Placebo patches provided The intervention replicated an OTC environment, with no counselling intervention and minimal study recording. Weekly visits required for CO measurement & adverse experience recording, but study sites were not in medical centres and there was no advice, counselling or interaction with medical personnel. Level of support: low
Outcomes	Abstinence at 6m (7 day PP) Validation: CO<=8ppm
Notes	1 & 2 vs 3 in patch vs placebo comparisons 2 vs 1 in free versus paid comparison (Comparison 12.1)
Allocation concealment	B – Unclear

#### Study **Herrera 1995**

Methods	Country: Venezuela Recruitment: community volunteers Randomization: method not stated. Stratified into high and low dependence groups, who were randomized to different treatments.
Participants	322 smokers >10 cpd, scoring >=4 on FTND, no serious illness. Only those who were ready to quit after 4 wks of behavioural treatment were randomized. 43% F, av.age ~38, av. cpd 33 for high dependence, 16 for low dependence
Interventions	Low dependence smokers (FTND 4-6): 1. 2mg nicotine gum 2. Placebo gum High dependence smokers (FTND 7-11): 1. 4mg nicotine gum plus 2. 2mg nicotine gum Level of support: high for all (12 group sessions over 6 wks + 6 weekly maintenance sessions) Participants also randomized to starting medication with increasing dose for 1 wk before TQD, or to start at full dose on TQD - there was no blinding for this.
Outcomes	Sustained abstinence at 2 yrs (1 yr also reported) Validation: expired CO<6ppm
Notes	Low dependence smokers included in comparison 1. High dependence smokers in comparison 2, 4mg vs 2mg gum. Relapse between 1 & 2 yrs similar between low dependence groups. Higher relapse in 4mg high dependence than 2mg
Allocation concealment	B – Unclear

#### Study **Hilleman 1994**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated, open label
Participants	140 smokers (excluding a buspirone treatment group), smoking > 20/day, FTND>= 8 55%F, av.age 46, av.cpd 25-26
Interventions	1. Nicotine patch (21mg/24 hr) for 6 wks, no weaning 2. Nicotine patch, 21mg 4 wks, weaning to 14mg 4 wks, 7mg 4 wks

### Characteristics of included studies (Continued)

	Level of support: high (12 weekly behaviour therapy sessions), does not contribute to intensity subgroup comparison
Outcomes	Abstinence at 6m Validation: Plasma thiocyanate
Notes	Does not contribute to main comparison. Contributes to both tapering versus no tapering and length of treatment comparisons
Allocation concealment	B – Unclear

#### Study **Hjalmarson 1984**

Methods	Country: Sweden Recruitment: smoking cessation clinic Randomization: randomized by therapy group (26). Unclear if enroller blind, but therapists blind
Participants	206 smokers 56% F, av.age 42, av. cpd 24
Interventions	1. Nicotine gum (2mg) (no restrictions on amount or duration of use) 2. Placebo gum Level of support: high (6 group sessions in 6 wks)
Outcomes	Sustained abstinence at 12m Validation: CO
Notes	
Allocation concealment	B – Unclear

#### Study **Hjalmarson 1994**

Methods	Country: Sweden Recruitment: smoking cessation clinic Randomization: all participants attending first treatment clinic session randomized so recruitment bias unlikely, but treatment allocator not blinded, so that household members could be given same medication. Therapist and subjects were blinded
Participants	248 smokers 57% F, av.age 45, av. cpd 22
Interventions	1. Nicotine nasal spray (0.5 mg/spray) used as required up to 40 mg/day for up to 1 yr. 2. Placebo spray Level of support: high (x8 45-60 min group sessions over 6 wks with clinical psychologist)
Outcomes	Sustained abstinence at 12m Validation: CO<10ppm
Notes	
Allocation concealment	B – Unclear

#### Study **Hjalmarson 1997**

Methods	Country: Sweden Recruitment: smoking cessation clinic Randomization: participants assigned a number on attending first group session. Numbers on a list randomizing to medication. Participants from the same household randomized to same treatment.
Participants	247 smokers (>10 cpd) who had previously made a serious attempt to stop using nicotine gum 64% F, av.age 48, av.cpd 21
Interventions	1. Nicotine Inhaler (recommended minimum 4/day, tapering after 3m, use permitted to 6m) 2. Placebo inhaler

**Characteristics of included studies (Continued)**

	Level of support: high (8 group meetings over 6 wks)
Outcomes	Sustained abstinence at 12m Validation: CO<10ppm at 2 and 6 wks and 3, 6, 12m.
Notes	
Allocation concealment	A – Adequate
<b>Study</b>	<b>Huber 1988</b>
Methods	Country: Germany Recruitment: community volunteers Randomization: method not stated
Participants	225 smokers (109 contribute to MA) No demographic information
Interventions	1. Nicotine gum alone 2. Behaviour therapy, 5 weekly group meetings 3. Nicotine gum (no details of dose) and behaviour therapy Level of support: high 4. 6m waiting list control
Outcomes	Abstinence at 12m Validation: none
Notes	3 vs 2 in comparison 1. No placebo. Quit rates derived from graphs. The nicotine alone group was not used in the MA; quit rates were higher than intervention 2.
Allocation concealment	B – Unclear
<b>Study</b>	<b>Hughes 1989</b>
Methods	Country: USA Recruitment: primary care Randomization: a random digit entered to their subject number used to dispense gum
Participants	315 daily smokers 56% F, av. age 37, av. cpd 29
Interventions	1. Nicotine gum (2mg for 3-4m) 2. Placebo gum Level of support: low (29-35 min at 1st visit including nurse & physician advice, & materials, follow-up appointment 1-2 wks later)
Outcomes	Sustained abstinence at 12m Validation: salivary cotinine<15ng/mL or thiocyanate<1.6mmol/L
Notes	Time spent at 1st visit is marginal for inclusion in low intensity support category.
Allocation concealment	A – Adequate
<b>Study</b>	<b>Hughes 1990</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	78 smokers 54% F, av.age 34-44, av. cpd 24-30
Interventions	1. Placebo gum 2. 1mg nicotine gum (unbuffered formula, available dose approx 0.5mg)

**Characteristics of included studies (Continued)**

	3. 2mg nicotine gum 4. 4mg nicotine gum Gum use not recommended for longer than 3m Level of support: low (similar to Hughes 1989)
Outcomes	Sustained abstinence at 6m Validation: Independent observer report
Notes	2+3+4 vs 1 in Comparison 1. Excluding the lowest dose would increase the treatment effect. 4 vs 3 in Comparison 2, low dependence smokers
Allocation concealment	B – Unclear

**Study Hughes 1991**

Methods	Country: USA Recruitment: primary care patients Randomization: sealed envelopes
Participants	106 smokers 52% F, av.age 38, av.cpd 26
Interventions	1. Free prescription for nicotine gum for up to 6m 2. Nicotine gum at cost of US\$6/box (96 pieces 2mg) 2. Nicotine gum at US\$20/box All participants received brief physician advice with 1 follow up.
Outcomes	Abstinence at 6m Validation: observer verification of all 6m quitters
Notes	Tested effect of price on gum use and efficacy. Results given in text, not included in any MA
Allocation concealment	A – Adequate

**Study Hughes 1999**

Methods	Country: USA (12 sites), Australia (1 site) Recruitment: community volunteers & referrals Randomization: method not stated
Participants	1039 smokers (>= 30 cpd) who had made a prior quit attempt, motivated to try again 50% M, av.age 43, av.cpd 38
Interventions	1. 42mg nicotine patch (24 hr, 6 wks + 10 wks tapering) 2. 35mg nicotine patch 3. 21mg nicotine patch 4. Placebo patch Level of support: high (group behaviour therapy for 7 wks, brief individual counselling at 5 dose tapering meetings. Self-help booklet)
Outcomes	Prolonged abstinence at 6m (from 2 wks post-quit) verified at each follow-up visit. (12m follow up only completed for 11 of 13 sites) Validation: CO=<10ppm
Notes	All doses pooled in comparison 1 against placebo. 44mg vs 22mg in dose-response comparison 6m abstinence rates used in analyses since not all centres completed 12m follow up due to sponsor termination of study. Denominators confirmed by author.
Allocation concealment	B – Unclear

**Study Hughes 2003**

Methods	Country: USA
---------	--------------

**Characteristics of included studies (Continued)**

	Recruitment: community volunteers Randomization: method not stated
Participants	115 smokers with a history of alcohol dependence, $\geq 30$ cpd 68% M, av.cpd 30
Interventions	1. Nicotine patch ( 21mg, 24 hr, 6 wks + 4 wks tapering + 2 wks placebo) 2. Placebo patch 12 wks Level of support: high (Group behaviour therapy x 6, brief individual counselling x3)
Outcomes	Sustained abstinence at 6m (from 2 wks post-quit) Validation: CO $\leq$ 10ppm at each follow-up visit
Notes	Unadjusted ORs used in MA not significant, significant when adjusted for smoking variables.
Allocation concealment	B – Unclear

**Study                      Hurt 1990**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	62 adult smokers ( $>20$ cpd) 53% F, av.age 39, av. cpd 30
Interventions	1. Nicotine patch (30mg 24 hrs, 6 wks + option of further 12 wks +/- tapering) 2. Placebo patch (continuing smokers at 6 wks were offered active patch) Level of support: high (brief advice from nurse co-ordinator at x 6 weekly visits)
Outcomes	Sustained abstinence at 12m (quit by wk 6, & all subsequent visits) Validation: CO $\leq$ 8ppm
Notes	
Allocation concealment	B – Unclear

**Study                      Hurt 1994**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	240 adult smokers ( $>20$ cpd) 53% F, av.age 43, av. cpd 30
Interventions	1. Nicotine patch (22mg/24 hr, 8 wks, no tapering) 2. Placebo patch Level of support: high (nurse counselling at 8 weekly visits, weekly phone calls to wk 12)
Outcomes	Abstinence at 12m (no puff since 9m visit) Validation: CO $\leq$ 8ppm
Notes	
Allocation concealment	B – Unclear

**Study                      ICRF 1994**

Methods	Country: UK Setting: primary care (19 general practices) Randomization: random allocation of study numbers to treatment group and sequential allocation of study numbers.
Participants	1686 smokers ( $>15$ cpd) 55% F, av.age 43, av. cpd 24

### Characteristics of included studies (Continued)

Interventions	1. Nicotine patch (21mg/24hr, 12 wks incl tapering) 2. Placebo patch Level of support: high (brief advice from nurse at 4 study visits)
Outcomes	Sustained abstinence at 12m (from wk 1) Validation: Salivary cotinine or CO
Notes	8 year follow up in Yudkin 2003, OR remained similar.
Allocation concealment	A – Adequate

#### Study **Jamrozik 1984**

Methods	Country: UK Recruitment: primary care (6 general practices) Randomization: alphabetical code list, doctors & patients blind
Participants	200 adult smokers who had failed to stop smoking during a previous study of the effect of physician advice No demographic information
Interventions	1. Nicotine gum (2mg) for 3m+ 2. Placebo gum Level of support: low (follow-up visits at 2, 4, 12 wks for data collection, no counselling reported)
Outcomes	PP abstinence at 6m Validation: expired CO $\leq$ 12ppm
Notes	
Allocation concealment	A – Adequate

#### Study **Jarvis 1982**

Methods	Country: UK Recruitment: smoking cessation clinic Randomization: in groups of 10 taken in order from waiting list, sequence generation & concealment not described
Participants	116 clinic attenders 55% F, av. age 41/38, av. cpd 31/27 (P<0.05)
Interventions	1. Nicotine gum (2mg) unrestricted amount for at least 3m 2. Placebo gum (1mg unbuffered nicotine) Level of support: high (group therapy x6 1 hr weekly)
Outcomes	Sustained abstinence at 12m (6m & 12m PP) Validation: CO (small number by confirmation from friend/relative only)
Notes	The placebo gum was intended to match the active gum in taste but deliver minimal amounts of nicotine
Allocation concealment	B – Unclear

#### Study **Jensen 1991**

Methods	Country: Denmark Recruitment: smoking cessation clinic Randomization: smokers randomized to groups and groups to treatment. No information on sequence generation or allocation concealment. Participants not blind
Participants	293 adult smokers (>10 cpd) in relevant arms 54% F, av. age 42, av. cpd 21-22
Interventions	1. Nicotine gum (2mg for 3m) 2. Silver acetate chewing gum (not used in MA)



**Characteristics of included studies (Continued)**

	3. Standard chewing gum Level of support: high (9 group meetings over a year, weekly to wk 4)
Outcomes	Sustained abstinence at 12m Validation: CO
Notes	12m data reported in Thorax 1990 paper, used from 2008
Allocation concealment	B – Unclear

**Study Jorenby 1995**

Methods	Country: USA Recruitment: community volunteers Randomization: double-blind, no further details
Participants	504 adult smokers (>=15 cpd) 53% F, av. age 44, av. cpd ~27
Interventions	1. Nicotine patch 22mg for 6 wks then 2 wks 11mg with minimal counselling 2. Same patch, individual counselling 3. Same patch, group counselling. 4. 44mg patch for 4 wks then 2 wks 22mg then 2 wks 11mg with minimal counselling 5. Same patch, individual counselling 6. Same patch, group counselling.
Outcomes	Abstinence (>1 wk) at 6m Validation: CO<10ppm
Notes	Does not contribute to comparison 1. Support levels collapsed in comparison 8 between high and standard dose
Allocation concealment	B – Unclear

**Study Jorenby 1999**

Methods	Country: USA (4 sites) Recruitment: community volunteers Randomization: method not stated. Unequal cell design, not balanced within sites
Participants	893 smokers, (>15 cpd) 52% F, av. age 42-44, av. cpd 25-28
Interventions	1. Nicotine patch (21mg/24hr for 6 wks, tapered for 2 wks) and sustained release bupropion 300mg for 9 wks from 1 wk before quit day 2. Bupropion 300mg and placebo patch 3. Nicotine patch and placebo tablets 4. Placebo patch and placebo tablets Level of support: high, <15 min individual counselling session at each weekly assessment. One telephone call 3 days after quit day
Outcomes	Abstinence at 12m (primary outcome for study was PP abstinence; this analysis uses continuous abstinence since quit day) Validation: Expired CO<10ppm at each clinic visit
Notes	3 vs 4 in main comparisons. Combinations compared in Comparison 9
Allocation concealment	B – Unclear

**Study Joseph 1996**

Methods	Country: USA, multicentre trial Recruitment: 10 Veterans Affairs Medical Centers Randomization: Co-ordinating centre used computer-generated schedule to randomly assign in blocks of 10
---------	--

**Characteristics of included studies (Continued)**

Participants	584 smokers (>15 cpd) with a history of cardiac disease. Patients with cardiac events within the last 2 wks were excluded.
Interventions	1. Nicotine patch, (21mg/24hr for 6 wks, 14mg for 2 wks, 7mg for 2 wks) 2. Placebo patch Level of support: High (self-help pamphlets and brief behavioural counselling on 3 occasions)
Outcomes	PP abstinence at 6m (Joseph 1996), 12m (Joseph 1999) Validation: CO $\leq$ 10ppm
Notes	
Allocation concealment	A – Adequate

**Study Kalman 2006**

Methods	Country: USA Recruitment: Veterans Admin Medical Centre and community-based substance abuse treatment facility Randomization: method not stated. (unblinded during dose tapering)
Participants	130 smokers ( $\geq$ 20 cpd with history of alcohol dependence & $\geq$ 2m abstinence from alcohol & illicit drugs) 84%M, av.age 47, Av. cpd 32
Interventions	Dose response trial 1. Nicotine patch (42mg (2x21mg)) 4 wks, then tapered for 8 wks 2. Nicotine patch (21mg & placebo) for 4 wks then same tapering as 1. (Level of support: high (x5 1 hr weekly group counselling sessions, 2 before TQD)
Outcomes	Abstinence at 36 wks (26 wks post EOT) (7 day PP) Validation: CO<10ppm
Notes	New for 2008 update
Allocation concealment	B – Unclear

**Study Killen 1984**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	64 adult smokers 72% F, av.age 44, av. cpd 32
Interventions	1. Nicotine gum (2mg) for 7 wks 2. Skills training 3. Skills training plus nicotine gum Level of support: high (group therapy)
Outcomes	Sustained abstinence at 10.5m Validation: CO
Notes	1+3 vs 2 used in comparison. 3 vs 2 would increase effect
Allocation concealment	B – Unclear

**Study Killen 1990**

Methods	Country: USA Recruitment: community volunteers who had abstained from smoking for 48 hrs Randomization: method not stated
Participants	1218 adult smokers 52% F, av.age 43, av. cpd 25.
Interventions	1. Nicotine gum (2mg, 8 wks) ad lib dosing

**Characteristics of included studies (Continued)**

	2. Nicotine gum on a fixed dose 3. Placebo gum 4. No gum Each group was also factorially randomized to 1 of 3 psychological interventions (all high support).
Outcomes	PP abstinence at 12m (7 day PP) Validation: cotinine except participants who moved away
Notes	Quit rates were higher on fixed dose than ad lib gum. Quit rates identical (18%) in placebo and no gum groups at 12m
Allocation concealment	B – Unclear

<b>Study</b>	<b>Killen 1997</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	424 smokers ~50% F, av.age ~45, av. cpd ~23
Interventions	2x2 factorial design, comparison between video & self-help manuals and manuals alone collapsed. 1. Nicotine patch (21mg/24hr) for 8 wks, 14mg for 4 wks, 7mg for 4 wks 2. Placebo patch 3. Nicotine patch and video (The video was shown at initial visit and a copy supplied for home use) 4. Placebo patch and video Level of support: low (All treatment groups received a self-help treatment manual designed to develop self-regulatory skills.
Outcomes	Sustained abstinence at 12m (7 day PP at 6 and 12m) Validation: saliva cotinine<20ng/ml with the exception of participants living outside the area
Notes	There was evidence of an interaction between NRT and video/self-help conditions but this does not alter the MA so the conditions are combined from 2007. Both self-help conditions treated as low intensity - classifying video as high intensity would marginally reduce effect in high intensity subgroup.
Allocation concealment	B – Unclear

<b>Study</b>	<b>Killen 1999</b>
Methods	Country: USA Recruitment: community volunteers responding to advertisements - heavy smokers selected from responders Randomization: method not stated
Participants	408 heavy smokers (> 25 cpd) 59% M, av.age 47, av. cpd 36, Modified FTND score 18
Interventions	1. 25mg nicotine patch for 6 wks (16 hr, no tapering) 2. 15mg nicotine patch for 6 wks Self-help treatment manual, short video showing patch use and placement
Outcomes	Sustained abstinence at 12m (7 day PP abstinence at both 6 and 12m) Validation: Saliva cotinine<20 ng/ml (not required for 3 individuals not in area)
Notes	Does not contribute to comparison 1. 85% of self-reported quitters provided samples for validation at 12m
Allocation concealment	B – Unclear

<b>Study</b>	<b>Kornitzer 1987</b>
Methods	Country: Belgium

**Characteristics of included studies (Continued)**

	Recruitment: worksite primary care clinic Randomization: method not stated
Participants	199 smokers (av cpd 24-5)
Interventions	1. Nicotine gum (4mg) for at least 3m 2. Nicotine gum (2mg) for same time period Level of support: low
Outcomes	PP abstinence at 12m Validation: cotinine and carboxyhemoglobin in a sub-sample of subjects
Notes	Contributes data only to 4mg vs 2mg Comparison 2
Allocation concealment	B – Unclear

**Study Kornitzer 1995**

Methods	Country: Belgium Recruitment: worksite volunteers Randomization: computer-generated list, blinded
Participants	374 healthy smokers (>10 cpd for >3 yrs) 61% M, av. age 40, av. cpd 25
Interventions	1. Nicotine patch (12 wks 15mg/16hr, 6 wks 10mg, 6 wks 5mg) and nicotine gum (2mg, as required) 2. Nicotine patch and placebo gum 3. Placebo patch and placebo gum. Level of support: high (nurse counselling)
Outcomes	Sustained abstinence at 12m Validation: CO<10 ppm
Notes	Contributes data to main comparison (2 vs 3) and to patch plus gum vs patch alone comparison.
Allocation concealment	A – Adequate

**Study Kralikova 2002**

Methods	Country: Czech Republic Recruitment: community volunteers 'wanting to reduce' Randomization: method not stated
Participants	314 smokers (>=15 cpd) 58% F, av. age 46, av. cpd 25
Interventions	1. Choice of 4mg nicotine gum (up to 24/day) or 10mg inhaler (6-12 daily) for up to 6m with further 3m tapering 2. Placebo gum or inhaler Common components: brief behavioural cessation/reduction support at clinic visits (9 scheduled)
Outcomes	Sustained abstinence at 12m Validation: CO<10ppm
Notes	Trial also included assessment of reduction. Reduction outcomes contribute to Cochrane review on harm reduction
Allocation concealment	B – Unclear

**Study Leischow 1996**

Methods	Country: USA Recruitment: community volunteers Randomization: computer-generated code
Participants	222 smokers (>20 cpd). (2 excluded from analysis having received incorrect prescription)

**Characteristics of included studies (Continued)**

	55% F, av.age 44, av. cpd 26
Interventions	1. Nicotine Inhaler (10mg). Advised to use 4-20 cartridges/day for 3m. After this tapering was encouraged until 6m. 2. Placebo inhaler Participants received advice and watched a video showing proper use of the inhaler. Level of support: high (brief individual smoking cessation support at each study visit, 10 in all)
Outcomes	Sustained abstinence at 12m Validation: CO<10ppm at each follow up
Notes	
Allocation concealment	B – Unclear

**Study Leischow 1999**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	300 smokers prepared to purchase patch and make a quit attempt 45% F, av.age 43, av. cpd 26
Interventions	1. Nicotine patch (15mg/16hr) which could be purchased (1 wk supply for US\$15) for up to 26 wks. No behavioural support apart from patch package insert. 2. Nicotine patch for purchase as 1. Prescription for 12 wks provided after physician visit. Prescription renewed on request up to 26 wks. Behavioural support based on NCI guidelines, 5-10 mins. Study staff also allowed to give behavioural support.
Outcomes	Continuous abstinence from date of first patch purchase at 12m (non-purchasers counted as failures) (PP rates also reported) Validation: CO < 9ppm
Notes	Does not contribute to main comparison. Compared different ways of buying patch - simulating OTC, or with physician prescription and support.
Allocation concealment	B – Unclear

**Study Leischow 2004**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	520 smokers prepared to purchase inhaler and make a quit attempt 51% F, av.age 48, av. cpd 26
Interventions	1. Nicotine inhaler could be purchased ad lib. Standard package information, no further behavioural support 2. Nicotine inhaler could be purchased ad lib via healthcare provider. Support materials and brief behavioural intervention given at 1st clinic visit and wk 2, av time 8 mins, 47% discussed inhaler use
Outcomes	Continuous abstinence at 12m Validation: CO
Notes	First included as Leischow 2003 based on abstract. Does not contribute to comparison 1. See Leischow 1999
Allocation concealment	B – Unclear

**Study Lerman 2004**

Methods	Country: USA Recruitment: community volunteers and referrals
---------	---

**Characteristics of included studies (Continued)**

	Randomization: computer-generated, operated by data manager. Allocation concealment judged adequate, after allocation only outcome assessors blind
Participants	350 smokers ( $\geq 10$ cpd) (includes 51 who withdrew before treatment) 54% F, av.age 46, av. cpd 21
Interventions	1. Nicotine patch (21 mg/24hr) for 8 wks incl tapering 2. Nicotine nasal spray (8-40 doses/day, max 5/hr) for 8 wks, tapering over final 4 wks Level of support: 7x90 min behavioural group counselling sessions. TQD in wk 3.
Outcomes	PP abstinence at 6m (Continuous no slips and prolonged lapse-free unvalidated outcomes also reported) Validation: CO $<10$ ppm
Notes	First included 2004 based on Patterson 2003 paper. Minor changes to data using Lerman 2004 in 2008 update. Choice of outcome does not change conclusion of no significant difference. Does not contribute to main comparison, only head-to-head comparison
Allocation concealment	A – Adequate

**Study Lewis 1998**

Methods	Country: USA Recruitment: hospitalised patients willing to make a quit attempt Randomization: predetermined computer-generated code
Participants	185 smokers ( $\geq 10$ cpd) 46% F, av.age 43-44, cpd 23-24
Interventions	1. Minimal intervention, 2-3 mins motivational message and self-help pamphlet 2. As 1. plus placebo patch. Nurse provided brief telephone counselling at 1, 3, 6 and 24 wks 3. As 2. plus nicotine patch (22mg/ 24hrs for 3 wks, tapered to 11mg for 3 wks) Level of support: low (since initial support was brief and further contacts in 2 were by phone)
Outcomes	PP abstinence at 6m Validation: CO $\leq 10$ ppm
Notes	3 vs 1+2 used in MAs (Restricting control to 2 only would reduce the OR to 1.6)
Allocation concealment	A – Adequate

**Study Llivina 1988**

Methods	Country: Spain Recruitment: smoking cessation clinic Randomization: method not stated
Participants	216 smokers Av. cpd 28-30
Interventions	1. Nicotine gum (dose not stated) for 1m 2. Placebo gum Level of support: High (group support)
Outcomes	Sustained abstinence at 12m Validation: CO
Notes	Reclassified as high support 2008
Allocation concealment	B – Unclear

**Study Malcolm 1980**

Methods	Country: UK Recruitment: community volunteers
---------	--

**Characteristics of included studies (Continued)**

	Randomization: method not stated
Participants	194 smokers 40-43% F, av.age 44-46, av. cpd 25-26
Interventions	1. Nicotine gum (2mg) at least 10/day for at least 3m 2. Placebo gum 3. Control Level of support: high (weekly individual counselling for 1m)
Outcomes	Sustained abstinence at 6m Validation: venous carboxyhaemoglobin<=1.6%
Notes	
Allocation concealment	B – Unclear

**Study Marshall 1985**

Methods	Country: UK Setting: primary care - patients responding to a postcard from a GP (i.e. selected by motivation) Randomization: method not stated, married couples allocated to same group
Participants	200 smokers, 21% had a smoking-related disease Av. age 41, av. cpd 22
Interventions	1. Physician advice plus nicotine gum 2. As 1. and offer of 4 follow-up visits over 3m
Outcomes	Sustained abstinence at 12m (and 6m) Validation: expired CO.
Notes	Does not contribute to comparison 1. Test of different intensity of support.
Allocation concealment	B – Unclear

**Study McGovern 1992**

Methods	Country: USA Recruitment: community volunteers Randomization: by clinic group
Participants	293 adult smokers. Av. cpd not stated. 58% smoked >25 cpd.
Interventions	1. ALA Freedom from Smoking clinic program plus nicotine gum (2mg for 3m) 2. ALA Freedom from Smoking clinic program alone (no placebo gum) Level of support: high (group)
Outcomes	PP abstinence at 12m Validation: salivary thiocyanate
Notes	
Allocation concealment	C – Inadequate

**Study Molyneux 2003**

Methods	Country: UK Recruitment: hospital Randomization: in blocks of 9, concealment not described
Participants	274 smokers (182 in relevant arms) admitted to medical and surgical wards, smoked in last 28 days 60% M, av.age 60, median cpd 17, 81% had previous quit attempt
Interventions	1. Choice of NRT products (15mg 16 hr patch/ 2mg or 4mg gum, 10mg inhalator/ 2mg sublingual tablet, 0.5mg spray), Brief (20 min) bedside counselling from a research doctor or nurse.

**Characteristics of included studies (Continued)**

	2. Brief counselling only 3. Usual Care, no smoking advice (not used in MA) Level of support: low
Outcomes	Continuous abstinence at 12m Validation: CO<10ppm
Notes	No placebo. 63% chose patch, 13% inhalator, 11% gum, 8% tablets and 1% nasal spray, 4% declined use
Allocation concealment	B – Unclear

**Study Moolchan 2005**

Methods	Country: USA Recruitment: community volunteers Randomization: central pharmacy, with replacement of non-completer
Participants	120 adolescent (age 13-17) smokers (>=10 cpd) 70% F, av.age 15, av. cpd 19
Interventions	1. Nicotine patch (21mg, or 14mg for <20 cpd) for 6 wks +placebo gum 2. Nicotine gum (4mg, or 2mg for <24 cpd) for 6 wks + placebo patch 3. Double placebo Level of support: high (x11 45-min individual counselling over 12 wks)
Outcomes	PP abstinence at 6m Validation: CO & cotinine
Notes	New for 2008 update Placebo group contributes twice to MA - too small to affect total Sustained abstinence at 3&6m could be derived from text, relative effect greater since no quitters on placebo
Allocation concealment	A – Adequate

**Study Mori 1992**

Methods	Country: Japan Recruitment: hospital Randomization: method not stated
Participants	264 smokers with smoking-related illness. Number of cpd not stated.
Interventions	1. Nicotine gum 2mg for 3m 2. Placebo gum Level of support: low
Outcomes	Abstinence (not defined) at 6m Validation: serum thiocyanate
Notes	
Allocation concealment	B – Unclear

**Study Nakamura 1990**

Methods	Country: Japan Recruitment: community volunteers Randomization: by number in screening programme, and by worksite
Participants	60 adult smokers. Av. cpd 31
Interventions	1. Nicotine gum (2mg, 2m or longer) 2. Non-placebo control group received counselling



**Characteristics of included studies (Continued)**

	Level of support: high
Outcomes	Sustained abstinence at 6m Validation: CO
Notes	
Allocation concealment	B – Unclear

<b>Study</b>	<b>Nebot 1992</b>
Methods	Country: Spain Recruitment: primary care Randomization: physicians randomized to treatment, method not stated. No information about avoidance of selection bias in recruitment of smokers so rated C
Participants	425 unselected smokers. 60-70% smoking > 15 cigs/day
Interventions	1. Brief counselling from physician 2. Physician counselling plus nicotine gum 3. Health education from nurse Level of support: low
Outcomes	PP abstinence at 12m Validation: CO
Notes	
Allocation concealment	C – Inadequate

<b>Study</b>	<b>Niaura 1994</b>
Methods	Country: USA Recruitment: outpatient settings and physician referrals (primary care subgroup) Randomization: method not stated. Stratified by nicotine dependence
Participants	77 low dependence (FTND<=6) and 96 high dependence smokers 50% F, av.age 42, av. cpd 29, FTND 4.7 for low dependence, 8.0 for high dependence
Interventions	1. Nicotine gum 2mg, ad lib for up to 4m (participants given prescription for gum, not free) 2. No gum Level of support: high (4 individual counselling sessions and ALA self-help treatment manuals)
Outcomes	Continuous abstinence at 12m Validation: saliva cotinine, or CO for gum users
Notes	No placebo used. Data collapsed across dependence levels. As predicted by the study, smokers with lower dependence had lower quit rates with than without gum. The OR would be higher (4.40) if inclusion restricted to the high dependence group.
Allocation concealment	B – Unclear

<b>Study</b>	<b>Niaura 1999</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated, no placebo
Participants	62 smokers in relevant arms 50% F, av. cpd 28, av.age 43.5
Interventions	1. Brief cognitive behavioral relapse prevention (CBRP) , 15 min sessions 2. Intensive CBRP with nicotine gum (2mg) 3. Intensive CBRP with cue exposure 4. Intensive CBRP with cue exposure + nicotine gum

**Characteristics of included studies (Continued)**

	Level of support: high (5 group sessions within 3 wks of TQD)
Outcomes	Sustained abstinence, 12m and all previous follow ups (1, 3, 6m) Validation: CO<8ppm
Notes	4 vs 3, behavioural support not identical in others. No placebo.
Allocation concealment	B – Unclear

<b>Study</b>	<b>Ockene 1991</b>
Methods	Country: USA Recruitment: primary care Randomization: Each physician delivered 1 of the 3 interventions according to instructions in a packet for each patient.
Participants	1223 unselected smokers, 57% F, av.age 35, av. cpd 22-23
Interventions	1. Advice only 2. Patient-centred counselling 3. Patient-centred counselling and offer of nicotine gum (2mg) plus minimal or intensive follow up by telephone. Level of support: mixed (not used in subgroup analysis)
Outcomes	Sustained abstinence at 12m (quit at 6m & 12m, reported in Ockene 1994) Validation: none
Notes	69% of group 3 accepted prescription and received at least 1 box of gum. 12m sustained rates, 3 vs 2, used in MA since 2008.
Allocation concealment	A – Adequate

<b>Study</b>	<b>Oncken 2007</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated, 3:5 ratio
Participants	152 postmenopausal women (<=10 cpd) Av.cigs/day 22, av.age 54/56.6
Interventions	1. Nicotine patch (21mg for 13 wks incl 4 wks tapering) 2. Placebo patch Level of support: high (7 visits incl 4 x 2 hr group counselling, 1 pre-TQD)
Outcomes	PP abstinence at 16m (12m post-EOT) Validation: CO<8ppm
Notes	New for 2008 update
Allocation concealment	B – Unclear

<b>Study</b>	<b>Otero 2006</b>
Methods	Country: Brazil Recruitment: community volunteers Randomization: method not stated
Participants	1199 smokers (includes 254 non-attenders) 63%F, av.age 42, 46% smoked >20 cpd
Interventions	Factorial design with multiple levels of behavioural support 1. Nicotine patch (21mg, 14mg for FTND<5) 8 wks incl tapering + behavioural support 2. Cognitive behavioural support only

**Characteristics of included studies (Continued)**

Level of support: Mixed - Low=single 20 min session. High= 1, 2, 3 or 4 weekly 1hr sessions. Maintenance or recycling sessions provided at 3, 6, 12m.

Outcomes	PP abstinence at 12m Validation: none
Notes	New for 2008 update. Contributes to both high & low support subgroups. No placebo. 29% of control group participants asked for nicotine patch after the 3m follow up which might have increase control group quit rates at 12m
Allocation concealment	B – Unclear

**Study Page 1986**

Methods	Country: Canada Recruitment: primary care (5 family practices in Ontario) Randomization: by day of attendance
Participants	275 unselected smokers. Primary care attenders aged 18-65 yrs Number of cpd not stated
Interventions	1. No advice 2. Advice to quit 3. Advice to quit plus offer of nicotine chewing gum prescription (2mg) Level of support: low
Outcomes	Sustained abstinence at 6m Validation: none
Notes	3 vs 1+2 No placebo
Allocation concealment	C – Inadequate

**Study Paoletti 1996**

Methods	Country: Italy Recruitment: community volunteers Randomization: method not stated, parallel group design
Participants	297 smokers (>=10 cpd) Stratified according to baseline cotinine levels 40% F, av.age 43, av. cpd 24 in low cotinine group (n=120), 30 in high group (n= 177)
Interventions	Stratum A (Baseline cotinine<250ng/ml) 1. Nicotine patch (15mg/16hr, 18 wks incl taper) 2. Placebo patch Stratum B (Baseline cotinine>250ng/ml) 3. Nicotine patch 15mg 4. Nicotine patch 25mg Level of support: low
Outcomes	PP abstinence at 12m Validation: CO and plasma cotinine
Notes	Stratum A in Comparison 1 Stratum B in Comparison 8 (high versus standard dose patch)
Allocation concealment	B – Unclear

**Study Perng 1998**

Methods	Country: Taiwan
---------	-----------------

**Characteristics of included studies (Continued)**

	Recruitment: outpatient chest clinics, volunteers Randomization: performed by an independent facility
Participants	62 smokers (>20 cpd) 94% M, av.age 62, av. cpd 26
Interventions	1. Nicotine patch (24mg/24 hr for 6 wks, no weaning) 2. Placebo patch Level of support: High (weekly visit to outpatient department for assessment, unclear if counselling was provided)
Outcomes	Abstinence at 12m Validation: CO<10ppm during patch use, but no validation at 12m
Notes	Level of support reclassified as high, 2008 update
Allocation concealment	A – Adequate

**Study Piper 2007**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	608 smokers 58% F, av.age 42, av cpd 22, no details of depression history
Interventions	1. Nicotine gum (4mg, 8 wks) and bupropion (300mg, 9 wks) 2. Placebo gum and bupropion 3. Double placebo (Not used in MA) All arms: 3x 10 min counselling
Outcomes	PP abstinence at 12m Validation: CO & cotinine
Notes	New for 2008 update. Identified from conference abstracts, we use data from paper published after date of search. Contributes to comparison of NRT + bupropion versus bupropion alone
Allocation concealment	B – Unclear

**Study Pirie 1992**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	417 women smokers. Av cpd 25-27.
Interventions	1. Group therapy 2. Group therapy plus weight control programme 3. Group therapy plus nicotine gum 4. Group therapy plus weight control programme and nicotine gum. Gum type: 2mg ad lib Level of support: high
Outcomes	Sustained abstinence at 12m Validation: expired CO
Notes	3 & 4 compared to 1 & 2
Allocation concealment	B – Unclear

**Study Prapavessis 2007**

Methods	Country: New Zealand
---------	----------------------

**Characteristics of included studies (Continued)**

	Recruitment: community volunteers Randomization: computer-generated but no information on concealment
Participants	121 women smokers (>10 cpd) (excludes drop-outs not starting programme)
Interventions	NRT as adjunct to either CBT or exercise programmes, collapsed for this review 1. Nicotine patch (21mg/24hr for 10 wks, no weaning) 2. No patch Level of support: High (36 45 min session over 12 wks of group CBT or supervised vigorous exercise, starting 6 wks before TQD)
Outcomes	Continuous abstinence since TQD at 12m from end of programme Validation: CO<10ppm, cotinine <10 ng/mL
Notes	New for 2008 update No placebo
Allocation concealment	B – Unclear

**Study Puska 1979**

Methods	Country: Finland Recruitment: community volunteers Randomization: method not stated
Participants	229 adult smokers, 80% smoking>5 cpd
Interventions	1. Nicotine gum (4mg) for 3 wks 2. Placebo gum for 3 wks Level of support: high (group therapy)
Outcomes	PP abstinence at 6m. Validation: none
Notes	
Allocation concealment	B – Unclear

**Study Puska 1995**

Methods	Country: Finland Recruitment: community volunteers Randomization: method not stated
Participants	300 volunteers aged 20-65, smoking >10 cpd for >3 yrs, no serious illness
Interventions	1. Nicotine patch (15mg/16hrs, 12 wks+ 6 wks taper) plus nicotine gum (2mg at least 4 daily) 2. Placebo patch plus nicotine gum (same regimen) Level of support: low (advice from study nurses)
Outcomes	Sustained abstinence at 12m Validation: expired CO<10ppm
Notes	Does not contribute to main comparison & subgroups, only combinations
Allocation concealment	B – Unclear

**Study Richmond 1993**

Methods	Country: Australia Recruitment: primary care Randomization: by week of attendance
Participants	450 adult smokers (350 in included arms). Av. cpd 15-21.
Interventions	1. Smokescreen programme plus nicotine gum, dose and duration not stated

**Characteristics of included studies (Continued)**

	2. Smokescreen programme alone 3. Brief advice & gum (Not included in MA) Level of support: high (5 visits during first 3m)
Outcomes	Continuous abstinence (from wk 1) at 12m Validation: expired CO<14ppm
Notes	No placebo Continuous abstinence rates from Richmond 1993 paper used from 2007. Group 3 not included.
Allocation concealment	C – Inadequate

<b>Study</b>	<b>Richmond 1994</b>
Methods	Country: Australia Recruitment: community volunteers Randomization: central pharmacy generation
Participants	315 smokers, av. cpd 29.
Interventions	1. Nicotine patch (24 hr, 22mg/24 hr, 10 wks incl tapering) 2. Placebo patch Level of support: high (group therapy)
Outcomes	Sustained abstinence at 12m (reported in Richmond 1997, which also reports 3 yr follow up, not used in MA) Validation: expired CO
Notes	3 yr abstinence 21/153 vs 8/152, OR 2.9 - higher than at 12m
Allocation concealment	A – Adequate

<b>Study</b>	<b>Rose 1994</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	48 smokers (>=20 cpd) 60% F, av.age 34, av. cpd 27-29
Interventions	2x2 factorial trial. Mecamylamine arms collapsed. 1. Nicotine patch (21mg/24 hr for 2 wks before TQD) 2. Placebo After TQD both groups received active patch for 6 wks, counselling at clinic visits & self-help materials
Outcomes	Sustained abstinence at 12m Validation: CO<=8ppm
Notes	Contributes only to pre-cessation comparison.
Allocation concealment	D – Not used

<b>Study</b>	<b>Rose 1998</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	80 smokers (>=20 cpd) 49% F, av.age 41, av. cpd 30
Interventions	2x2 factorial trial. Mecamylamine pretreatment arms collapsed. 1. Nicotine patch (21mg/24 hr for 4 wks before TQD)

**Characteristics of included studies (Continued)**

	2. Placebo After TQD both groups received active patch & mecamylamine for 6 wks, counselling at clinic visits & self-help materials
Outcomes	Sustained abstinence at 6m Validation: CO $\leq$ 8ppm
Notes	Contributes only to pre-cessation comparison.
Allocation concealment	D – Not used

<b>Study</b>	<b>Rose 2006</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	96 smokers ( $\geq$ 20 cpd) 53% F, av. age 45, av. cpd 29
Interventions	2x3x3 factorial trial - only pre-cessation patch condition contributes to MA, other conditions collapsed. 1. Nicotine patch (21mg/24 hr for 2 wks before TQD) 2. Placebo All participants received mecamylamine 2.5mg bid for 4 wks post-TQD, and either 0, 21 or 42mg patch.
Outcomes	PP abstinence at 6m Validation: CO $\leq$ 8ppm
Notes	Contributes only to pre-cessation comparison. Post-quit conditions did not affect cessation, data not reported in paper
Allocation concealment	B – Unclear

<b>Study</b>	<b>Roto 1987</b>
Methods	Country: Finland Recruitment: primary care (occupational health centres) Randomization: method not stated
Participants	121 smokers ( $>$ 10 cpd, $>$ 1 yr) 43% F
Interventions	1. Nicotine gum (2mg and 4mg), + advice 2. Advice only (no placebo) Level of support: low
Outcomes	Abstinence at 6m (not defined) Validation: not described
Notes	
Allocation concealment	B – Unclear

<b>Study</b>	<b>Russell 1983</b>
Methods	Country: UK Recruitment: primary care - consecutive attenders admitting to being cigarette smokers and consenting to participate at 6 general practices Randomization: according to week of attendance
Participants	2106 adult smokers. Av. cpd 17.5
Interventions	1. No intervention 2. Advised to stop smoking plus provided with a “give up smoking” booklet

**Characteristics of included studies (Continued)**

3. As group 2, plus offer of nicotine gum prescription, Individual therapy, Single visit, 1 minimal content, 1 more intensive content, untrained therapist  
Level of support: low

Outcomes	Sustained abstinence at 4 and 12m Validation: 66% of those claiming to have quit validated with CO
Notes	3 vs 2+1 used in comparison. Using only 2 as control has negligible effect on OR Only 53% of group 3 tried the gum Use of quit rates adjusted for estimated validation failure and protocol violation would increase relative effect of gum.
Allocation concealment	C – Inadequate

**Study                      Sachs 1993**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	220 adult smokers. Av. cpd 28-9.
Interventions	1. Nicotine patch (15mg/16hr, 12 wks + 6 wks tapering) 2. Placebo patch Level of support: high (physician advice, 8 visits during treatment period)
Outcomes	Sustained abstinence at 12m Validation: CO
Notes	
Allocation concealment	B – Unclear

**Study                      Schneider 1985A**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	60 heavy smokers (>1 pack/day) 60%F, av.age 40/37, av. cpd 35/31
Interventions	Study A (clinic support): 1. Nicotine gum, (2mg duration not stated) 2. Placebo gum Level of support: high (individual support at multiple clinic assessment visits, daily during week 1, weekly to wk 5)
Outcomes	Sustained abstinence at 12m Validation: CO
Notes	Reported in same papers as Schneider 1985B. Shared study ID until 2008. Schneider 1983 provides demographic data so now used as primary reference. Jarvik & Schneider 1984 reports outcomes by dependency score for 48/60 participants.
Allocation concealment	B – Unclear

**Study                      Schneider 1985B**

Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	36 heavy smokers (>1 pack/day)



**Characteristics of included studies (Continued)**

	no demographic details
Interventions	Study B (pilot dispensary study): 1. Nicotine gum, (2mg duration not stated) 2. Placebo gum Level of support: low (weekly laboratory visits for 5 wks but no support provided)
Outcomes	Sustained abstinence at 12m Validation: CO
Notes	Reported in same papers as Schneider 1985A. Shared study ID until 2008.
Allocation concealment	B – Unclear

**Study Schneider 1995**

Methods	Country: USA Recruitment: community volunteers (radio and newspaper ads) Randomization: method not stated
Participants	255 adults with no serious illness, smoking >15 cpd for >2 yrs with baseline CO level >20ppm. Av. cpd 28-29.
Interventions	1. Nicotine nasal spray 2. Placebo spray Nicotine dosage: 0.5mg of nicotine per spray. Not less than 8 doses/day and not more than 32 doses/day for 6 wks, with free use for further 6m Level of support: high (repeated clinic visits for assessment)
Outcomes	Sustained abstinence at 12m Validation: CO<8 ppm
Notes	
Allocation concealment	B – Unclear

**Study Schneider 1996**

Methods	Country: USA Recruitment: community volunteers Randomization: centralized computer-generated by a 3rd party
Participants	223 adult smokers (>=10 cpd) 37% F, av.age 44, av. cpd 29/26 (significantly higher in active group)
Interventions	1. Nicotine inhaler (4-20 inhalers per day) for up to 6m, with weaning from 3m 2. Placebo inhaler Level of support: high (repeated clinic visits for assessment)
Outcomes	Sustained abstinence at 12m Validation: CO and salivary cotinine
Notes	
Allocation concealment	A – Adequate

**Study Schuurmans 2004**

Methods	Country: South Africa Recruitment: community volunteers Randomization: computer-generated, independent, blinding maintained
Participants	200 smokers 44% F, av.age 43, av. cpd 23/26

**Characteristics of included studies (Continued)**

Interventions	1. Pretreatment with nicotine patch for 2 wks prior to quit date. Then active patch (15mg) patch for 12 wks including weaning. 4 sessions of counselling over 10 wks. 2. Pretreatment with placebo patch. The active patch as 1.
Outcomes	Sustained abstinence at 6m Validation: CO<10ppm at each visit
Notes	Does not contribute to main comparison
Allocation concealment	A – Adequate

**Study Segnan 1991**

Methods	Country: Italy Recruitment: primary care - consecutive patients attending 44 general practices Randomization: sequential, sealed envelopes
Participants	923 practice attenders aged 20-60. Av. cpd not stated. Therapists: GPs who had undergone a 3 hr training session
Interventions	1. Advice and leaflet 2. Repeated counselling (followup at 1, 3, 6, 9m) 3. Repeated counselling plus prescription for nicotine gum unless contraindicated, dose not stated, up to 3m 4. Repeated counselling plus spirometry Level of support: high
Outcomes	Sustained abstinence at 12m Validation: urinary cotinine
Notes	3 vs 1+2+4
Allocation concealment	A – Adequate

**Study Shiffman 2002 (2mg)**

Methods	Country: USA & UK (15 sites) Recruitment: community volunteers Randomization: method not stated
Participants	917 smokers, time to first cigarette >30 mins. 58% F, Av age 41, cpd 17
Interventions	1. Nicotine lozenge, 2mg. Recommended dose 1 every 1-2 hrs, min 9, max 20/day for 6 wks, decreasing 7-12 wks, available as needed 13-24 wks 2. Placebo lozenge, same schedule Level of support: high (brief advice at 4 visits in 4 wks from enrolment)
Outcomes	Continuous abstinence at 12m (Sustained from 2 wks, no slips allowed). Validation: CO<=10ppm at all follow ups. (only abstainers continued in study)
Notes	Dose based on dependence level. Low dependence group here. High dependence group in Shiffman 2002 (4mg)
Allocation concealment	B – Unclear

**Study Shiffman 2002 (4mg)**

Methods	Country: USA & UK (15 sites) Recruitment: community volunteers Randomization: method not stated
Participants	901 smokers, time to first cigarette <30 mins 55% F, Av age 44, cpd 26

### Characteristics of included studies (Continued)

Interventions	1. Nicotine lozenge, 4mg. Recommended dose 1 every 1-2 hrs, min 9, max 20/day for 6 wks, decreasing 7-12 wks, available as needed 13-24 wks. 2. Placebo lozenge, same schedule
Outcomes	Continuous abstinence at 12m. (Sustained from 2 wks, no slips allowed). Validation: CO $\leq$ 10ppm at all follow ups. (only abstainers continued in study)
Notes	Dose based on dependence level. High dependence group here. Low dependence group in Shiffman 2002 (2mg)
Allocation concealment	B – Unclear

#### Study **Sonderskov 1997**

Methods	Country: Denmark Recruitment: customers seeking to buy nicotine patches over the counter at 42 pharmacies Randomization: sequential treatment packages, stratified by smoking level
Participants	522 smokers of >10 cpd. Smokers of >20 cpd used a higher dose patch than lower rate smokers. 50% F, av.age 39
Interventions	1. Nicotine patch (24 hr). >20/day smokers used 21mg for 4 wks, 14mg for 4 wks, 7mg for 4 wks. Smokers of <20/day used 14mg for first 8 wks, 7mg for 4 wks 2. Placebo patches Level of support: Low (brief instructions on patch use at baseline, visit to collect further patches at 4 & 8 wks, no behavioural support)
Outcomes	Abstinence at 6m - no reported smoking in the last 4 wks, by telephone interview with neutral independent assessor Validation: none
Notes	
Allocation concealment	A – Adequate

#### Study **Stapleton 1995**

Methods	Country: UK Setting: primary care Randomization: computer-generated list
Participants	1200 smokers considered by GP to be highly dependent and motivated to give up. Av. cpd 23-4
Interventions	1. Nicotine patch standard dose (15mg/16 hr for 18 wks) 2. Nicotine patch with dose increase to 25mg at 1 wk if required 3. Placebo patch group The nicotine patch groups were further randomized to gradual tapering or abrupt withdrawal at wk 12. Level of support: High (physician advice & brief support at 1, 3, 6, 12 wks)
Outcomes	Sustained abstinence at 12m Validation: CO
Notes	The dose increase after 1 wk did not affect cessation, 1+2 vs 3 in comparison 1.
Allocation concealment	A – Adequate

#### Study **Sutherland 1992**

Methods	Country: UK Recruitment: smoking cessation clinic Randomization: drew card with A or P for active or placebo allocation
Participants	227 smokers. Av. cpd 25-27

**Characteristics of included studies (Continued)**

Interventions	1. Nicotine nasal spray, maximum 40 mg/day 2. Placebo spray Level of support: High (4 wks group support)
Outcomes	Sustained abstinence at 12m Validation: CO
Notes	Follow up beyond 1 yr reported in Stapleton 1998 Abstinence for 3 yrs 19/116 vs 7/111, OR 2.9
Allocation concealment	B – Unclear

**Study TNSG 1991**

Methods	Country: USA (9 sites) Recruitment: community volunteers (treated at smoking cessation clinics) Randomization: method not stated
Participants	808 smokers 60% F, av.age 43, av. cpd 31
Interventions	1. Nicotine patch (21mg /24 hr, 6 wks+) 2. Nicotine patch 14mg 3. Placebo patch Abstainers at end of wk 6 entered a randomized blinded trial of weaning. Level of support: high (group therapy, 6+ sessions)
Outcomes	Sustained abstinence at 6m Validation: CO
Notes	2 trials pooled and data relating to a 7mg patch group used in only 1 trial omitted. Long-term (4-5 yr) follow-up data reported for 7/9 sites (Daughton 1999). Data not used in MA -OR would be higher
Allocation concealment	B – Unclear

**Study Tonnesen 1988**

Methods	Country: Denmark Recruitment: primary care Randomization: by numbered envelope
Participants	113 low to medium dependence smokers (19 or less on Horn-Russell scale) 56% F, av.age 45, av. cpd 20 60 highly dependent smokers 58% F, av.age 45, av. cpd 26-28
Interventions	Group A: Low/medium dependence 1. Nicotine Gum (2mg) for 16 wks 2. Placebo Group B: High dependence 1. Nicotine gum 4mg for 6 wks then 2mg 2. Nicotine gum 2mg Level of support: high (informal group support, 6 sessions)
Outcomes	Sustained abstinence at 12m (24m also reported) Validation: expired CO
Notes	Group A in comparison 1, Group B in comparison 2, Abstinence at 24m 17/60 vs 5/53, OR 3.8, relative effect greater than at 12m
Allocation concealment	A – Adequate

**Characteristics of included studies (Continued)**

<b>Study</b>	<b>Tonnesen 1991</b>
Methods	Country: Denmark Recruitment: community volunteers Randomization: packages labelled with consecutive numbers from computer-generated random code
Participants	289 smokers ( $\geq 10$ cpd) 70% F, av.age 45, av. cpd 22
Interventions	1. Nicotine patch (15mg/16 hr for 12 wks with tapering) 2. Placebo patch Level of support: High (7 clinic visits including a few minutes of advice)
Outcomes	Sustained abstinence at 12m (also reported 24m in Tonnesen 1992, 3 yrs in Mikkelsen 1994) Validation: expired CO
Notes	Classification of support corrected to high in 2008 update. 2 yr abstinence 17/145 vs 6/144, OR 4.6. 3 yr abstinence 15/145 vs 4/144, OR 4.0
Allocation concealment	A – Adequate

<b>Study</b>	<b>Tonnesen 1993</b>
Methods	Country: Denmark Recruitment: community volunteers Randomization: computer-generated randomization code
Participants	286 smokers ( $\geq 10$ cpd) 60% F, av.age 39, av. cpd 20
Interventions	1. Nicotine inhaler (2-10/day) up to 6m 2. Placebo inhaler Level of support: High (brief advice at 8 clinic visits, 0, 1, 2, 3, 6, 12, 24, 52 wks)
Outcomes	Sustained abstinence at 12m (from wk 2, paper also reports with slips outcome) Validation: expired CO
Notes	
Allocation concealment	A – Adequate

<b>Study</b>	<b>Tonnesen 2000</b>
Methods	Country: Denmark Recruitment: referrals to lung clinic Randomization: computer-generated list of random numbers, unclear whether allocation concealed (open label)
Participants	446 smokers ( $\geq 10$ cpd) 52% F, av.age 49, av. cpd 18
Interventions	1. 5mg nicotine patch (placebo) 2. 15mg (16 hr) nicotine patch for 12 wks (up to 9m on request) 3. Nicotine inhaler (4-12/day ad lib) 4. Combination, 15mg patch and inhaler Level of support: High (Physician advice at baseline, brief (15min) nurse counselling at 2, 6 wks, 3, 6, 9, 12m)
Outcomes	Sustained abstinence at 12m, (from wk 2, paper also reports PP and with slips rates) Validation: CO $<$ 10ppm at all visits
Notes	In main comparison for patch vs placebo but not inhaler. Also 1 & 2 vs 4 in combination, and 3 vs 2 in head to head comparisons.

## Characteristics of included studies (Continued)

Allocation concealment B – Unclear

Study	Tonnesen 2006
Methods	Country: Denmark Recruitment: lung clinic patients & newspaper adverts Randomization: blocked list, no information on concealment
Participants	370 smokers (at least 1 cpd) with COPD (Mean FEV1 was 56% of predicted) 52% F, av.age 61, av. cpd 20 (8% <7/day), 71% had previously tried NRT
Interventions	2x2 factorial trial of lozenge and behavioural support. 1. Nicotine sublingual tablet (2mg), recommended dose depended on baseline cpd, from min 3 to max 40 per day 2. Placebo Level of support: high -Either 4 clinic visits (0, 2 wks, 6, 12m) & 6 phone calls, total time 2.5hrs, or 7 visits (0, 2, 4, 8, 12 wks) & 5 calls, total 4.5h.
Outcomes	Sustained abstinence at 12 months (from 2 wks) Validation: CO<10ppm at all visits
Notes	New for 2008 update Behavioural support arms collapsed. Both involved multiple clinic visits
Allocation concealment	B – Unclear

Study	Villa 1999
Methods	Country: Spain Recruitment: volunteers working in a university health and safety department Randomization: method not described, randomized by group
Participants	47 smokers (excludes 5 who did not attend at least 2 sessions) 72% F, av.age 36, cpd 24-26
Interventions	1. Nicotine gum (2mg) 2. No gum Level of support: High (8 weekly group sessions, 5 before TQD. Reduction prior to quitting)
Outcomes	Abstinence at 12m (not defined) Validation: none
Notes	No placebo
Allocation concealment	B – Unclear

Study	Wallstrom 2000
Methods	Country: Sweden Recruitment: community volunteers Randomization: computer assignment
Participants	247 smokers (>= 10 cpd) 59% F, av.age 45, av. cpd 18-20
Interventions	1. Nicotine sublingual tablet. Recommended dosage 1 tab/hr for smokers with FTND < 7, 2 tabs/hr for scores >= 7. After 3m treatment, tapering period of 3m if necessary 2. Placebo tablet Level of support: High (brief 5 mins counselling at study visits (0, 1, 2, 3, 6 wks, 3, 6m)
Outcomes	Sustained abstinence at 12m (from wk 2, paper also reports with slips rates) Validation: CO<10ppm
Notes	

## Characteristics of included studies (Continued)

Allocation concealment A – Adequate

---

<b>Study</b>	<b>Westman 1993</b>
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	158 smokers (excludes 1 participant who used nicotine gum throughout) 57% F, av.age 41, av. cpd 30
Interventions	1. Nicotine patch (25mg/24 hr, 6 wks incl weaning) 2. Placebo patches Level of support: High (Brief counsellor support at 3 clinic visits, 4 telephone counselling sessions, self-help materials)
Outcomes	Sustained abstinence at 6m (from 2 wks post-TQD) Validation: CO<8ppm
Notes	
Allocation concealment	B – Unclear

---

<b>Study</b>	<b>Wisborg 2000</b>
Methods	Country: Denmark Recruitment: volunteers, antenatal clinic Randomization: centrally held list
Participants	250 pregnant women who continued to smoke after 1st trimester Av.age 28, av. cpd 14; 43% primiparous
Interventions	1. Nicotine patch (15mg/16 hr, tapering to 10mg, 11 wks total) 2. Placebo patch Level of support: high. 4x 15-20 min sessions of midwife counselling at 0, 4, 11 wks from enrolment, and 4 wks before expected delivery
Outcomes	Abstinence at 1 yr post partum (telephone interview). (Rates at 3m post partum and 4 wks prior to delivery also reported) Validation: Cotinine<26ng/ml at 4 wks pre-delivery visit only
Notes	First long-term study of nicotine patch in pregnancy. Compliance with patch use was low. Only 17% of active and 8% of placebo used all patches.
Allocation concealment	A – Adequate

---

<b>Study</b>	<b>Wong 1999</b>
Methods	Country: USA Recruitment: community volunteers Randomization: computer-generated schedules, stratified by gender
Participants	100 smokers (>10 cpd for > 1 yr) 53% F, av.age 42, av. cpd 28
Interventions	Factorial study of nicotine patch and naltrexone, no placebo patch Nicotine patch: 21mg (24 hr) for 8 wks, tapering to 14mg for 4 wks Naltrexone: 50mg/day for 12 wks Level of support: High (individual counselling, 15-20 mins at 8 study visits)
Outcomes	Continuous abstinence at 6m Validation: CO<=8ppm

---

Notes	One site from a multicentre trial. No significant main effects of naltrexone, so arms collapsed.
Allocation concealment	A – Adequate

Study	Zelman 1992
Methods	Country: USA Recruitment: community volunteers Randomization: method not stated
Participants	116 smokers (excludes 10 early treatment drop-outs evenly distributed across conditions) 54% F, av. age 29-35, av. cpd 25-27
Interventions	1. Rapid smoking + support counselling 2. Rapid smoking + skills training 3. Nicotine gum 2mg, average 10 pieces/day, duration not stated + skills training 4. Nicotine gum + support counselling. Level of support: high (6 x 60-75 min group sessions over 2 wks, starting on quit day)
Outcomes	Sustained abstinence at 12m (not more than 2 consecutive days of smoking) Validation: Independent observer report
Notes	No placebo. Group support variants collapsed; 3 & 4 compared to 1 & 2
Allocation concealment	B – Unclear

ALA=American Lung Association; CBT=cognitive behavioural therapy; CO=carbon monoxide in exhaled air; cpd=cigarettes per day; COPD=chronic obstructive pulmonary disease; EOT=end of treatment; FTND=Fagerstrom Test for Nicotine Dependence; hr=hour; ITT=intention to treat; m=month(s); MA=meta-analysis; OTC=over the counter; PP=point prevalence; TQD=target quit date; wk=week

### Characteristics of excluded studies

Study	Reason for exclusion
Allen 2005	Short-term study of effect of nicotine patch on weight change during early abstinence
Aubin 2006	Short-term study of the effect of different types of nicotine patch on sleep and smoking urges
Batra 2005	Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, Stead 2007
Bolliger 2000	Trial of nicotine inhaler for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, Stead 2007
Bolliger 2007	Pilot study, not powered to detect efficacy differences between gum, inhaler and mouth spray
Brantmark 1973	Double-blind gum/placebo only for 1st week of clinic, then both groups offered active gum during 6m follow-up period
Carpenter 2003	Compared 2 methods of reducing smoking. Control group also offered NRT if a quit attempt planned.
Chou 2004	Only 3m follow up
Christen 1984	Only 15 wk follow up
Cohen 1989a	Primarily a trial of training dentists. Included in Cochrane review of training of health professionals (Lancaster 1996)
Cohen 1989b	Primarily a trial of training doctors. Included in Cochrane review of training of health professionals (Lancaster 1996)
Croghan 2007	Provides a short-term comparison between nicotine patch, bupropion, and combination therapy. Initial failures randomized to retreatment so no long-term control group.
Dey 1999	Compared free and paid prescription for nicotine patch. Only 14 wk follow up
Elan Pharm 88-02	No long-term follow up. Long-term follow up for 1 site included as Hurt 1990



Elan Pharm 90-03	No long-term follow up. Long-term follow up for 1 site included as Fiore 1994 (Study 1)
Etter 2004	Trial of a choice of NRT products for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, Stead 2007
Fagerstrom 1993	Endpoint withdrawal symptoms not cessation
Fagerstrom 1997	Short-term crossover trial of different types of NRT. For 2 wks smokers could choose a method, for other 2 they were randomly assigned to one of gum, patch, spray, inhaler or tablet. Smoking reduction assessed.
Fagerstrom 2000	Short-term crossover trial comparing 2 nicotine delivery devices
Finland unpublished	Only 3m follow up. Comparison of patch & nasal spray (n=51) versus nasal spray alone (n=50). Sustained abstinence rates 18% in each group. Used in a sensitivity analysis of combination therapies.
Foulds 1993	Follow up less than 6m
Glover 1992	Follow up less than 6m
Hajek 1999	Follow up less than 6m. There were no significant differences in 12 wk abstinence rates between gum, patch, spray or inhaler groups.
Hanson 2003	Follow up only 10 wks; primary outcomes were withdrawal, craving, safety and compliance among adolescents
Haustein 2003	Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, Stead 2007
Hotham 2006	RCT of nicotine patch as adjunct to counselling for pregnant smokers. Only 20 people in each condition, with high withdrawal and low compliance. Results favoured patch condition at delivery (3 versus 0).
Hughes 1989b	No long-term follow up, primarily a trial of the effect of instructions.
Hurt 1995	Analysis of prior nicotine patch studies (to determine if recovering alcoholic smokers were more nicotine-dependent than non-alcoholics and whether the efficacy of nicotine patch therapy was comparable)
Hurt 2003	All participants received nicotine patch
Jarvik 1984	Reports subgroup analysis by level of nicotine dependence. See Schneider 1985A for main outcomes.
Kapur 2001	Only 12 wks follow up. Trial of nicotine patch in pregnant smokers. 30 participants.
Korberly 1999	Insufficient data in unpublished abstracts to include.
Kozak 1995	Open label study in which smokers with higher nicotine dependence scores were given higher patch doses
Krumpe 1989	Only 10 wks follow up
Kupecz 1996	Participants were randomized by month of treatment to group therapy with nicotine patch (n=21) or gum (n=17).
Landfeldt 1998	Only 12 wks follow up reported in abstract. No evidence of benefit from combining patch and nasal spray compared to nasal spray alone
Leischow 1996b	Only 10 wks follow up
Levin 1994	Only 9 wks follow up
Lin 1996	Only 8 wks follow up
Marsh 2005	Only 3m follow up, safety study comparing 4mg lozenge to 4mg gum
McCarthy 2006	Only 3m follow up, study of withdrawal symptoms
Meier 1990	Short-term follow up. Compared dependence individualized to standard dose patch.
Merz 1993	Only 3m follow up
Millie 1989	Only 2m follow up
Minneker 1989	Only 9 wks follow up
Molander 2000	Crossover study with 2 day smoke-free periods
Mooney 2005	All participants used nicotine gum
Mulligan 1990	Only 6 wks follow up

### Characteristics of excluded studies (Continued)

Okuyemi 2007	Intervention combined nicotine gum and multiple sessions of motivational interviewing
Pomerleau 2003	Compared extended treatment (18 wks) to 10 wk treatment with nicotine patch. No follow up beyond 18 wks
Rennard 2006	Trial of nicotine inhaler for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, Stead 2007
Roddy 2006	Only 13 wks follow up. At this point there were no quitters in either the treatment or control group. There were particularly high losses to follow up (64% overall) and low compliance (median duration of patch use 1 wk).
Rose 1990	Only 3 wks follow up
Sachs 1995	Only 6 wks follow up
Shiffman 2000a	Compared 10 and 6 wks of patch treatment without longer follow up. Main outcome was craving and withdrawal.
Shiffman 2000b	Comparison between 24 and 16 hr patches. Assessment of craving and abstinence over 2 wks.
Shiffman 2002a	Only 10 wks follow up
Shiffman 2002b	Not a randomized trial. Compared prescription and OTC patch in different populations using different methods.
Shiffman 2006	Only 6 wks follow up. High dose (35mg) patch.
Sutherland 1999	Only 3m follow up. Comparison of patch & nasal spray (n=104) versus patch alone (n=138) or nasal spray alone (n=138). Sustained abstinence rates after 12 wks of treatment 41%, 39%, 40%. Used in a sensitivity analysis of combination therapies.
Sutherland 2005	Only 12 wks follow up
Sutton 1987	Control group received no treatment so effect of nicotine gum is confounded with the brief counselling
Sutton 1988	Control group received no treatment so effect of nicotine gum is confounded with the behavioural support
Thorsteinsson 2001	No long-term follow up reported
Tzivoni 1998	Follow up less than 6m
Uyar 2005	Unpublished, insufficient detail in abstract on nicotine patch dose, length of treatment, level of support.
Velicer 2006	Participants were sent nicotine patches if they were assessed as potentially ready to quit. They did not have to set a quit date.
Vial 2002	Treatment groups differed from control in amount of counselling as well as use of NRT
Warner 2005	Goal of intervention was relief of stress and withdrawal postoperatively
Wennike 2003	Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane review of harm reduction interventions, Stead 2007
Wiseman 2005	2-week crossover study
Working Group 1994	Follow up less than 6m

OTC=over the counter

### Characteristics of ongoing studies

<b>Study</b>	<b>Coleman 2007</b>
Trial name or title	Smoking, Nicotine and Pregnancy (SNAP)
Participants	1050 pregnant women
Interventions	Nicotine or placebo transdermal patches with behavioural support
Outcomes	Smoking status 6m after childbirth
Starting date	2007

## Characteristics of ongoing studies (Continued)

Contact information tim.coleman@nottingham.ac.uk

Notes

### ADDITIONAL TABLES

**Table 01. Nicotine replacement therapies**

Type	Available doses
Nicotine transdermal patches	5 mg, 10 mg, 15 mg doses worn over 16 hours 7 mg, 14 mg, 21 mg doses worn over 24 hours
Nicotine chewing gum	2 mg and 4 mg doses
Nicotine sublingual tablet	2 mg dose
Nicotine lozenge	1 mg, 2 mg and 4 mg doses
Nicotine inhalation cartridge plus mouthpiece	Cartridge containing 10mg
Nicotine metered nasal spray	0.5mg dose/spray

**Table 02. Glossary of terms**

Term	Definition
Abstinence	A period of being quit, i.e. stopping the use of cigarettes or other tobacco products, May be defined in various ways; see also: point prevalence abstinence; prolonged abstinence; continuous/sustained abstinence
Biochemical verification	Also called 'biochemical validation' or 'biochemical confirmation': A procedure for checking a tobacco user's report that he or she has not smoked or used tobacco. It can be measured by testing levels of nicotine or cotinine or other chemicals in blood, urine, or saliva, or by measuring levels of carbon monoxide in exhaled breath or in blood.
Bupropion	A pharmaceutical drug originally developed as an antidepressant, but now also licensed for smoking cessation; trade names Zyban, Wellbutrin (when prescribed as an antidepressant)
Carbon monoxide (CO)	A colourless, odourless highly poisonous gas found in tobacco smoke and in the lungs of people who have recently smoked, or (in smaller amounts) in people who have been exposed to tobacco smoke. May be used for biochemical verification of abstinence.
Cessation	Also called 'quitting' The goal of treatment to help people achieve abstinence from smoking or other tobacco use, also used to describe the process of changing the behaviour
Continuous abstinence	Also called 'sustained abstinence' A measure of cessation often used in clinical trials involving avoidance of all tobacco use since the quit day until the time the assessment is made. The definition occasionally allows for lapses. This is the most rigorous measure of abstinence
'Cold Turkey'	Quitting abruptly, and/or quitting without behavioural or pharmaceutical support.
Craving	A very intense urge or desire [to smoke]. See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in smoking cessation trials'

**Table 02. Glossary of terms** (Continued)

<b>Term</b>	<b>Definition</b>
	Nicotine & Tobacco Research 2004; 6(4): 599-614
Dopamine	A neurotransmitter in the brain which regulates mood, attention, pleasure, reward, motivation and movement
Efficacy	Also called 'treatment effect' or 'effect size': The difference in outcome between the experimental and control groups
Harm reduction	Strategies to reduce harm caused by continued tobacco/nicotine use, such as reducing the number of cigarettes smoked, or switching to different brands or products, e.g. potentially reduced exposure products (PREPs), smokeless tobacco.
Lapse/slip	Terms sometimes used for a return to tobacco use after a period of abstinence. A lapse or slip might be defined as a puff or two on a cigarette. This may proceed to relapse, or abstinence may be regained. Some definitions of continuous, sustained or prolonged abstinence require complete abstinence, but some allow for a limited number or duration of slips. People who lapse are very likely to relapse, but some treatments may have their effect by helping people recover from a lapse.
nAChR	[neural nicotinic acetylcholine receptors]: Areas in the brain which are thought to respond to nicotine, forming the basis of nicotine addiction by stimulating the overflow of dopamine
Nicotine	An alkaloid derived from tobacco, responsible for the psychoactive and addictive effects of smoking.
Nicotine Replacement Therapy (NRT)	A smoking cessation treatment in which nicotine from tobacco is replaced for a limited period by pharmaceutical nicotine. This reduces the craving and withdrawal experienced during the initial period of abstinence while users are learning to be tobacco-free The nicotine dose can be taken through the skin, using patches, by inhaling a spray, or by mouth using gum or lozenges.
Outcome	Often used to describe the result being measured in trials that is of relevance to the review. For example smoking cessation is the outcome used in reviews of ways to help smokers quit. The exact outcome in terms of the definition of abstinence and the length of time that has elapsed since the quit attempt was made may vary from trial to trial.
Pharmacotherapy	A treatment using pharmaceutical drugs, e.g. NRT, bupropion
Point prevalence abstinence (PPA)	A measure of cessation based on behaviour at a particular point in time, or during a relatively brief specified period, e.g. 24 hours, 7 days. It may include a mixture of recent and long-term quitters. cf. prolonged abstinence, continuous abstinence
Prolonged abstinence	A measure of cessation which typically allows a 'grace period' following the quit date (usually of about two weeks), to allow for slips/lapses during the first few days when the effect of treatment may still be emerging. See: Hughes et al 'Measures of abstinence in clinical trials: issues and recommendations'; Nicotine & Tobacco Research, 2003; 5 (1); 13-25
Relapse	A return to regular smoking after a period of abstinence
Secondhand smoke	Also called passive smoking or environmental tobacco smoke [ETS] A mixture of smoke exhaled by smokers and smoke released from smouldering cigarettes, cigars, pipes, bidis, etc. The smoke mixture contains gases and particulates, including nicotine, carcinogens and toxins.
Self-efficacy	The belief that one will be able to change one's behaviour, e.g. to quit smoking

**Table 02. Glossary of terms** (Continued)

<b>Term</b>	<b>Definition</b>
SPC [Summary of Product Characteristics]	Advice from the manufacturers of a drug, agreed with the relevant licensing authority, to enable health professionals to prescribe and use the treatment safely and effectively.
Tapering	A gradual decrease in dose at the end of treatment, as an alternative to abruptly stopping treatment
Tar	The toxic chemicals found in cigarettes. In solid form, it is the brown, tacky residue visible in a cigarette filter and deposited in the lungs of smokers.
Titration	A technique of dosing at low levels at the beginning of treatment, and gradually increasing to full dose over a few days, to allow the body to get used to the drug. It is designed to limit side effects.
Withdrawal	A variety of behavioural, affective, cognitive and physiological symptoms, usually transient, which occur after use of an addictive drug is reduced or stopped. See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in smoking cessation trials' Nicotine & Tobacco Research 2004; 6(4): 599-614

## ANALYSES

### Comparison 01. Any type of NRT versus placebo/ no NRT control

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Smoking cessation at 6+ months follow up	111	43040	Relative Risk (Fixed) 95% CI	1.58 [1.50, 1.66]

### Comparison 02. Subgroup: Definition of abstinence

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Nicotine gum. Smoking cessation	53	19090	Relative Risk (Fixed) 95% CI	1.43 [1.33, 1.53]
02 Nicotine patch: Smoking cessation	41	18237	Relative Risk (Fixed) 95% CI	1.66 [1.53, 1.81]

### Comparison 03. Subgroup: Level of behavioural support

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Nicotine gum. Smoking cessation	52	18268	Relative Risk (Fixed) 95% CI	1.43 [1.34, 1.54]
02 Nicotine patch. Smoking cessation	42	18236	Relative Risk (Fixed) 95% CI	1.67 [1.53, 1.81]
03 Long versus short support	3	800	Relative Risk (Fixed) 95% CI	1.14 [0.88, 1.47]

**Comparison 04. Subgroup: Recruitment /treatment setting**

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Nicotine gum. Smoking cessation	53	19090	Relative Risk (Fixed) 95% CI	1.43 [1.33, 1.53]
02 Nicotine patch. Smoking cessation	41	18237	Relative Risk (Fixed) 95% CI	1.66 [1.53, 1.81]
03 Nicotine Inhaler/inhalator. Smoking cessation	4	976	Relative Risk (Fixed) 95% CI	1.90 [1.36, 2.67]
04 Nicotine tablet/lozenge. Smoking cessation	6	3109	Relative Risk (Fixed) 95% CI	2.00 [1.63, 2.45]
05 Nicotine Intranasal spray. Smoking cessation	4	887	Relative Risk (Fixed) 95% CI	2.02 [1.49, 2.73]
06 Combination of NRT. Smoking cessation	1	245	Relative Risk (Fixed) 95% CI	1.07 [0.57, 1.99]
07 Choice of NRT. Smoking cessation	1	182	Relative Risk (Fixed) 95% CI	2.50 [0.81, 7.68]

**Comparison 05. Nicotine gum: 4mg versus 2mg dose**

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Smoking Cessation	7	856	Relative Risk (Fixed) 95% CI	1.43 [1.12, 1.83]

**Comparison 06. Nicotine gum: Fixed versus ad lib dose schedule**

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Smoking cessation	2	689	Relative Risk (Fixed) 95% CI	1.22 [0.92, 1.61]

**Comparison 07. Nicotine patch: High versus standard dose patches**

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Smoking cessation at maximum follow up	7	4634	Relative Risk (Fixed) 95% CI	1.15 [1.01, 1.30]

**Comparison 08. Nicotine patch: 16hr or 24hr use, subgroups & direct comparison**

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Smoking Cessation			Relative Risk (Fixed) 95% CI	Subtotals only

**Comparison 09. Nicotine patch: Duration of therapy, subgroups & direct comparison**

<b>Outcome title</b>	<b>No. of studies</b>	<b>No. of participants</b>	<b>Statistical method</b>	<b>Effect size</b>
01 Smoking Cessation			Relative Risk (Fixed) 95% CI	Subtotals only

### Comparison 10. Nicotine patch: Effect of weaning/tapering dose at end of treatment

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Smoking Cessation	41	16342	Relative Risk (Fixed) 95% CI	1.59 [1.47, 1.73]

### Comparison 11. Combinations of different types of NRT

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Long-term smoking cessation	7	3202	Relative Risk (Fixed) 95% CI	1.35 [1.11, 1.63]

### Comparison 12. Direct comparisons between NRT types

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Smoking cessation	3	1494	Relative Risk (Fixed) 95% CI	0.86 [0.62, 1.18]

### Comparison 13. Purchased NRT without support versus physician support

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
02 Smoking cessation using physician prescribed NRT versus NRT without support (all NRT purchased)	2	820	Relative Risk (Fixed) 95% CI	4.58 [1.18, 17.88]

### Comparison 14. Precessation treatment with nicotine patch

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Smoking cessation	4	424	Relative Risk (Fixed) 95% CI	1.79 [1.17, 2.72]

### Comparison 15. Nicotine patch and bupropion; direct comparisons and combinations

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Smoking cessation at longest follow up			Relative Risk (Fixed) 95% CI	Subtotals only

## INDEX TERMS

### Medical Subject Headings (MeSH)

Administration, Cutaneous; Administration, Inhalation; Chewing Gum; Nicotine [\*administration & dosage]; Nicotinic Agonists [\*administration & dosage]; Randomized Controlled Trials as Topic; Smoking [\*prevention & control]; Smoking Cessation [\*methods]; Tablets

### MeSH check words

Humans

## COVER SHEET

**Title** Nicotine replacement therapy for smoking cessation

Nicotine replacement therapy for smoking cessation (Review)

Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd

84

<b>Authors</b>	Stead LF, Perera R, Bullen C, Mant D, Lancaster T
<b>Contribution of author(s)</b>	LS, TL & CB have extracted data for the most recent update. The review text was updated by LS with review and suggestions from all other authors. CB contributed in particular to the sections on precessation use of NRT.
<b>Issue protocol first published</b>	1996/2
<b>Review first published</b>	1996/2
<b>Date of most recent amendment</b>	13 November 2007
<b>Date of most recent SUBSTANTIVE amendment</b>	01 November 2007
<b>What's New</b>	For Issue 1 2008 new studies were added, some comparisons were reorganised, and the effect measure was changed from the odds ratio to the risk ratio. Minor changes were made to the conclusions about the evidence for combinations of NRT types.
<b>Date new studies sought but none found</b>	Information not supplied by author
<b>Date new studies found but not yet included/excluded</b>	Information not supplied by author
<b>Date new studies found and included/excluded</b>	01 November 2007
<b>Date authors' conclusions section amended</b>	01 November 2007
<b>Contact address</b>	Mrs Lindsay Stead Review Group Co-ordinator Department of Primary Health Care University of Oxford Old Road Campus Headington Oxford OX3 7LF UK E-mail: lindsay.stead@dphpc.ox.ac.uk Tel: +44 1865 289285 Fax: +44 1865 289287
<b>DOI</b>	10.1002/14651858.CD000146.pub3
<b>Cochrane Library number</b>	CD000146
<b>Editorial group</b>	Cochrane Tobacco Addiction Group
<b>Editorial group code</b>	HM-TOBACCO

## GRAPHS AND OTHER TABLES




**Analysis 01.01. Comparison 01 Any type of NRT versus placebo/ no NRT control, Outcome 01 Smoking cessation at 6+ months follow up**


Review: Nicotine replacement therapy for smoking cessation

Comparison: 01 Any type of NRT versus placebo/ no NRT control

Outcome: 01 Smoking cessation at 6+ months follow up




(... Continued)




(Continued ...)

(... Continued)




(Continued ...)

(... Continued)



(Continued ...)

(... Continued)




### Analysis 02.01. Comparison 02 Subgroup: Definition of abstinence, Outcome 01 Nicotine gum. Smoking cessation


Review: Nicotine replacement therapy for smoking cessation

Comparison: 02 Subgroup: Definition of abstinence

Outcome: 01 Nicotine gum. Smoking cessation




(... Continued)



(Continued ...)

(... Continued)






## Analysis 02.02. Comparison 02 Subgroup: Definition of abstinence, Outcome 02 Nicotine patch: Smoking cessation


Review: Nicotine replacement therapy for smoking cessation

Comparison: 02 Subgroup: Definition of abstinence

Outcome: 02 Nicotine patch: Smoking cessation




(... Continued)



(Continued ...)

(... Continued)




### Analysis 03.01. Comparison 03 Subgroup: Level of behavioural support, Outcome 01 Nicotine gum. Smoking cessation


Review: Nicotine replacement therapy for smoking cessation

Comparison: 03 Subgroup: Level of behavioural support

Outcome: 01 Nicotine gum. Smoking cessation




(... Continued)



(Continued ...)

(... Continued)




### Analysis 03.02. Comparison 03 Subgroup: Level of behavioural support, Outcome 02 Nicotine patch. Smoking cessation


Review: Nicotine replacement therapy for smoking cessation

Comparison: 03 Subgroup: Level of behavioural support

Outcome: 02 Nicotine patch. Smoking cessation



(... Continued)




**Analysis 03.03. Comparison 03 Subgroup: Level of behavioural support, Outcome 03 Long versus short support**

Review: Nicotine replacement therapy for smoking cessation

Comparison: 03 Subgroup: Level of behavioural support

Outcome: 03 Long versus short support






**Analysis 04.01. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 01 Nicotine gum. Smoking cessation**


Review: Nicotine replacement therapy for smoking cessation

Comparison: 04 Subgroup: Recruitment /treatment setting

Outcome: 01 Nicotine gum. Smoking cessation




(... Continued)



(Continued ...)

(... Continued)




**Analysis 04.02. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 02 Nicotine patch. Smoking cessation**


Review: Nicotine replacement therapy for smoking cessation

Comparison: 04 Subgroup: Recruitment /treatment setting

Outcome: 02 Nicotine patch. Smoking cessation




(... Continued)



(Continued ...)

(... Continued)




### Analysis 04.03. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 03 Nicotine Inhaler/inhalator. Smoking cessation

Review: Nicotine replacement therapy for smoking cessation

Comparison: 04 Subgroup: Recruitment /treatment setting

Outcome: 03 Nicotine Inhaler/inhalator: Smoking cessation




### Analysis 04.04. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 04 Nicotine tablet/lozenge. Smoking cessation

Review: Nicotine replacement therapy for smoking cessation

Comparison: 04 Subgroup: Recruitment /treatment setting

Outcome: 04 Nicotine tablet/lozenge. Smoking cessation




### Analysis 04.05. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 05 Nicotine Intranasal spray. Smoking cessation


Review: Nicotine replacement therapy for smoking cessation

Comparison: 04 Subgroup: Recruitment /treatment setting

Outcome: 05 Nicotine Intranasal spray. Smoking cessation



(... Continued)




**Analysis 04.06. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 06 Combination of NRT. Smoking cessation**

Review: Nicotine replacement therapy for smoking cessation

Comparison: 04 Subgroup: Recruitment /treatment setting


Outcome: 06 Combination of NRT. Smoking cessation






**Analysis 04.07. Comparison 04 Subgroup: Recruitment /treatment setting, Outcome 07 Choice of NRT. Smoking cessation**

Review: Nicotine replacement therapy for smoking cessation  
 Comparison: 04 Subgroup: Recruitment /treatment setting  
 Outcome: 07 Choice of NRT. Smoking cessation




**Analysis 05.01. Comparison 05 Nicotine gum: 4mg versus 2mg dose, Outcome 01 Smoking Cessation**

Review: Nicotine replacement therapy for smoking cessation  
 Comparison: 05 Nicotine gum: 4mg versus 2mg dose  
 Outcome: 01 Smoking Cessation




(Continued ...)

(... Continued)



### Analysis 06.01. Comparison 06 Nicotine gum: Fixed versus ad lib dose schedule, Outcome 01 Smoking cessation

Review: Nicotine replacement therapy for smoking cessation  
 Comparison: 06 Nicotine gum: Fixed versus ad lib dose schedule  
 Outcome: 01 Smoking cessation




### Analysis 07.01. Comparison 07 Nicotine patch: High versus standard dose patches, Outcome 01 Smoking cessation at maximum follow up

Review: Nicotine replacement therapy for smoking cessation

Comparison: 07 Nicotine patch: High versus standard dose patches

Outcome: 01 Smoking cessation at maximum follow up




### Analysis 08.01. Comparison 08 Nicotine patch: 16hr or 24hr use, subgroups & direct comparison, Outcome 01 Smoking Cessation


Review: Nicotine replacement therapy for smoking cessation

Comparison: 08 Nicotine patch: 16hr or 24hr use, subgroups % direct comparison

Outcome: 01 Smoking Cessation



(... Continued)




### Analysis 09.01. Comparison 09 Nicotine patch: Duration of therapy, subgroups & direct comparison, Outcome 01 Smoking Cessation


Review: Nicotine replacement therapy for smoking cessation

Comparison: 09 Nicotine patch: Duration of therapy, subgroups % direct comparison

Outcome: 01 Smoking Cessation




(... Continued)



(Continued ...)

(... Continued)




### Analysis 10.01. Comparison 10 Nicotine patch: Effect of weaning/tapering dose at end of treatment, Outcome 01 Smoking Cessation

Review: Nicotine replacement therapy for smoking cessation

Comparison: 10 Nicotine patch: Effect of weaning/tapering dose at end of treatment


Outcome: 01 Smoking Cessation



(Continued ...)




(... Continued)



(Continued ...)

(... Continued)




### Analysis 11.01. Comparison 11 Combinations of different types of NRT, Outcome 01 Long-term smoking cessation

Review: Nicotine replacement therapy for smoking cessation


Comparison: 11 Combinations of different types of NRT

Outcome: 01 Long-term smoking cessation



(Continued ...)

(... Continued)




### Analysis 12.01. Comparison 12 Direct comparisons between NRT types, Outcome 01 Smoking cessation

Review: Nicotine replacement therapy for smoking cessation

Comparison: 12 Direct comparisons between NRT types

Outcome: 01 Smoking cessation




**Analysis 13.02. Comparison 13 Purchased NRT without support versus physician support, Outcome 02 Smoking cessation using physician prescribed NRT versus NRT without support (all NRT purchased)**

Review: Nicotine replacement therapy for smoking cessation

Comparison: 13 Purchased NRT without support versus physician support

Outcome: 02 Smoking cessation using physician prescribed NRT versus NRT without support (all NRT purchased)




**Analysis 14.01. Comparison 14 Precessation treatment with nicotine patch, Outcome 01 Smoking cessation**

Review: Nicotine replacement therapy for smoking cessation

Comparison: 14 Precessation treatment with nicotine patch

Outcome: 01 Smoking cessation



**Analysis 15.01. Comparison 15 Nicotine patch and bupropion; direct comparisons and combinations, Outcome 01 Smoking cessation at longest follow up**

Review: Nicotine replacement therapy for smoking cessation

Comparison: 15 Nicotine patch and bupropion; direct comparisons and combinations

Outcome: 01 Smoking cessation at longest follow up

